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Why this thesis?
Osteoarthritis (OA) is the most prevalent chronic joint disease, with a substantial impact 
on individuals and society1-3. Current OA research and daily clinical practice are mainly 
focused on a specific localization, whereas in many patients with OA, multiple joint sites are 
involved. The hand, spine and lower limb weight-bearing joints i.e. the hip and knee are 
the most common sites of disease involvement4. Generalized osteoarthritis (GOA) includes 
a subset of patients with clinically polyarticular OA and is an important and widely used OA 
phenotype5-7. However, to date research on (the management of) GOA is very limited. The 
purpose of this thesis is to improve knowledge on the non-pharmacological, non-surgical 
management of patients clinically diagnosed with GOA. In particular, we examined the clinical 
burden of patients with GOA and evaluated the efficacy of a non-pharmacological treatment 
program for patients with GOA. This chapter outlines the definition of GOA, as well as the 
epidemiology, pathophysiology and clinical symptoms. Furthermore, it summarizes evidence 
of the current non-pharmacological management of patients with GOA in daily practice and 
finally it introduces the research questions discussed in this thesis.
Definition of generalized osteoarthritis
The term GOA was introduced by Kellgren and Moore in 19528. Since then, multiple 
definitions of GOA have been suggested in the literature7. In Table 1, studies reporting 
explicit definitions of GOA are summarized. This table makes it clear that so far no agreed 
and validated definition of GOA is available; the threshold number of affected joints as well 
as the pattern of joint involvement have been described differently. The table shows 14 
different definitions of GOA. Most definitions state that GOA involves at least three joints 
or joint groups. Besides, most definitions include the interphalangeal joints of the hands. 
In the literature, it has even been proposed that hand OA might be a marker for GOA9-13. 
However, defining GOA by the presence of hand OA is not widely accepted since GOA is 
also used to describe patients with OA in multiple joints without hand involvement14. The 
involvement of the knee in the definition of GOA is also common as shown in the table. 
However, there is little agreement on the necessity or appropriateness of the involvement of 
other joints such as the hip, spine or feet7,15,16. Indeed, increasing evidence shows that hand 
and knee OA aggregate together much more often than other joints11,17-19. In summary, we 
can state that most definitions of GOA include at least 3 joints or joint groups involving both 
the upper and lower extremities. Most definitions of GOA are based on radiographic findings 
independent of clinical symptoms. Since there is an imperfect correlation between symptoms 
and radiographic OA20 and symptoms are likely to be more important in functional outcomes, 
it is important to consider clinical symptoms next to structural changes in the definition of 
GOA21.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
10  |  Chapter 1
Definition of GOA in this thesis
In this thesis we used a pragmatic definition of GOA formulated by Hoogeboom et al.22 which 
was based upon the current scientific literature and combined both radiological findings and 
clinical symptoms. We defined GOA as: 
- Having complaints in three or more of eight joint areas (i.e. feet, knees, hips, lumbar 
spine, neck, shoulders, elbows and hands), and 
- Having at least two objective signs that indicate OA in at least two of eight joint 
areas (objective signs indicating OA are: malalignment, crepitation, limited range of 
motion, palpable osteophytes/nodules or radiographic signs including the presence 
of joint space narrowing and/or osteophytes).
Epidemiology of GOA
In Table 1, data on the prevalence of GOA are summarized. To date, it is very difficult to 
accurately assess the prevalence of GOA given the variability of GOA definitions used and 
populations (setting, gender, age etc.) being assessed. As shown in the table, estimates of 
the frequency of GOA range from 1-90%, depending on the population studied. Despite the 
limited scientific literature on the prevalence of GOA, it has been suggested that patients with 
GOA represent a relatively large subgroup of patients with OA23-26. The number of patients 
with GOA is expected to grow substantially due to the aging population and the increasing 
prevalence of obesity throughout the world1,27.
Table 1. Summary of studies reporting explicit definitions of GOA and data on its prevalence
Author (year) GOA definition Setting Prevalence of 
GOA (%)
Kellgren (1952)8 Heberden’s nodes and OA in CMC joint; 
radiological and clinical 
Patients with OA attending an 
outpatient rheumatology clinic
52%
Lawrence (1969)28 OA in ≥ 3 joints or OA in ≥ 5 joints, 
at least one joint K&L grade ≥ 2; 
radiological
General population 20-25% ≥ 3 joints
8-9% ≥ 5 joints
Doherty (1983)29 OA in > 3 IP joints; radiological Patients who had undergone 
unilateral knee meniscectomy
43%
Hart (1993)30 OA in DIP/PIP and CMC joint in addition 
to the knee; radiological and clinical
Women aged 45-64 years from 
the general population
Radiological: 2%
Radiological and 
clinical: 1%
Loughlin (1994)31 Heberden’s nodes before age 60 and OA 
in ≥ 3 joint groups
ns 100% (population 
selected for GOA)
Dougados (1996)32 Either bilateral digital OA or spine and 
bilateral knee OA; radiological and 
clinical
Patients with OA from a 
hospital rheumatology 
department
44% 
Cooper (1996)33 Age based: OA in ≥ 2 joints age 45-47 
years or OA in ≥ 5 joints age 60-64; 
radiological K&L grade ≥ 2
Women from the general 
population
7% overall
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Gunther (1998)24 OA in ≥ 2 DIP/PIP joints and ≥ 1 CMC 
joint in addition to the hip or knee; 
radiological K&L grade ≥ 2
Hospital-based population 
awaiting hip or knee 
arthroplasty
Knee OA: 35%
Hip OA: 19%
Overall: 27%
Malaviya (1998)34 Heberden’s nodes and DIP and PIP OA; 
radiological and clinical
Patients with OA attending an 
outpatient rheumatology clinic
4%
Naito (1999)35 OA in > 3 IP joints in each hand; 
radiological K&L score ≥ 2
Women with knee OA from an 
orthopaedic outpatient clinic
45%
Huang (2000)36 Hand OA (≥ 3 IP joints), hip OA and knee 
OA; radiological K&L score ≥2
Women with knee, hip, 
or hand OA visiting an 
orthopaedic outpatient clinic
17%
Min (2005)37 OA at multiple joints of the hand or OA 
in ≥ 2 of 4 joint sites (hand, knee, hip, 
spine); radiological*Ɨ and symptomaticƗ
Rotterdam study* and GARP 
studyƗ
23% 
66% 
Miura (2008)38 Bilateral knee and lumbar spine OA; 
radiological K&L score ≥ 2
General population 13%
Riyazi (2008)39 OA at multiple joints of the hand or OA 
in ≥ 2 joint sites (hand, spine, knee, hip); 
symptomatic and radiological
GARP studyƗ 90%
Carroll (2009)9 Type I: OA in ≥ 2 DIP or PIP joints and 
both knees or MTP1 joints 
Type II: OA in ≥ 2 MCP joints and OA in ≥ 
1 atypical joint; clinical and radiological 
criteria 
Patients with OA referred 
to a hospital rheumatology 
department
Type I: 58%
Type II: 42%
Forestier (2011)23 3 GOA criteria sets:
1: Heberden’s nodes or OA in IP joint
2: OA in ≥ 2 joints and spine OA
3: bilateral digital OA or spine and 
bilateral knee OA; radiological and 
clinical manifestations
Patients with established 
knee OA
1: 14%
2: 41%
3: 42%
52% met at least 
one of the three 
definitions
Abbreviations: OA = osteoarthritis, CMC = carpometacarpal, IP = interphalangeal, DIP = distal interphalangeal, MTP 
= Metatarsophalangeal, ns = not specified or no data, K&L = Kellgren & Lawrence
*Population-based cohort study on the determinants and prognosis of chronic diseases in the elderly
Ɨ Genetics, Arthrosis and Progression (GARP) Study on Dutch Caucasian sib pairs with predominantly symptomatic OA 
at multiple sites to identify determinants of OA susceptibility and progression 
Pathophysiology and risk factors
Osteoarthritis is a complex disease in which all structures that constitute a joint might be 
involved. The pathophysiology of OA has long been thought to be a failure of the repair 
process of damaged cartilage due to biomechanical changes in the joint. However, recent 
evidence shows an additional and integrated role of bone, synovial tissue and peri-articular 
tissues such as ligaments and muscles1 (Figure 1). Moreover, it has been recognized that 
synovial inflammation (synovitis) is common in OA, resulting clinically in joint swelling and 
pain40. The role of genetic factors in the development of GOA has received considerable 
attention during the last decade. Increasing evidence shows that genetic factors are a major 
risk factor for GOA, probably more than in other forms of OA17,37,39,41,42. This finding has been 
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shown especially by the GARP study, defining GOA as having OA at multiple joints of the hand 
or OA in ≥ 2 joint sites (hand, spine, knee, hip). Furthermore, an increased frequency of GOA 
or higher risk of GOA progression was found to be associated with a higher age, a higher 
BMI15,43,44 and a higher bone mineral density45,46. Results are, however inconsistent across 
studies, what might be explained by the lack of a uniform definition of GOA.
9general introduction
OA is characterized by a failure of the repair process of damaged cartilage due to bio-
mechanical changes in the joint.7 However, recent evidence shows an additional and inte-
grated role of bone and synovial tissue, and patchy chronic synovitis that is evident in the 
disease.8 Patients with hip or knee OA present similar symptoms (Figure 2). Usage-related 
pain is the most important symptom, often worse towards the end of the day, relieved by 
rest. Other typical symptoms are morning or inactivity stiffness, impaired function, and 
bone deformation; all contributing to the disability of OA and diminishing of patients’ 
quality of life.7 The extent and severity of symptoms vary considerably among patients.9
Identified risk factors of hip and knee OA are increasing age, intense sport activity, higher 
body mass index, previous injury, and genetic predisposition. Additional risk factors of 
knee OA are muscle weakness, smoking, malalignment, and female gender.7,10 However, 
the prevention of OA is difficult, as these factors increase the risk for OA only moderately 
and the presence of single factors might not be strong enough to justify their use in iden-
tifying subjects who should receive preventive interventions.10 The presence of multiple 
risk factors and their interaction with each other, are probably the key factors to identify 
people at major risk. 
In general, hip and knee OA develops progressively over several years. An extensive syste-
matic review shows a deterioration of pain and functional status in patients with hip or 
knee OA after 3 years of follow-up.9 However, this was not seen for the first 3 years of fol-
low-up. Prognostic factors of the progression of OA include biomechanical, psychological, 
and clinical factors.11-13 Those factors that are modifiable, e.g. reduced muscle strength, 
laxity of the knee joint, proprioceptive inaccuracy, overweight, and a lack of physical activity, 
are therefore considered important elements for treatment. 
Figure 2. A normal joint and osteoarthritic joint 
Subchondral bone changes (sclerosis)
Joint space narrowing
Cartilage damage
Inflammation of the synovium (synovitis)
New bone formation (osteophyte)
Thickening of the joint capsule
Muscle weakness
Dutch Arthritis Foundation ©.  
Printed with permission.
AS proefschrift binnenwerk.indd   9 13-04-14   20:57
Figure 1. Normal joint and osteoarthritic joint
Clinical symptoms of GOA
The predominant symptoms of GOA are pain, joint stiffness and loss of function, mostly 
related to mobility (in particular walking) and doing household chores. However, the impact 
of GOA on clinical outcomes is largely unknown since OA populations are mostly examined 
for a specific joint or group of joints without considering the involvement of multiple joints. 
Previous studies have examined the association between multiple joint involvement (e.g. joint 
pain comorbidity) and clinical outcomes in joint specific OA cohorts (hip or knee OA), showing 
poorer outcomes for pain, function and quality of life than in single joint OA25,26,47,48. However, 
in those studies, the nature of the additional musculoskeletal complaints is unknown and 
might be unrelated to OA. So far, only one study assessed the impact of GOA on health status, 
showing that patients with GOA did not have a poorer quality of life than individuals with 
hip or knee OA only49. However, the limited sample size in that study (n = 30) prevents firm 
conclusions. Improved understanding of the health status of patients with GOA can be used 
by clinicians and researchers to improve the management and quality of care for patients 
with GOA.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General introduction  |  13
1
Assessment of GOA
The assessment of daily function has emerged as an integral part of OA clinical practice and 
research, using health-related patient-reported outcome measures (HR-PROs). As such, 
numerous disease-specific validated HR-PROs are available to assess functional limitations 
in patients with OA, such as the Western Ontario and McMaster Universities Arthritis Index 
(WOMAC). However, existing OA-specific HR-PROs all focus on a specific localization of 
OA (e.g. the hands, hips or knees), reflecting either activities of lower extremity or upper 
extremity function. Since individuals with GOA typically suffer from limitations of both 
upper and lower extremity function, existing OA specific instruments inadequately reflect 
functional limitations, limiting their use in GOA. In addition, no studies have reported on 
the measurement properties of existing HR-PROs to assess functional limitations in patients 
with GOA. As such, we lack a validated instrument. To increase the body of knowledge on 
the functional limitations of patients with GOA, instruments with adequate measurement 
properties, in particular content validity and responsiveness, are warranted. In this thesis, we 
evaluated the measurement properties of the Health Assessment Questionnaire Disability 
Index (HAQ-DI), widely used in rheumatoid arthritis (RA), to assess daily function in patients 
with GOA. These results can be used to guide clinicians and researchers in the assessment of 
functional limitations in patients with GOA. 
Non-pharmacological treatment for people with GOA
Several international consensus-based clinical guidelines for the management of OA are 
available, emphasizing the importance and efficacy of non-pharmacological, non-surgical 
treatment modalities50-54. However, these guidelines all focus on single joint involvement 
(i.e. the hand, hip or knee), without considering the involvement of multiple joints50,51,53,54. 
Recently, the Osteoarthritis Research Society International (OARSI) published the first 
recommendations for the non-surgical management of OA for several OA subpopulations, 
including multiple joint OA (defined as OA in other joints in addition to the knee)52. However, 
due to the limited research performed on the management of multiple joint OA, the 
authors only considered balneotherapy/spa therapy (defined as the use of baths containing 
thermal mineral waters) appropriate for patients with multiple joint OA, whereas no other 
recommendations could be formulated. Indeed, studies evaluating the effectiveness of non-
pharmacological treatment for patients with GOA are very scarce. To our knowlegde, only 
two studies investigated the effect of a non-pharmacological intervention for patients with 
GOA. Recently, Foresterier et al.55 showed that crenobaltherapy (spa therapy) in combination 
with home exercises provided better improvements in pain and function than home exercises 
alone. However, in that study the primary outcome measure was physcial function measured 
with the WOMAC which comprises only items of lower extremity function. Another study 
by Bolthuis et al.57 investigated the efficacy of an intensive exercise program for patients 
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with GOA. In that study however, the definition of GOA was unclear and patients recently 
underwent joint replacement, hampering the generalizability of the findings. The lack 
of research on the management of GOA and the substantial group of patients with GOA 
warrant the development and evaluation of a non-pharmacological, non-surgical treatment 
program for patients with GOA necessitating a clinically relevant GOA definition and 
appropriate outcome measures. In absence of recommendations for the management of 
GOA, guidelines for the treatment of single joint OA could be considered as starting point to 
develop interventions for patients with GOA. Recommendations in these guidelines could be 
used to tailor treatment options to the needs of patients with GOA. In a recently published 
systematic review evaluating OA guidelines, three non-pharmacological core interventions 
have been identified which should be included in the management of patients with GOA: (1.) 
education and self-management; (2.) exercise and weight loss; and (3.) assistive devices and 
home adaptations53.
Education and self-management
Existing guidelines uniformly recommend education, lifestyle advices and self-management. 
Self-management interventions can be described as behavioural interventions designed 
to encourage people to take an active role in the management of their own condition56,57. 
These interventions often target on patient education and lifestyle modification57. Substantial 
variation exists in the delivery of self-management interventions, such as the mode of care 
delivery (face-to-face, internet, telephone or written information such as care booklets), the 
audience (group, individual) or the duration and frequency57. In general, small effect sizes of 
self-management programs for people with OA have been reported in systematic reviews and 
clinical guidelines for the management of hip and knee OA (ES = 0.06 for pain, 95% CI 0.02 to 
0.10 and ES = 0.06 for physical function, 95% CI 0.02 to 0.10)50,58. Nevertheless, the importance 
of self-management is uniformly advocated in international clinical guidelines in order to 
manage the disease effectively50,51,53,58. It is therefore conceivable that recommendations 
regarding self-management are rather based on clinical expertise and patient values than on 
research evidence.
A recommended and widely endorsed component of OA self-management programs 
within the context of multidisciplinary treatment is activity pacing. Activity pacing is the advice 
most frequently given by British and Dutch rheumatology nurses to patients with RA and it 
is one of the self-management strategies most frequently applied by patients to decrease 
pain and fatigue59-63. In OA research and clinical practice, activity pacing is mainly based on 
the principle of energy conservation. However, the use of activity pacing is purely pragmatic 
and it remains a poorly understood concept64-66. The implications of a poor conceptualization 
of activity pacing are significant in both research and rheumatology practice. Therefore 
in this thesis we attempt to clarify the concept of activity pacing among an international, 
multidisciplinary group of experts.
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Exercises and weight loss
There is strong agreement within guidelines regarding the effectiveness of exercises, 
especially for patients with hip and knee OA. There is less agreement on the benefits of 
exercises related to hand OA53,67. A recently published systematic review showed land-based 
therapeutic exercises to reduce pain (ES = -0.49, 95% CI -0.39 to -0.59), improve physical 
function (ES = -0.52, 95% CI -0.39 to -0.65) and improve quality of life (ES = 0.28, 95% CI 0.15 to 
0.40) in people with knee OA68. The authors concluded that the magnitude of the treatment 
effect for pain and physical function was influenced by the number of individual face-to-face 
contact occasions with the healthcare provider supervising the program. In hip OA, exercises 
have shown to reduce pain (ES = -0.38, 95% CI -0.55 to -0.20) and improve physical function 
(ES = -0.33, 95% CI -0.53 to -0.13)69. Furthermore, water-based exercises showed small to 
moderate effect sizes for pain (ES = 0.19, 95% CI 0.04 to 0.35) and function (ES = 0.26, 95% 
CI 0.11 to 0.42) in people with hip and knee OA58,70. Weight loss is strongly recommended in 
overweight individuals with knee OA. Small to moderate effect sizes for pain (ES = 0.20, 95% 
CI 0.00 to 0.39) and function (ES = 0.23, 95% CI 0.04 to 0.42) have been shown71. Currently, 
no evidence is available supporting the effect of weight loss in patients with hip OA50,58. 
Increasing evidence recognizes that the combination of exercises and weight loss should be 
the mainstays of rehabilitation for people with knee and hip OA72,73. Furthermore, evidence is 
growing for beneficial effects of tai chi. A systematic review showed tai chi to improve pain in 
patients with hip or knee OA with effect sizes ranging from 0.28 to 1.6774.
Assistive devices and home adaptations
Assistive devices and home adaptations can help patients to improve or maintain activities 
of daily living and/or reduce pain. Walking aids, assistive technology and adaptations at 
home are therefore important and often used by people with hip or knee OA50. The value of 
some of these interventions is so obvious and has an immediate effect that further research 
into the effectiveness of these interventions can hardly be expected50. The use of a cane in 
patients with knee OA has been investigated, showing that daily cane use can reduce pain (ES 
= 0.18, 95% CI -0.42 to 0.87) and improve physical function (ES = 0.13, 95% CI -0.11 to 0.42)75. 
International guidelines generally recommend that in all patients with hip or knee OA walking 
aids, assistive technology and adaptations at home should be considered systematically and 
recurrently50,53,76. Several guidelines recommend to discuss appropriate footwear in patients 
with hip or knee OA50,76,77.
Cost-effectiveness of non-pharmacological treatment for people with GOA
Despite evidence for non-pharmacological, non-surgical interventions to manage OA, evidence 
for the cost-effectiveness of these interventions is limited as concluded in a systematic review 
on the cost-effectiveness of non-pharmacological interventions for patients with hip and 
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knee OA78. Based on the available studies, the authors suggested that exercise programs 
appear to be the best value for money in the management of hip and knee OA. In hand OA, 
it has also been shown that exercises are the most cost-effective management strategy79. 
However, no economic evaluations are available for non-pharmacological interventions for 
the management of patients with GOA. In this thesis, we evaluated the cost-effectiveness of 
two non-pharmacological treatment programs for patients with GOA. 
Outline of this thesis
The primary aim of this thesis is to examine the health status of patients with GOA and to 
evaluate the (cost)effectiveness of a non-pharmacological multidisciplinary face-to-face 
group-based treatment program for patients with GOA compared to a telephone-based 
treatment program during the first year after treatment was started. The content of the 
chapters in this thesis is outlined below.
In chapter 2, the health status of patients with GOA as measured by self-reported health 
realted quality of life and activity limitations is described. 
In chapter 3, results of a randomzed clinical trial comparing the effectiveness of a non-
pharmacological multidisciplinary face-to-face group-based treatment program with a 
telephone-based treatment program on daily function for patients with GOA (during the first 
year after treatment was started) are presented. 
Chapter 4 describes from a societal perspective a cost-effectiveness and cost-utility analysis 
alongside the randomized clinical trial described in Chapter 4. 
In chapter 5, the measurement properties, i.e. interpretability, validity, reliability and 
responsiveness of the Health Assessment Questionnaire Disability Index (HAQ-DI) to measure 
daily function in patients with GOA are evaluated.
In chapter 6, a comparison of the responsiveness of four widely used patient reported 
outcome measures (i.e. the McMaster University Osteoarthritis Index (WOMAC), the Lower 
Extremity Functional Scale (LEFS), the Knee disability and Osteoarthritis Outcome Score 
(KOOS) and the Lequesne Algofunctional index (LAI)) to measure physical function in patients 
with knee OA is described. These results can be used to guide clinicians and researchers in 
selecting the most appropriate physical function measure in clinical trials to evaluate the 
effectiveness of an intervention in patients with knee OA.
In chapter 7, patients’ views on a tailored-made self-management tool for patients with hip 
or knee osteoarthritis, i.e. the self-management booklet “Care for Osteoarthritis” (in Dutch: 
“Zorgwijzer Artrose ©”) are presented. This booklet was developed to educate patients about 
their disease and existing treatment options and to improve self-management and patient-
healthcare provider communication.
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In chapter 8, the results of an international Delphi survey to clarify the concept of activity 
pacing as a non-pharmacological intervention in rheumatology care are presented. This study 
is a collaboration between clinicians and healthcare professionals experienced with activity 
pacing among 12 different countries. 
Chapter 9 summarizes the results of this thesis and discusses the main findings. Furthermore, 
implications for clinical practice and directions for future research are provided. 
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CHAPTER 2
The clinical burden of generalized osteoarthritis 
represented by self-reported health-related quality of life 
and activity limitations: a cross-sectional study
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Abstract
Objective
The involvement of multiple joints is common in osteoarthritis (OA), often referred to as 
generalized osteoarthritis (GOA). However, since research and practice mainly focus on a 
specific OA localization, the health status of patients with GOA is largely unknown. Therefore, 
we aimed to describe the clinical burden of GOA in terms of self-reported health related 
quality of life (HRQoL) and activity limitations.
Methods
In this cross-sectional study, individuals clinically diagnosed with GOA and referred to 
multidisciplinary treatment, completed questionnaires on socio-demographics, joint 
involvement, HRQoL (SF-36) and activity limitations (HAQ-DI). SF-36 physical (PCS) and mental 
component summary scores (MCS) were calculated using norm-based data. The patient’s 
specific most important activity limitations were linked to the International Classification of 
Functioning, Disability and Health.
Results
A total of 147 patients participated (85% female; mean (SD) age 60 (8) years). The majority 
(93%) had symptomatic OA in both the upper and lower extremities. Predominant joints with 
symptomatic OA were the hands (85%) and knees (82%). Mean (SD) SF-36 PCS and MCS 
scores were 37 (7) and 48 (10) respectively, showing a broad impact of GOA on the physical 
component of health. The mean (SD) HAQ-DI score was 1.27 (0.50) indicating moderate to 
severe functional limitations. Activities concerning mobility and domestic life were considered 
most important activity limitations, especially walking.
Conclusions
The results show a high clinical burden of GOA in terms of HRQoL and activity limitations. 
This study point to the need of developing non-pharmacological interventions for patients 
with GOA that should target on improving the physical component of health and mobility 
limitations.
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Introduction
Osteoarthritis (OA) is the most prevalent chronic joint disease that can affect multiple joints1. 
The hands and the lower limb weight-bearing joints i.e. the hip and knee are the most 
common sites of disease involvement2. Generalized osteoarthritis (GOA) is an important and 
widely accepted OA phenotype, describing the often polyarticular nature of OA3-5. The term 
GOA was first used by Kellgren and Moore in 19526. Since then multiple definitions of GOA 
have been suggested. However, a recently published review showed that there is still no 
widely accepted and validated definition of GOA5. Nevertheless, it has been suggested that 
individuals with GOA might represent a relatively large subgroup of patients with OA7-9. In 
knee OA populations, approximately 50% of patients can be classified as GOA according to 
three different criteria sets7.
Current research and clinical practice mostly examine OA populations for a specific 
localization of OA, without considering the involvement of multiple joints. As such, research 
on GOA is very limited. The impact of GOA on patient’s health status is therefore largely 
unknown. A few previous studies have examined the association between multiple joint 
involvement (e.g. joint pain comorbidity) and health outcomes in patients with hip and 
knee OA, showing poorer outcomes for pain, function and quality of life than in single joint 
OA10-13. However, in those studies the nature of the additional musculoskeletal complaints is 
unknown and might be unrelated to OA. To the best of our knowledge there are no studies 
that comprehensively assessed the health status of patients clinically diagnosed with GOA. 
So far, only one study assessed the impact of GOA on health status, showing that patients 
with GOA (radiographic OA in ≥ 2 joints) did not have a poorer quality of life than individuals 
with hip or knee OA only14. However, the limited sample size in that study (n = 30) prevents 
firm conclusions.
Improved understanding of the health status of patients with GOA is warranted 
considering the high prevalence of GOA and the lack of research. Information on the health 
status of patients with GOA might be used by clinicians and researchers to improve the 
management and quality of care for patients with GOA. Therefore the aim of the current 
study was (1) to describe the clinical burden of patients clinically diagnosed with GOA in 
terms of self-reported health related quality of life (HRQoL) and activity limitations, and (2) to 
identify commonly reported, self-perceived activity limitations and participation restrictions 
in patients with GOA.
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Method
Study Design
For this cross-sectional study, we used baseline data from a randomized clinical trial 
comparing the effectiveness of two multidisciplinary non-pharmacological treatment 
programs for patients with GOA, performed at the outpatient rheumatology departments 
of the Sint Maartenskliniek Hospitals in the Netherlands. Participants were allocated to 
either a multidisciplinary group-based self-management program or a telephone-based 
self-management program. The complete study design has been described previously15. The 
Institutional Review Board of the Radboud University Medical Nijmegen Centre approved the 
study and all patients signed informed consent.
Participants
Recruitment to the study took place between January 2010 and March 2013. During an 
outpatient visit, patients clinically diagnosed with GOA and referred by their rheumatologist 
for treatment were invited for a screening visit with an occupational therapist, physical 
therapist and researcher to consider eligibility to participate in the trial. Patients were eligible 
when meeting all of the following inclusion criteria: (1) aged ≥ 18 years; (2) having objective 
signs of OA in at least two joint areas on the basis of the patient’s medical file (objective signs 
included: malalignment, crepitation, limited range of motion, palpable osteophytes/nodules 
or radiographic signs including the presence of joint space narrowing and/or osteophytes); 
(3) having clinical symptoms in ≥ 3 out of 8 joint areas; (4) being limited in the performance of 
daily activities (Health Assessment Questionnaire Disability Index (HAQ-DI) score > 0.5); and 
(5) being motivated to alter your lifestyle and willing to participate in a group. Excluded were 
patients who were: (1) diagnosed with another rheumatic disease; (2) awaiting surgery; (3) 
already participated unsuccessfully in a self-management program; (4) having psychosocial 
problems interfering with the scope of the treatment program (on the basis of clinical 
judgement of a physical therapist and occupational therapist); (5) incapable of coming to the 
hospital; or (6) unable to write and or understand the Dutch language.
Data collection
Prior to the start of the treatment programs all patients completed a standardized set of health 
related patient-reported outcome measures to assess socio-demographic characteristics, 
fatigue, joint involvement, activity limitations and HRQoL. Socio-demographic characteristics 
included age, sex, education, marital status and occupation. Height and weight were recorded 
to calculate the body mass index (BMI). Fatigue was measured with the “Subjective Fatigue” 
subscale of the Checklist Individual Strength (CIS) (score range 8-56 points, scores of ≥ 35 
represent severe fatigue16). 
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Joint involvement
To identify the localization of symptomatic OA in eight joint areas (i.e. feet (including 
ankles), knees, hips, lumbar spine, neck, shoulders, elbows and hands (including wrists)) the 
following question was assessed in the baseline questionnaire: “In which of these joints do 
you experience symptoms (pain/stiffness) for more than half of the time?” The locations 
of symptoms were identified by each patient on a paper manikin, which permitted the 
identification of symptom locations on either side of the body17. In addition, objective signs of 
OA and its localization were registered by the first author by screening each patient’s medical 
file.
Health related quality of life
Health related quality of life was measured with the Short Form 36 Health Survey (SF-36), 
a widely used generic questionnaire that comprises eight areas of health status: physical 
functioning, physical role limitations, bodily pain, general health, vitality, social functioning, 
emotional role limitations and mental health18. Additionally, the SF-36 comprises two summary 
scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS) 
score. We used SF-36 scores of the Dutch general population to standardize the scores of the 
patients in the current study in order to apply the norm based scoring whereby we adjusted 
for age19,20. All scores were standardized to a mean (SD) of 50 (10). Lower scores represent 
worse health status.
Activity limitations measured with the HAQ-DI
Participants completed the Dutch consensus HAQ-DI21. The HAQ-DI measures difficulties 
with the performance of 20 daily activities retrospectively over the preceding week with four 
response categories: no difficulty (0), some difficulty (1), much difficulty (2) and unable to 
do (3). The activities are classified into eight categories with two or three activities each: 
dressing and grooming, arising, eating, walking, personal hygiene, reaching, gripping and 
usual activities (i.e. shopping, doing chores, getting in and out of a car)22. The highest scores 
of each category are summed and averaged resulting in a disability index ranging from 0 to 
3, where scores of 0-1 are generally considered to represent mild to moderate disability, 1-2 
moderate to severe disability and 2-3 severe to very severe disability22. We did not correct 
HAQ-DI scores for using assistive devices.
Activity limitations and participation restrictions measured with the patient specific complaints 
questionnaire (PSK)
The PSK was administered by an occupational therapist with the aim to elicit activity 
limitations and participation restrictions that are specific and relevant to the individual 
patient23. Patients were asked to identify the three most important activities, currently 
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difficult to perform because of their GOA. No list of activities was used to allow patients 
freedom in their responses. In addition, patients rated the severity of each activity on a 10 cm 
visual analogue scale (VAS) (0 = no difficulty, 10 = impossible)23. Patient specific approaches 
to measure functional limitations have been shown to be reliable, valid and responsive in 
patients with several musculoskeletal conditions23,24. These activity limitations were then 
linked to the Activities and Participation component of the International Classification of 
Functioning, Disability and Health (ICF)25. This component describes a person’s functional 
status whereby Activities refer to the execution of specific tasks and Participation refer 
to the involvement in life situations. The ICF categories of the Activities and Participation 
component are designated by the letter d, followed by a numeric classification that indicates 
the chapter and specific category within the ICF classification. In the current study, each 
activity limitation was systematically linked to the most precise ICF category (3rd or 4th level) 
independently by three assessors (SK, DK, JG) using established linking rules26. In case of 
disagreement, agreement was established through a consensus meeting. When a patient 
reported different activity limitations or participation restrictions within the same PSK item, 
different ICF categories were identified. This process resulted in a list of ICF codes on different 
levels of the ICF within the area of Activities and Participation.
Statistical analysis
Descriptive statistics were used to describe the main characteristics of the study population 
and to explore comparability between the participants and eligible patients. Mean (SD) SF-
36 subscale and component summary scores were calculated to identify the patient’s health 
status. The mean (SD) total HAQ-DI score as well as mean (SD) HAQ-DI scores of each HAQ-DI 
category were calculated to identify the patient’s functional status. Additionally, we assessed 
for each HAQ-DI category, the percentage of patients that reported to have either no/some 
difficulty (score 0 or 1) or much difficulty (score 2 or 3) with performing everyday activities. 
The most commonly reported activity limitations and participation restrictions by patients 
with GOA were identified by analysing the frequencies of the assigned ICF categories from 
the PSK. All statistical analyses were performed using STATA 10.1.
Results
Patient characteristics
In total, 236 patients were eligible to participate in the study of whom 158 (67%) agreed to. 
Main reasons for patients not to participate were having a preference for the multidisciplinary 
group-based treatment (n = 46; 59%) or lacking confidence towards the telephone-based 
treatment (n = 24; 31%). No differences were found between the group of eligible patients 
and the participants with regard to age, whereas there were relatively less women in the 
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group of eligible patients (72% vs. 85%, p = 0.01). Of the 158 participants, 11 were lost before 
the first measurement (i.e. provided no data), meaning that 147 patients were included in 
the analysis of the current study. Characteristics of the study population are summarized in 
Table 1. 
Table 1. Socio demographic and disease related characteristics of 147 individuals with GOAa
Patient characteristics
Female 125 (85)
Age, years; mean ± SD 60 ± 8
Body Mass Index, kg/m2; mean ± SD 28.1 ± 4.7
Education > 12 years 43 (29)
Marital status, married 113 (77)
Work status, currently employed 55 (37)
Duration of complaints ≥ 5 years 110 (75)
Localization of symptoms:
Upper extremities (neck, shoulder, elbow, hand) 138 (94)
Lower extremities (lumbar spine, hip, knee, foot) 145 (99)
Combination of upper and lower extremities 136 (93)
Activity limitations, HAQ-DI (0-3); mean (SD) 1.27 (0.50)
Severe fatigued, CIS score ≥ 35 83 (56)
a Values are the numbers (percentage) unless indicated otherwise
Abbreviations: SD = Standard Deviation; HAQ-DI = Health Assessment Questionnaire Disability Index; 
CIS = Checklist Individual Strength
Joint involvement
The median number of self-reported joint areas with symptomatic OA was 5 (interquartile 
range 4-6) and the median number of joint areas with objective signs of OA was 2 (interquartile 
range 2-3). The majority of patients (n = 136; 93%) had symptomatic OA in both the upper 
half (neck, shoulder, elbow, hand) and lower half (lumbar spine, hip, knee, foot) of the body. 
The prevalence of self-reported and objective signs of OA for each joint area is depicted in 
Figure 1. The predominant joints with symptomatic OA were the hands (n = 125; 85%) and 
knees (n = 121; 82%), whereas symptoms in the elbow joints were the least often reported 
(n = 41; 28%). The predominant joints with objective signs of OA were also the hands 
(n = 114; 78%) and knees (n = 78; 53%) as recorded in the patient’s medical files, whereas 
objective OA signs in the elbows were the least often recorded (n = 3; 2%). We found the 
combination of hand and knee OA to be most common, both self-reported (n = 106; 72%) as 
well as recorded in the medical files (n = 58; 39%).
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Figure 1. Percentages of symptomatic and objective signs of OA for each joint area. The green bars 
represent the percentage of self-reported symptomatic OA, the blue bars represent the percentage of 
objective OA signs as recorded in the patient’s medical files and the red bars represent the percentage 
of both self-reported symptoms and objective signs of OA
Health related quality of life
Mean scores for the PCS, MCS and subscales of the SF-36 are presented in Figure 2. Mean 
(SD) PCS and MCS scores were 37.4 (6.9) and 47.8 (10.5), respectively. Mean (SD) scores were 
worst for the subscales physical function, physical role limitations, bodily pain and vitality, i.e. 
37.4 (7.7), 39.0 (8.3), 40.0 (6.6) and 40.3 (5.5), respectively. Highest scores were obtained 
for the subscales mental health and emotional role limitations i.e. 47.7 (8.6) and 45.4 (12.0). 
Activity limitations measured with the HAQ-DI
The mean (SD) total HAQ-DI score for the total study population was 1.27 (0.50), indicating 
moderate to severe activity limitations22. One hundred-eleven patients (76%) obtained a 
HAQ-DI score ≥ 1. The analysis of the HAQ-DI categories revealed that patients in the current 
study reported the greatest amount of difficulty with performing activities in the categories 
usual activities (i.e. shopping, doing chores, get in and out of a car) and reaching (i.e. bending 
down to pick up clothing from the floor, reach and get down a 5 pound object from above 
your head). Mean HAQ-DI scores for these categories were 1.61 and 1.58 respectively (Figure 
3). More than half of the patients reported to have “much difficulty” with performing these 
activities. Patients reported the least amount of difficulty with performing activities in the 
category dressing and grooming (dress yourself, shampoo your hair) as this category obtained 
the lowest mean (SD) HAQ-DI score i.e. 0.86 (0.66). Thirteen percent of the patients reported 
to have “much difficulty” with performing these activities.
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Figure 2. SF-36 physical and mental component summary and subscale scores of 147 patients with 
generalized osteoarthritis. The bars show the mean scores and standard deviations
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Figure 3. Mean HAQ-DI scores for each HAQ-DI category and the percentage of patients that reported 
to have either no/some difficulty or at least much difficulty with performing everyday activities 
represented for each category
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Activity limitations measured with the PSK
The total number of self-perceived activity limitations and participation restrictions obtained 
with the PSK was 440 (one patient mentioned only two limitations). These were linked to 463 
ICF codes within the area of Activities and Participation of the ICF (d-codes), comprising 30 
unique ICF categories. Of these 463 codes, 316 (68%) pertained to the chapter mobility (d4), 
85 (18%) to domestic life (d6), 27 (6%) to community, social and civic life (d9) and 19 (4%) to 
self-care (d5). The remaining codes pertained to the chapters major life areas (d8), learning 
and applying knowledge (d1) and general tasks and demands (d2). Patients reported a 
broad spectrum of activity limitations and participation restrictions. The ten most frequently 
reported GOA-related activity problems and participation restrictions with corresponding ICF 
codes and mean (SD) severity scores are presented in hierarchical order in Table 2. Activities 
concerning mobility (d4) and domestic life (d6) were most frequently mentioned as being 
important activity limitations by patients with GOA; walking (d450) was most commonly 
reported. The category moving around (d455) can be further specified to the 4th level of the 
ICF as all activities in this category concerned climbing stairs (d4551). The severity of the 
activity limitations and participation restrictions were all above 6.0 with the highest score of 
7.3 (on a 10 points scale) for caring for household objects (d650).
Table 2. Ten most frequently reported activity limitations and participation restrictions with 
corresponding ICF codes and severity scores in 147 patients with GOA. 
ICF code Activity Number of patients (%) Mean (SD) severity
d450 Walking 72 (16) 6.7 (2.1)
d415 Maintaining a body position 59 (13) 6.4 (2.4)
d410 Changing basic body position 52 (11) 7.1 (1.8)
d640 Doing housework 45 (10) 6.9 (1.7)
d455 Moving around 35 (8) 6.5 (2.0)
d430 Lifting and carrying objects 31 (7) 6.1 (2.0)
d440 Fine hand use 28 (6) 6.5 (2.0)
d650 Caring for household objects 27 (6) 7.3 (1.7)
d920 Recreation and leisure 26 (6) 6.1 (2.2)
d475 Driving 20 (4) 6.2 (2.9)
Abbreviations: SD = Standard Deviation
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Discussion
This is the first study that comprehensively describes the health status of patients clinically 
diagnosed with GOA. The results show that GOA has a broad impact on the physical 
component of health. Furthermore, the majority of our patients were moderate to severely 
impaired in performing daily activities. Patients reported a broad spectrum of important 
activity limitations and participation restrictions; activities concerning mobility and domestic 
life were considered as most important activity limitations, especially walking. In addition, 
more than half of the patients reported having “much difficulty” with activities such as 
shopping or doing chores and activities concerning reaching. These results offer starting 
points for clinicians and researchers to improve treatment programs for patients with GOA 
tailored to their needs and problems.
The present study showed that patients with GOA experience a markedly reduced quality 
of life, reflecting a high clinical burden. In particular, the physical component of health was 
affected. The observed level of physical health in the present study is comparable to that of 
patients with chronic, inflammatory arthritis such as rheumatoid arthritis (RA)27,28. Mental 
health was less affected compared to physical health in our study sample. One previous study 
assessed the PCS and MCS scores in a relatively small number of patients with GOA (n = 
30)14, showing comparable scores as obtained in the current study. Our results indicate that 
effective interventions for GOA should be developed focussing on improving the physical 
component of health.
Patients in this study were moderately to severely impaired in performing daily activities as 
reflected by a mean HAQ-DI score of 1.27. This score is considerably higher than the average 
HAQ-DI score of 0.50 observed in Dutch patients with symptomatic OA at multiple joint sites 
participating in the Genetics, Arthrosis and Progression (GARP) study29. In another study 
among Dutch patients with OA (localization not specified) visiting an outpatient rheumatology 
department, a mean HAQ-DI score of 1.00 was reported30. Considering the abovementioned, 
it seems that the functional status of patients with GOA is more affected compared to other 
Dutch OA populations. Comparisons are however hampered by the fact that the patients 
in the current study were a selected group of patients with functional disability who were 
referred to multidisciplinary treatment. However, since our study population represents 
patients seeking help, this is probably the most interesting group for clinicians.
Understanding the nature of GOA related activity limitations and participation restrictions 
might be important to develop treatment targets tailored to the patients’ needs and 
problems. The results of the PSK showed that our patients reported a broad spectrum of 
activity limitations and participation restrictions. Activities involving the lower extremities 
were considered to be the most important activity limitations, especially walking. This finding 
cannot be explained by a predominance of lower limb OA by our patients, but might be 
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due to a high impact of mobility limitations on a patient’s well-being. Moreover, self-care 
limitations were rarely reported as being important activity limitations. This is in contrast 
with the ICF core sets for OA in which self-care activities are assumed to be key issues for 
patients with OA31. Dressing is even one out of three ICF categories of the brief core set for 
OA representing activities that minimally should be addressed when measuring disability in 
clinical studies31,32. Only one of these three activities was identified as an important activity 
limitation in our study. This discrepancy might be due to that we restricted patients to identify 
only three activity limitations. Nonetheless, our results point to the need of developing 
effective interventions to improve mobility, especially walking.
This study has some potential limitations that should be addressed. In this study we used 
a pragmatic definition of GOA in the absence of a widely accepted and validated definition. In 
the literature, the threshold number of affected joints as well as the localization of involved 
joints have been described differently5. Besides, previous GOA definitions mainly rely on 
radiographic findings independent of clinical symptoms, whereas symptoms are likely to be 
more important in functional outcomes33. We are one of the first that defined GOA from a 
clinical rather than a radiographic perspective. Second, due to pragmatic reasons we were 
not able to systematically obtain radiographs of all joint areas of each participant. Since 
we recorded objective signs of OA on the basis of information available in the patient’s 
medical file, it is conceivable that there is an underestimation of the number of joint areas 
with objective OA in our study population. Another limitation is that we did not assess co-
morbidities in this study population. The presence of co-morbidities might have influenced 
the reported functional limitations and quality of life.
In conclusion, we generated empirical data showing a high clinical burden in terms of 
HRQoL and activity limitations in patients clinically diagnosed with GOA. This study contributes 
to the understanding of the deprived health status of individuals with GOA which is warranted 
considering the high prevalence of GOA and the lack of research on GOA. The results point to 
the need of developing effective interventions for patients with GOA to improve the physical 
component of health and to improve mobility, especially walking. Moreover, the broad 
spectrum of activity limitations underlines that treatment should be individualised according 
to the problems of the individual patient.
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Abstract
Objective
To compare the effectiveness of a non-pharmacological multidisciplinary face-to-face self-
management treatment program with a telephone-based program on daily function in 
patients with generalized osteoarthritis (GOA). 
Methods
A pragmatic single-blind randomized clinical superiority trial involving 147 patients clinically 
diagnosed with GOA, randomly allocated to either a six week non-pharmacological 
multidisciplinary face-to-face treatment program comprising seven group sessions or a six 
week telephone-based treatment program comprising two group sessions combined with 
four telephone contacts. Both programs aimed to improve daily function and to enhance 
self-management to control the disease. The programs critically differed in mode of delivery 
and intensity. Daily function (primary outcome) and secondary outcomes were assessed at 
baseline, 6, 26 and 52 weeks. Data were analyzed using linear or logistic multilevel regression 
models corrected for baseline, sex and group-wise treatment.
Results
No differences in effectiveness between both treatment programs were observed on the 
primary outcome (group difference (95% CI): -0.03 (-0.14, 0.07)) or on secondary outcome 
measures, except for a larger improvement in pain in the face-to-face treatment group 
(group difference (95% CI): 1.61 (0.01, 3.21)). Within groups, significant improvements were 
observed on several domains, especially in the face-to-face group. However, these benefits 
are relatively small and unlikely to be of clinical importance.
Conclusions
We found no differences in treatment effect between patients with GOA who followed a non-
pharmacological multidisciplinary face-to-face self-management program and those who 
received a telephone-based program. Besides, our findings demonstrated limited benefits of 
a self-management program for individuals with GOA.
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Introduction
Osteoarthritis (OA) can affect multiple joints, but is most common in the hand, spine and 
the weight-bearing joints i.e. the hip and knee1,2. In recent years, clinically relevant OA 
subpopulations or so called phenotypes have been classified whereby different joint groups 
are generally seen as distinct phenotypes1,3,4. A commonly used and widely accepted 
phenotype is generalized osteoarthritis (GOA)3,4, describing a subset of patients with clinically 
polyarticular OA5. To date, a wide variety of GOA definitions have been described in the 
literature, however no agreed and validated definition is available so far5. Most definitions of 
GOA include at least 3 joints or joint groups, but there is little agreement on the necessity or 
appropriateness of including a specific joint or combination of joints. It has been suggested 
that individuals with GOA might represent a relatively large subgroup of patients with OA. In 
knee OA, approximately 50% of patients can be classified as GOA6-8. 
Several international guidelines for the management of OA are available emphasizing the 
effectiveness of non-pharmacological, non-surgical interventions, such as education, self-
management, weight reduction and exercise therapy9-14. However, these guidelines all focus 
on single joint involvement (i.e. hand, hip or knee), without considering the involvement 
of multiple joints. Recently, the Osteoarthritis Research Society International (OARSI) was 
the first to publish recommendations for the non-surgical management of OA for several 
subpopulations, including multiple joint OA (i.e. OA in other joints in addition to the knee)12. 
However, due to the limited research on the management of multiple joint OA, the authors 
only considered balneotherapy (defined as the use of baths containing thermal mineral 
waters) appropriate for patients with multiple joint OA, whereas no other recommendations 
could be formulated. Yet, it is likely that recommendations for hip and knee OA also apply for 
individuals with GOA.
Considering the substantial group of patients with GOA, the lack of knowledge on the 
non-pharmacological management of GOA and the high physical and psychological burden 
associated with GOA7,8,13,15,16, the development and evaluation of a treatment program for 
patients with GOA is warranted. Therefore, our research group systematically developed a 
non-pharmacological, multidisciplinary face-to-face treatment program for individuals with 
GOA based on recommendations for the management of hip and knee OA14 and tailored to 
the needs of patients with GOA17. Treatment components of the program included education, 
self-management and exercises. Besides, a less intensive telephone-based treatment 
program was developed since increasing evidence shows telephone-based interventions to 
be cost-efficient18 and to improve symptoms and promote lifestyle changes19,20. The aim of 
the current study was to compare the effectiveness of both treatment programs on daily 
function during the first year after treatment. We hypothesized the face-to-face treatment 
program to be superior in effect on daily function, since this program is more extensive and 
more strictly supervised.
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Methods
Study Design 
This study was a pragmatic parallel group, single-blind randomized clinical superiority trial 
comparing the effectiveness of a six week non-pharmacological multidisciplinary supervised 
face-to-face treatment program with a six week telephone-based treatment program on daily 
function in patients with GOA. The effectiveness over one year was examined. Details of 
the trial development and design have been published previously17. The protocol adhered to 
the CONSORT guidelines for non-pharmacological interventions21. The study was performed 
at the outpatient rheumatology departments of the Sint Maartenskliniek Nijmegen and 
Woerden, the Netherlands from January 2010 to April 2014 and was approved by the local 
ethics committee (CMO region Arnhem, Nijmegen) and registered in the Dutch Trial Register 
(trial number NTR2137). All participants signed informed consent prior to the baseline data 
collection.
Setting and participants
During an outpatient visit, patients clinically diagnosed with GOA and referred by their 
rheumatologist for treatment were invited for a screening visit to consider eligibility for 
the trial. Patients were included when: (1) having at least two objective signs indicating 
OA in ≥ 2 joint areas on the basis of the patient’s medical record (objective signs included: 
malalignment, crepitation, limited range of motion, palpable osteophytes or nodules or 
radiographic signs including the presence of joint space narrowing and/or osteophytes); 
(2) having complaints in ≥ 3 out of 8 joint areas (i.e. feet, knees, hips, lumbar spine, neck, 
shoulders, elbows and hands); (3) being limited in the performance of daily activities (Health 
Assessment Questionnaire Disability Index (HAQ-DI) score ≥ 0.5); and (4) motivated to 
alter their lifestyle and willing to participate in a group (assessed by a standardized set of 
questions). Excluded were patients who were: (1) diagnosed with another rheumatic disease; 
(2) awaiting surgery; (3) already participated unsuccessfully in a self-management program; 
(4) having psychosocial problems interfering with the scope of the treatment; (5) incapable of 
coming to the hospital; or (6) unable to write and or understand the Dutch language.
Interventions
The overall goals of both treatment programs were to improve daily function and to enhance 
self-management skills to control the disease. The face-to-face treatment program was 
provided by a multidisciplinary team comprising a physical therapist, occupational therapist, 
specialized rheumatology nurse and dietician. The telephone-based treatment was provided 
by a specialized rheumatology nurse and physical therapist. The most critical differences 
between both treatments were the mode of care delivery, the number of involved healthcare 
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providers, the number of group sessions and the number of sessions including an exercise 
program. For an overview of the content of both programs see Appendix 1. The healthcare 
providers were trained in techniques of motivational interviewing22 and were specialized in 
treating patients with musculoskeletal disorders and teaching self-management principles. 
To standardize both programs, slide presentations for all sessions and manuals for healthcare 
providers and patients were used. Protocol adherence of healthcare providers was maintained 
by meetings during the trial.
Face-to-face treatment group
The multidisciplinary face-to-face program comprised six therapeutic group sessions (6-8 
patients and 2-4 hours) and a group evaluation delivered during six weeks, supervised by a 
physical therapist. In the first session information about the program was given, expectations 
were discussed and patients filled in activity and diet diaries. Information about OA, pain 
management and medication was also provided in this session. Additionally, patients 
participated in a general exercise program to improve the quality of movement and posture 
(i.e. walking, sitting) and to implement exercises in the home situation. This exercise program 
was continued in session two (standing, kneeling, lifting) and three (stair climbing, lying). 
Information on physical activity and activity pacing was given in session two and information 
on food consumption was given in sessions three and four. Furthermore, in session three 
patients were asked to set personal goals regarding pain management, physical activity 
and activity pacing which were closely monitored and discussed in the next three sessions. 
Besides, patients participated in a specific exercise program based on the principles of graded 
activity and tailored to the patient’s health problems in sessions four, five and six. Acceptance 
as a strategy to cope with the disease was discussed in session five. To introduce patients with 
other strategies to manage their symptoms, introduction lessons of tai chi, brisk walking and 
hydrotherapy were given. The program was evaluated in the final session and future personal 
goals were formulated.
Telephone-based treatment group
Patients allocated to the telephone-based treatment attended two face-to-face group 
sessions (6-8 patients) with a duration of 2-2.5 hours and were further monitored by four 
individual telephone contacts (15-30 minutes per contact) with a specialized rheumatology 
nurse. In the first group session, patients were educated about the program, OA, pain 
management, medication, physical activity, activity pacing, food consumption and acceptance 
of the disease. Besides, patients completed activity and diet diaries. During the individual 
telephone contacts, patients set personal goals regarding pain management, physical activity 
and activity pacing which were closely monitored and discussed. The second group session 
included an exercise program tailored to the patient’s health problems to improve the quality 
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of movement and posture and to implement the exercises in the home situation. Besides, 
patient’s personal goals were discussed. The treatment program was evaluated during the 
final telephone contact.
Randomization and blinding
Patients were allocated to the treatment groups (allocation ratio 1:1) by an independent 
person using a computer generated randomization sequence table consisting of randomly 
varied block sizes (2 to 6). Assignments were communicated by e-mail to the outpatient 
clinics and patients were informed by mail. This study has a partly blinded design as due to 
the nature of the interventions neither patients nor healthcare providers could be blinded for 
allocation. The assessor (NC) was blinded for randomization and allocation and the statistical 
analyses were performed blindly. Participants were instructed not to disclose details about 
their group allocation with the assessor. The allocation of healthcare providers was done on 
basis of availability. 
Measurements and outcomes
Primary and secondary outcome measures were collected prior to the start of the treatment 
(i.e. baseline), after finishing the treatment (i.e. 6 weeks) and 26 and 52 weeks after starting 
the treatment. Demographic data were collected at baseline.
Primary outcome measure
The primary outcome measure was daily function measured with the Dutch consensus HAQ-
DI23. The HAQ-DI examines difficulties with the performance of 20 daily activities (classified 
into 8 categories) scored from 0 (without any difficulty) to 3 (unable to do). The highest 
scores of each category are summed and averaged resulting in a disability index ranging from 
0 (no disability) to 3 (very severe disability).
Secondary outcome measures
Health related quality of life (HRQoL) was measured with the Short Form 36 Health Survey 
(SF-36), comprising eight areas of health status and a physical (PCS) and mental component 
summary score (MCS)24. Pain was assessed using the SF-36 bodily pain subscale. Fatigue was 
measured with the eight-itemed “Subjective Fatigue” subscale of the Checklist Individual 
Strength (CIS)25. The patient specific complaints questionnaire (PSK) was administered to elicit 
patient specific and relevant activity limitations26. Patients identified the three most important 
GOA-related functional limitations and scored the severity on a 0-10 scale, with higher total 
scores indicating more severe limitations. Self-efficacy was assessed with the General Self-
Efficacy Scale (GSES)27 and illness cognitions were measured using the subscales acceptance 
and helplessness of the Illness Cognitions Questionnaire (ICQ)28. Pain-related fear for moving 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Effectiveness of two non-pharmacological treatment programs for GOA  |  43
3
was measured with the Tampa scale for kinesiophobia (TSK) with total scores ranging from 
17-68 (higher scores indicating more fear)29. Physical activity levels were measured with the 
Short Questionnaire to Assess Health enhancing physical activity (SQUASH) and presented as 
the number of patients meeting the Dutch recommendation for physical activity (moderate 
physical activity for >30 minutes for 5 days/week)30. Moreover, patients rated their health 
status on a visual analogue scale (EQ VAS) ranging from 0 (worst imaginable health status) to 
100 (best imaginable health status). After finishing the treatment, change in daily function 
was rated on a 7-point Likert transition question ranging from completely recovered to vastly 
worsened. Costs were also assessed, but these results are presented elsewhere.
Study endpoints
The primary endpoint was the difference in mean HAQ-DI score between both treatment 
groups i.e. the average score obtained from the 6, 26 and 52 week time points (long-term 
effect). The six week time point of the HAQ-DI provided a secondary endpoint. Other 
secondary endpoints were the between group differences of the secondary outcome 
measures and the within group differences of all outcome measures. Furthermore, as there is 
no validated outcome measure to asses the health status of patients with GOA, we evaluated 
both programs with a responder analysis using a set of self-constructed responder criteria17 
adapted from the OMERACT-OARSI knee and hip responder criteria31. Patients were classified 
as responder if ≥ 3 of the following 6 areas improved by ≥ 20% (average from the 6, 26 
and 52 week time points): physical function (PSK), pain (SF-36), fatigue (CIS), physical activity 
(SQUASH), acceptance (ICQ) and patient global assessment (PGA) (EQ VAS).
Statistical analysis
We estimated that a sample size of 170 patients was needed to provide a power of 80% 
to show superiority of the face-to-face treatment by at least 0.26 points on the HAQ-DI32, 
assuming a standard deviation (SD) of 0.66, a significance level of 0.05 and a 15% drop-out 
rate17. 
Data were analysed using Stata/IC 13.1. Missing data were estimated using multiple 
imputation by changed equation in order to preserve power and reduce bias33,34. A total 
of 20 imputed data sets were predicted based on all other observed variables. Primary 
analyses were done according to the intention-to-treat (ITT) principle35. Secondary analysis 
included per-protocol analysis excluding major protocol violations (i.e. patients who either 
discontinued treatment, crossed over to the other group or missed >3 sessions). Descriptive 
statistics were used to describe the characteristics of the study population and to explore 
baseline comparability. Data were analysed with a multilevel mixed linear regression model 
with the mean scores obtained from the 6, 26 and 52 week time points as dependent variable 
and treatment group, sex and baseline value as covariates. In order to account for the group-
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wise treatment, group was included as random effect. Scores obtained immediately after 
treatment were also evaluated using the same multilevel mixed linear regression model. 
Within group changes were evaluated by analysing the mean changes scores from baseline 
with associated 95% confidence intervals (CI). The number of responders were analysed 
similar to the continuous outcomes using multilevel mixed logistic regression and were 
presented as odds ratios. No statistical adjustment was made for multiple testing.
Results
Participant’s flow diagram is presented in Figure 1. A total of 236 (70%) patients were 
considered eligible for the trial of whom 158 (67%) were enrolled. Main reasons not to 
participate were having a preference for the face-to-face treatment (n = 46; 59%) or lacking 
confidence towards the telephone-based treatment (n = 24; 31%). Due to time constraints, 
we needed to stop the inclusion after 158 patients out of the targeted 170 patients were 
enrolled. No differences were found between the eligible patients who did not participate 
and the study population with regard to age, whereas there were relatively less women in the 
group of eligible patients (72% vs. 85%, p = 0.01). The majority of participants (n = 116; 73%) 
were included in the Maartenskliniek Nijmegen. Eighty-one participants were allocated to the 
face-to-face treatment and 77 to the telephone-based treatment. Six patients from the face-
to-face group and five from the telephone group were lost before the baseline measurement 
meaning that data from 147 participants were available for the ITT analysis. These drop-outs 
can be explained by the time between inclusion and start of the treatment (up to six weeks) 
due to the group-wise treatment. The percentage of missing data on the primary outcome 
was 0%, 7%, 12% and 14% at baseline, 6, 26 and 52 weeks, respectively. 
Baseline characteristics of the study population are presented in Table 1. The majority was 
female, nearly 90% of patients reported symptoms in both the upper and lower extremities 
and the mean (SD) HAQ-DI score was 1.27 (0.50) for the face-to-face group and 1.26 (0.49) 
for the telephone-based treatment group. There were no relevant differences in baseline 
characteristics between groups. A total of 19 healthcare providers were involved. 
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Excluded (n = 103) 
- Not meeting inclusion criteria (n = 79)   
- Randomization not possible (n = 8) 
- No complaints/no need for help (n = 14) 
- Other reasons (n = 2) 
Invited to participate in trial 
(n = 236) 
Assessed for eligibility  
(n = 339) 
Randomization 
(n = 158) 
Declined (n = 78) 
- Preference for face-to-face group (n = 46) 
- Lack of confidence telephone group (n = 24) 
- Other (n = 8) 
Allocated to face-to-face treatment (n =81) 
 Received treatment (n = 76) 
- Lost to follow-up; no data available (n=1) 
 Did not receive treatment (n = 5) 
- Time constraints/too much effort (n = 4) 
- Referred back to rheumatologist (n = 1) 
Allocated to telephone-based treatment (n = 77) 
 Received treatment (n = 73)  
- Lost to follow-up; no data available (n = 1) 
 Did not receive treatment (n = 4) 
- Time constraints/ too much effort (n = 2) 
- Comorbidity (n = 2) 
6 week follow-up assessment (n = 70) 
 Missing (n = 4) 
 Lost to follow-up (n = 1) 
- No benefit of participating (n = 1) 
 
 
6 week follow-up assessment (n = 67)  
 Lost to follow-up (n = 5) 
- Too much effort (n = 3) 
- Diagnosed with RA (n = 1) 
- Illness partner (n = 1) 
26 week follow-up (n = 68) 
 Missing (n = 2) 
 Lost to follow-up (n = 4) 
- Comorbidity (n = 1) 
- Too much effort (n = 1) 
- Unknown (n = 2) 
 
26 week follow-up (n = 64) 
 Missing (n = 1) 
 Lost to follow-up (n = 2) 
- Too much effort (n = 1) 
- Unknown (n = 1) 
 
52 week follow-up (n = 67) 
 Missing (n = 3) 
 
52 week follow-up (n = 61) 
 Missing (n = 3) 
 Lost to follow-up; comorbidity (n = 1) 
 
Intention to treat analysis (n = 75) 
 Excluded from analysis; no data available (n = 6) 
 
Per-protocol analysis (n = 72) 
 Excluded from analysis (n = 9) 
- No data available (n = 6) 
- Protocol violation (n = 3) 
o Crossed over to telephone group (n = 2) 
o Discontinued treatment (n = 1) 
 
Intention to treat analysis (n = 72) 
 Excluded from analysis; no data available (n = 5) 
 
Per-protocol analysis (n = 67) 
 Excluded from analysis (n = 10) 
- No data available (n = 5) 
- Protocol violation (n = 5) 
o Crossed over to face-to-face group (n = 2) 
o Missed > 3 sessions (n = 2) 
o Discontinued treatment (n = 1)  
Figure1. Flow diagram
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Table 1. Baseline characteristics of participants allocated to the face-to-face and telephone-based 
treatment group
Face-to-face 
treatment 
(n = 75) 
Telephone-based 
treatment 
(n = 72) 
Age, years; mean (SD) 61 (8) 59 (8)
Female; n (%) 64 (85) 61 (85)
Body Mass Index, kg/m2; mean (SD) 28 (5) 28 (5)
Currently employed; n (%) 28 (37) 27 (38)
Number of symptomatic joint areas; median (IQR) 5 (4-6) 5 (4-6)
Localization of symptoms; n (%)
Upper extremities (shoulder, elbow, hand) 68 (91) 66 (92)
Neck/lumbar spine 54 (72) 53 (74)
Lower extremities (hip, knee, foot) 72 (96) 69 (96)
Combination of upper and lower extremities 65 (87) 63 (88)
Daily function, HAQ-DI (0-3); mean (SD) 1.27 (0.50) 1.26 (0.49)
Abbreviations: SD = Standard deviation; IQR = interquartile range; HAQ-DI = Health Assessment 
Questionnaire Disability Index
Primary endpoint
Patients in the face-to-face treatment group showed a larger improvement in daily function 
over one year follow-up compared to the patients in the telephone-based treatment group, 
however this difference was not statistically significant (mean group difference HAQ-DI (95% 
CI): -0.03 (-0.14, 0.07)) (Table 2). The limits of the 95% CI do not reach the predefined relevant 
difference in treatment effect of 0.26 points.
Table 2. Baseline data, mean changes from baseline (95% CI) and mean differences (95% CI) in change 
scores between groups on the primary outcome measure1.
Face-to-face 
treatment 
(n = 75)
Telephone-based 
treatment
(n = 72)
Δ 95% CI Δ 95% CI
Group difference2 
(95%CI)
Daily function (HAQ-DI)
Baseline; mean (SD) 1.27 (0.50) 1.26 (0.49)
Δ 6 weeks -0.03 (-0.11, 0.05) -0.06 (-0.15, 0.03) 0.01 (-0.10, 0.13)
Δ average 1 year -0.06 (-0.14, 0.02) -0.02 (-0.11, 0.06) -0.03 (-0.14, 0.07)
1Results are described as intention-to-treat
2Multilevel mixed linear regression analyses corrected for baseline values, sex and group-wise treatment.
Abbreviations: SD = standard deviation; CI = confidence interval
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Secondary endpoints
At the six week time point of the HAQ-DI, a small, non-significant difference in effectiveness 
between groups was observed (mean group difference (95% CI): 0.01 (-0.10, 0.13)). The upper 
and lower confidence limits exclude a clinically important difference in treatment effect. A 
small significant difference between groups was observed for pain at the long term in favor 
of the face-to-face treatment program, indicating that this program was more effective in 
reducing pain than the telephone-based program (mean group difference (95% CI): 1.61 
(0.01, 3.21)) (Table 3). Directly after treatment, significantly fewer patients in the face-to-
face group met the self-reported Dutch recommendation for physical activity compared to 
the telephone group (odds ratio (95% CI): 0.32 (0.11, 0.97)). Within groups, no significant 
improvements were found on our primary outcome measure. On several secondary outcome 
measures significant, but relatively small improvements were observed at the short and long-
term, especially in the face-to-face group. After one year, 17 (22%) participants in the face-
to-face treatment group and 13 (18%) participants in the telephone-based group fulfilled the 
responder criteria (odds ratio (95% CI): 1.22 (0.50, 3.00)) (Table 4). 
Per-protocol analysis
Per-protocol analysis of the primary endpoint was performed excluding eight protocol 
violators i.e. three participants in the face-to-face group (crossed-over to the telephone-based 
treatment group n = 2, discontinued treatment n =1) and five participants in the telephone-
based treatment group (crossed over to the face-to-face treatment group n = 2, missed > 3 
sessions n = 2, discontinued treatment n = 1). The estimated between group difference of the 
primary endpoint did not change (mean group difference (95% CI): -0.04 (-0.14, 0.07)).
Treatment adherence and adverse effects
The mean number of sessions participants attended was 6.6 (out of 7) in the face-to-face 
group and 5.5 (out of 6) in the telephone-based treatment group. We did not systematically 
assess adverse effects, though patients were encouraged to report adverse effects to the 
supervised healthcare professional. However, no adverse effects related to the treatment 
programs were reported.
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Table 3. Baseline data, mean changes from baseline (95% CI) and mean differences (95% CI) in change 
scores between groups on secondary outcome measures1. 
Face-to-face
treatment
(n = 75)
Telephone-based 
treatment
(n = 72)
Δ 95% CI Δ 95% CI
Group difference2
(95% CI)
Pain (SF-36)
Baseline; mean (SD) 39.60 (7.31) 40.45 (5.81)
Δ 6 weeks 3.19 (1.53, 4.85) 0.96 (-0.76, 2.67) 1.82 (-0.15, 3.80)
Δ average 1 year 2.83 (1.32, 4.33) 0.76 (-0.71, 2.23) 1.64 (0.06, 3.22)
Patient specific function (PSK)
Baseline; mean (SD) 19.81 (5.51) 19.88 (4.17)
Δ 6 weeks -1.16 (-2.44, 0.13) -1.53 (-2.78, -0.28) 0.19 (-1.45, 1.82)
Δ average 1 year -1.87 (-2.93, -0.81) -1.43 (-2.56, -0.29) -0.49 (-1.87, 0.89)
Fatigue (CIS)
Baseline; mean (SD) 36.12 (7.23) 36.13 (7.52)
Δ 6 weeks -1.08 (-3.28, 1.11) -1.04 (-2.76, 0.69) -0.32 (-2.81, 2.17)
Δ average 1 year -2.03 (-3.76, -0.29) -1.10 (-2.73, 0.52) -1.09 (-2.95, 0.78)
Physical function (PCS SF-36)
Baseline; mean (SD) 37.65 (6.65) 37.17 (7.33)
Δ 6 weeks 2.25 (0.64, 3.85) 1.58 (0.11, 3.04) 0.89 (-1.09, 2.86)
Δ average 1 year 1.58 (-0.08, 2.81) 1.13 (-0.32, 2.58) 0.49 (-1.15, 2.12)
Mental function (MCS SF-36)
Baseline; mean (SD) 47.59 (10.31) 47.96 (10.96)
Δ 6 weeks 0.34 (-1.85, 2.52) 0.82 (-1.57, 3.21) -0.37 (-3.36, 2.63)
Δ average 1 year 1.97 (0.12, 3.81) 0.21 (-1.87, 2.29) 1.74 (-0.42, 3.90)
Acceptance (ICQ)
Baseline; mean (SD) 14.52 (3.82) 14.86 (4.21)
Δ 6 weeks 0.93 (-0.01, 1.87) 1.17 (0.32, 2.02) -0.29 (-1.41, 0.84)
Δ average 1 year 1.36 (0.61, 2.12) 0.93 (0.17, 1.70) 0.33 (-0.58, 1.24)
Helplessness (ICQ)
Baseline; mean (SD) 12.65 (3.70) 12.87 (3.32)
Δ 6 weeks -0.41 (-1.18, 0.35) -0.48 (-1.24, 0.28) -0.10 (-1.12, 0.91)
Δ average 1 year -0.61 (-1.26, 0.05) -0.56 (-1.26, 0.13) -0.21 (-1.05, 0.63)
Self-efficacy (GSES)
Baseline; mean (SD) 31.13 (4.48) 31.06 (4.43)
Δ 6 weeks -0.21 (-1.46, 1.04) 0.03 (-1.24, 1.31) -0.11 (-1.79, 1.58)
Δ average 1 year 0.28 (-0.65, 1.21) -0.44 (-1.51, 0.63) 0.84 (-0.44, 2.12)
Kinesiophobia (TSK)
Baseline; mean (SD) 36.60 (7.65) 36.79 (7.05)
Δ 6 weeks -1.34 (-3.27, 0.58) -1.91 (-3.89, 0.06) 0.49 (-2.24, 3.23)
Δ average 1 year -1.41 (-2.95, 0.12) -1.05 (-2.70, 0.60) -0.48 (-2.52, 1.56)
PGA (EQ VAS)
Baseline; mean (SD) 53.84 (17.59) 53.42 (14.70)
Δ 6 weeks 8.43 (3.67, 13.20) 5.22 (0.83, 9.61) 3.26 (-1.14, 7.67)
Δ average 1 year 6.59 (2.63, 10.55) 3.73 (-0.06, 7.51) 3.18 (-0.32, 6.68)
Physical activity (SQUASH)3
Baseline; n (%) 54 (72) 50 (70)
6 weeks; n (%) 50 (67) 58 (80) 0.32 (0.11, 0.97)4
1 year; n (%) 56 (75) 48 (67) 1.55 (0.65, 3.74)
1Results are described as intention-to-treat
2Multilevel mixed linear regression analyses corrected for baseline values, sex and group-wise treatment.
3Number of participants (%) meeting recommendation for physical activity 
4Multilevel mixed logistic regression corrected for baseline values, sex and group-wise treatment, 
presented as odds ratios with associated confidence interval
Abbreviations: SD = standard deviation; CI = confidence interval; PGA = patient global assessment
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Table 4. Patients classified as responder for both treatment groups including odds ratios (95% CI)1
Face-to-face 
treatment 
(n = 75)
Telephone-based 
treatment
(n = 72)
Odds ratio 
(95% CI)
Physical function (PSK) 20 (27) 17 (23) 1.28 (0.51, 3.21)
Pain (SF-36) 15 (20) 9 (12) 1.78 (0.69, 4.63)
Fatigue (CIS) 17 (22) 10 (14) 1.73 (0.66, 4.55)
Physical activity (SQUASH) 28 (37) 27 (38) 0.98 (0.45, 2.13)
Acceptance (ICQ) 23 (31) 22 (30) 1.05 (0.50, 2.27)
PGA (EQ VAS) 26 (34) 23 (32) 1.05 (0.47, 2.33)
Responders2 17 (22) 13 (18) 1.22 (0.50, 3.00)
1Results are the numbers (percentage) unless indicated otherwise
2Patients are considered responder if ≥ 3 of the areas presented in the table improved by ≥ 20%. 
Abbreviations: CI = confidence interval; PGA = patient global assessment
Discussion
This is the first study on the effectiveness of a self-management program for patients clinically 
diagnosed with GOA. We compared the effectiveness of two modes of therapy delivery i.e. 
face-to-face versus telephone. Based on the results, there is insufficient evidence of an 
important difference in effect on daily function between both groups. The results indicate 
absence of evidence because the limits of the 95% CI do not cover the predefined relevant 
change of 0.26 points36. Furthermore, we found no significant differences in effectiveness 
between both groups on the secondary outcomes, except for pain, the face-to-face program 
was more effective in reducing pain at the long-term. Within groups, significant improvements 
were observed on several domains, especially in the face-to-face treatment group, although 
these benefits are relatively small and unlikely to be of clinical importance.
The observed small within group changes indicate an insufficient content of our treatment 
programs to achieve important changes. Nevertheless, both programs comprised numerous 
treatment elements that should be included in self-management programs as recommended 
in international guidelines for the management of OA, like education, exercises and goal-
setting10,37. Probably, our programs addressed too much treatment elements what might 
have hampered patients to pick up relevant information for themselves. In order to achieve 
important changes in daily function, it might be more beneficial to include fewer treatment 
elements. Increasing evidence supports the existence of only small effects of OA self-
management programs as reported in systematic reviews38,39 and clinical guidelines10,37. 
Nevertheless, the importance of self-management is uniformly recognized in international 
clinical guidelines in order to manage the disease effectively10,11,13,37.It is therefore conceivable 
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that recommendations regarding self-management are based on clinical expertise and patient 
values rather than on research evidence.
The choice of our primary outcome measure could be argued. To date, there is a significant 
heterogeneity in outcome measures to evaluate OA self-management interventions and no 
validated outcome measure is available39. Usually, main outcome measures are pain and/
or physical function39. However, self-management programs are often not intended to only 
reduce pain or improve physical function, but typically target on multiple domains of daily 
living. Since there are no validated outcome measures for clinical improvement in GOA, 
we chose the HAQ-DI as primary outcome measure in the current study. However, our 
interventions also targeted other dimensions relevant in GOA, such as pain, fatigue, physical 
activity and acceptance. We therefore evaluated our treatment programs with a responder 
criteria set adapted from the OMERACT-OARSI responder criteria31 including the areas our 
interventions aimed to address. Future research is needed to understand which outcomes 
are most relevant to assess the effectiveness of self-management programs in GOA.
Interestingly, during the inclusion period we observed that many patients preferred 
the face-to-face treatment program and were somewhat reluctant towards the telephone-
based treatment. Ninety percent of the eligible patients who declined to participate did so 
because they preferred the face-to-face treatment. This preference can be supported by a 
study examining the acceptability of face-to-face, internet and telephone treatment delivery 
in primary care, showing the highest level of interest in face-to-face treatment delivery40.
There are some important limitations that need to be addressed. First, this study was 
developed as a pragmatic trial implemented in daily clinical practice, so due to pragmatic 
considerations we did not include a control group receiving no treatment (e.g. waiting list). 
Second, this study involved patients clinically diagnosed with GOA referred for rehabilitation 
which might hamper the generalizability of our findings to other OA populations. In the 
absence of a widely accepted and validated definition of GOA, we used a pragmatic definition. 
Future research is needed to determine an appropriate definition for clinical and research 
use5. Third, as we did not make statistical adjustments for multiple testing, there is a risk 
of positive results arising by chance alone (type 1 error), whereas the small loss of power 
might have increased the chance of a type 2 error. The inclusion proceeded at a lower pace 
than expected as many patients declined to participate because they preferred the face-
to-face treatment group. So, due to time constraints we needed to stop the inclusion after 
158 out of 236 patients agreed to participate. Finally, we did not measure adherence to 
homework assignments in order to ensure blinding to group assignment of the assessor who 
was responsible for the data collection. The success of blinding was however not evaluated.
In this clinical trial we demonstrated no evidence of important differences in treatment 
effect between patients with GOA who followed a non-pharmacological multidisciplinary 
face-to-face self-management program and those who received a telephone-based treatment 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Effectiveness of two non-pharmacological treatment programs for GOA  |  51
3
program. Furthermore, both treatment programs showed small significant improvements on 
several domains, however these are unlikely to be of clinical importance. We also observed 
that many participants preferred face-to-face treatment delivery above telephone delivery. 
The results imply that the choice of treatment delivery can be based on the patients and 
healthcare providers preferences, costs or the availability of facilities and/or healthcare 
systems. Furthermore, our findings contribute to the increasing evidence of the limited effect 
of self-management programs for patients with OA. Future research is needed to understand 
which outcomes are most relevant to assess the effectiveness of GOA self-management 
programs.
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CHAPTER 4
Cost-utility and cost-effectiveness analysis of 
face-to-face versus telephone-based non-pharmacological 
multidisciplinary treatment for patients with generalized 
osteoarthritis
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Abstract
Objective
To evaluate from a societal perspective the cost-utility and cost-effectiveness of a non-
pharmacological face-to-face treatment program compared with a telephone-based 
treatment program for patients with generalized osteoarthritis (GOA). 
Methods
An economic evaluation was carried out alongside a randomized clinical trial involving 147 
patients with GOA. Program costs were estimated from time registrations. One year medical 
and non-medical costs were estimated using cost questionnaires. Quality adjusted life years 
(QALYs) were estimated using the EuroQol classification system, EuroQol rating scale and 
Short Form-6D. Daily function was measured using the Health Assessment Questionnaire 
(HAQ-DI). Cost and effect differences were estimated using multilevel regression analysis and 
cost-effectiveness acceptability curves.
Results
The medical costs of both programs were estimated at €387 and €252, respectively. The 
difference in total societal costs was non-significantly in favour of the face-to-face program 
(difference (95% CI): €708 (€-5058, 3642)). QALYs were similar for both groups according 
to the EuroQol, but were significantly in favour of the face-to-face group according to the 
SF-6D (difference (95% CI): 0.022 (0.000, 0.045)). Daily function was similar according to the 
HAQ-DI. Since both societal costs and effects were in favour of the face-to-face program, the 
economic assessment favoured this program, regardless society’s willingness to pay. For a 
range between €20.000-€80.000 per QALY, there was a 65%-90% chance that the face-to-
face program had better cost utility.
Conclusion
This economic evaluation from a societal perspective showed that a non-pharmacological, 
face-to-face treatment program for patients with GOA was likely to be cost-effective relative 
to a telephone-based program.
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Introduction
Osteoarthritis (OA) is the most prevalent chronic joint disease affecting mainly the hand, 
knee and hip joints1. Next to the health burden, OA represent a significant economic burden 
on individuals, healthcare systems and society with costs accounting for 1%-2.5% of the 
gross domestic product in Western countries2-4. Because OA leads to considerable costs, 
it is important that clinical evaluations of OA interventions are accompanied by economic 
evaluations in order to inform decision makers about the efficiency of healthcare resources 
and to guide healthcare policy and decision processes5,6.
Non-pharmacological, non-surgical interventions like education, self-management, 
exercises and weight reduction have been emphasized as first line treatments for the 
management of patients with OA in international evidence-based clinical guidelines7,8. 
Many trials have demonstrated positive effects of these interventions on the predominant 
symptoms of OA i.e. pain and function9,10. However, high quality evidence of the cost-
effectiveness of non-pharmacological interventions for OA is limited as shown by a recently 
published systematic review on the cost-effectiveness of non-pharmacological, non-surgical 
interventions for patients with hip and knee OA11. Based on the available studies, the authors 
suggested that exercise programs appear to be the best value for money in the management 
of patients with hip and knee OA. Yet, high quality economic evaluations alongside clinical 
studies are needed6,11. 
To date, there have been no economic evaluations of non-pharmacological interventions 
for patients diagnosed with generalized osteoarthritis (GOA). GOA is a widely used and 
accepted OA phenotype describing the often polyarticular nature of OA12. Although it has been 
suggested that individuals with GOA represent a relatively large subgroup of patients with 
OA (e.g. approximately 50% of patients with knee OA can be classified as having GOA)13, OA 
populations are mostly examined for a specific localization of the disease (usually the hands, 
hips or knees) without considering the involvement of multiple joints. As such, research on 
(the management of) GOA is very limited. Recently, we evaluated the effectiveness of a non-
pharmacological multidisciplinary, face-to-face treatment program versus a telephone-based 
treatment program on daily function for individuals with GOA (accepted for publication). That 
study showed small, non-significant differences in effectiveness on daily function and other 
clinical outcomes between both treatment programs. In this article, we present the results 
of an incremental cost-effectiveness and cost-utility analysis of the face-to-face treatment 
program in comparison to the telephone-based treatment program.
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Methods
Study design
We conducted an economic evaluation alongside a randomized single-blind clinical 
superiority trial comparing the effectiveness of a non-pharmacological multidisciplinary face-
to-face treatment program with a telephone-based treatment program for patients with 
GOA. Details of the trial design have been published previously14. The economic evaluation 
was conducted from a societal perspective in accordance with current Dutch guidelines for 
economic evaluations15. The time horizon of the study was limited to the duration of the trial 
(i.e. one year). The study was performed at the outpatient rheumatology departments of the 
Sint Maartenskliniek Nijmegen and Woerden, the Netherlands from January 2010 to April 
2014 and was approved by the local ethics committee (CMO region Arnhem, Nijmegen) and 
registered in the Dutch Trial Register (Trial Register Number NTR2137). All participants signed 
informed consent.
Study population
Patients recently diagnosed with GOA by their rheumatologist and referred for non-
pharmacological multidisciplinary treatment, were screened for eligibility to participate in the 
trial during a screening visit. Patients were included when: (1) having at least two objective 
signs indicating OA in ≥ 2 joint areas on the basis of the patient’s medical record (objective 
signs included: malalignment, crepitation, limited range of motion, palpable osteophytes 
or nodules or radiographic signs including the presence of joint space narrowing and/or 
osteophytes); (2) having complaints in ≥ 3 out of eight joint areas; and (3) being limited in 
the performance of daily activities (Health Assessment Questionnaire Disability Index (HAQ-
DI) score ≥ 0.5). Excluded were patients who were: (1) diagnosed with another rheumatic 
disease; (2) awaiting surgery; (3) having psychosocial problems interfering with the scope 
of the treatment; (4) already participated unsuccessfully in a self-management program; (5) 
incapable of coming to the hospital; and (6) unable to write/understand the Dutch language. 
In total, 158 patients were included. For more details on the study population, we refer to 
the clinical paper.
Treatment programs
The overall goals of both treatment programs were to improve daily function by optimizing 
the patient’s lifestyle and to enhance self-management skills to control the consequences 
of the disease. The contents of the treatment programs were comparable, but several 
critical differences were apparent i.e. the mode of care delivery, the number of involved 
healthcare providers, the number of group sessions and the number of sessions including 
an exercise program. The multidisciplinary face-to-face treatment program comprised seven 
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therapeutic group sessions during six weeks with a total duration of 21.5 hours per patient, all 
performed at the outpatient department. This program was provided by a multidisciplinary 
team comprising a physical therapist, occupational therapist, specialized rheumatology 
nurse and dietician. Main components were education, goal setting with respect to multiple 
domains of daily living and improving self-management skills to cope with the consequences 
of the disease. Additionally, patients participated in a general and individually tailored 
exercise program to improve the quality of movement and to implement exercises in the 
home situation. Patients allocated to the telephone-based treatment program attended 
two face-to-face group sessions at the outpatient clinic, which were further monitored by 
four individual telephone contact moments. This program was provided by a specialized 
rheumatology nurse and physical therapist. The total duration of this program was 5.4 hours 
per patient. Main components of this program were education and goal setting with respect 
to multiple domains of daily living. These goals were closely monitored and discussed during 
the telephone contact moments. In both programs, the involved healthcare providers were 
trained in techniques of motivational interviewing and were specialized in treating patients 
with musculoskeletal disorders and teaching self-management principles.
Outcome measures
Clinical outcome and utility measures
The primary outcome measure of the clinical trial was daily function measured with the 
Dutch consensus HAQ-DI16 assessed at baseline, 6, 26 and 52 weeks. The HAQ-DI examines 
difficulties with performing 20 daily activities, resulting in a disability index ranging from 0 
(no disability) to 3 (very severe disability). The primary endpoint of the clinical trial was the 
difference in mean HAQ-DI score between both treatment programs over one year follow-up 
i.e. the average score obtained from the 6, 26 and 52 week time points. 
We measured utility in three ways. Utility is the valuation of a patients’ health state on a 
scale anchored at 0 (as bad as death) to 1 (full health). Patients described their general health 
status using the EuroQol-5D (EQ-5D)17 assessed at baseline, 6, 13, 26, 36 and 52 weeks. 
From the EQ-5D classification system, a utility index was calculated. The EQ-5D is the most 
commonly used and validated utility measure for use in economic evaluations18. Furthermore, 
patients rated their health status using the EuroQol rating scale (RS) from 0-100, where 0 
indicates worst imaginable health and 100 indicates best imaginable health. The rating scale 
was transformed (TRS) into a utility score using the formula: TRS = 1-(1-RS/100)1.61 19. Quality 
of life was also measured using the widely used and validated Short Form 36 Health Survey 
(SF-36) assessed at baseline, 6, 26 and 52 weeks. This measure was converted into a six-
dimensional health state classification; the Short Form 6D (SF-6D) utility index, describing a 
patient’s health status20. The SF-6D is a more recent instrument which is increasingly used 
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for economic evaluations of clinical interventions18,21. Currently, there is no consensus on 
the best utility measure for use in economic evaluations22. We estimated quality adjusted 
life years (QALYs) for each patient by the area under the EQ-5D, SF-6D and TRS utility curves. 
A QALY integrates effects in terms of both quality of life and the duration of time in such a 
health state and is a frequently used measure for healthcare resource allocation decisions22. 
Costs
In addition to the program costs, during the one year follow-up period, participants reported 
all GOA-related direct medical costs (i.e. healthcare-related) and non-medical costs (i.e. other 
health-related) using cost questionnaires at 6, 13, 26, 39 and 52 weeks23. Prices were generally 
obtained from standard cost prices (including overhead costs) published in the Dutch costing 
guideline designed to reflect societal costs and to standardize economic evaluations15. 
Otherwise, we used published cost prices or market prices. Costs were converted to a 2014 
price level using the price index rate for the Dutch healthcare sector (www.cbs.nl). Because 
the follow-up period of this study was limited to one year, no discounting was applied. 
Costs of both treatment programs
Costs of the treatment programs per patient were estimated using a bottom-up cost price 
analysis, based on time registrations. The medical costs included direct consultation time and 
the indirect time required to prepare sessions and administration time. Program costs also 
included non-medical costs i.e. the patient’s invested time and travel costs. Furthermore, 
costs for accommodation were included. The group-based treatment sessions are assumed 
to take place in gyms, rented at €20 per hour based on market prices. This includes costs for 
materials. 
Medical costs
Direct medical costs included in the current study were costs of GOA-related healthcare 
resource utilization. Resources comprised the number of consultations with all relevant 
healthcare providers (e.g. general practitioner, physical therapist, rheumatology nurse, 
medical specialist etc.), GOA-related hospitalization and type and dose of medication 
used over the period of one year. We computed the costs of healthcare resource use by 
multiplying the price per resource by the number of consultations consumed. To estimate 
the costs of GOA-related surgery, prices of surgical operations were obtained from the Dutch 
Health Authority (www.nza.nl). Type and dose of medication was reported by the patients, 
or otherwise we used the standard daily dose (https://kennisbank.knmp.nl). Purchased 
medication was valued using prices of medication (www.medicijnkosten.nl) plus €6 for each 
purchase other than over-the-counter medications15,24.
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Non-medical costs
The reported healthcare costs included time and travel costs (direct non-medical costs) 
required to visit healthcare providers. Patient time was valued at €12.50 per hour (price for 
informal care) and travel costs at 20 cents per kilometre travelled plus €3 parking costs15. 
Patients reported their means of transportation and travel distance to the healthcare 
resources. Other direct non-medical costs were costs for home care, assistive devices and 
house adaptations. The number of hours of home care or domestic help needed by patients 
was extracted from the questionnaire. Assistive devices at home and house adaptations 
were valued as reported by patients, or otherwise market prices were used. Productivity 
costs assessed in the current study were costs due to absenteeism from paid work. Patients 
reported their working status and absenteeism in the questionnaires. We used the friction 
cost method to calculate the costs of productivity losses, considering productivity loss due to 
absenteeism only for the period that is needed to replace an employee25. Current guidelines 
set this friction period at 23 weeks26. Production loss was valued using age and sex specific 
incomes of the Dutch population taking into account an elasticity of 0.8 between reduced 
labour time and productivity15.
Statistical analysis
Data were analysed using Stata/IC 13.1. Multiple imputation by changed equation was used 
to estimate missing data in order to preserve power and reduce bias27,28. A total of 20 imputed 
data sets were predicted based on available data. Analyses were done according to the 
intention-to-treat principle, meaning that patients were analysed according to randomized 
treatment assignment29. The sample size was based on clinical outcomes14. 
In our economic evaluation, the net benefits of both treatment programs were estimated 
for a range of society’s willingness to pay (WTP) values using the formula: net benefit = 
WTP × effect (QALY or HAQ-DI) – costs30. This net benefit was calculated for each patient 
individually and compared between groups. The more cost-effective treatment program is 
the program with the higher average net benefits, depending on a range of thresholds for 
the society’s WTP. When none of the treatment programs appeared to be dominant (i.e. 
was more effective and less costly), then the incremental cost-effectiveness ratio (ICER) was 
estimated by dividing the difference in mean costs between both treatment programs by 
the difference in mean HAQ-DI score or QALYs gained. Given the statistical uncertainty of 
differences between costs and QALYs, cost-effectiveness acceptability curves (CEAC) were 
constructed to evaluate the probability that the face-to-face treatment program was cost-
effective compared to the telephone-based program, depending on a range of thresholds for 
the WTP for an additional QALY or HAQ-DI point31,32. Differences in costs and QALYs between 
both treatment groups were analysed using multilevel mixed linear regression models with 
mean scores as dependent variable and treatment group, sex and baseline value as covariates 
with group included as random effect. 
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Results
In total, 147 patients were included in the economic evaluation; 75 allocated to the face-to-
face treatment group and 72 allocated to the telephone-based treatment group. The mean 
(SD) age across both treatment groups was 60 (8), 85% of participants were female and ≥ 
90% reported symptoms in both the upper and lower extremities. There were no relevant 
differences in baseline characteristics between groups. On average, 8% of the HAQ-DI 
measurements, 11% of the utility measurements and 12% of the healthcare resource use 
measurements were missing.
Utilities and clinical outcome
Table 1 reports EQ5D, TRS, and SF-6D scores at each time point. For all three utility measures, 
the valuation of health after one year follow-up was more favourable in the face-to-face 
treatment group, however these differences were not statistically significant (Figure 1). 
A statistically significant (p = 0.049) difference in QALYs between both treatment groups was 
observed for the SF-6D (mean group difference (95% CI): 0.022 (0.000, 0.045)). At baseline, 
the mean (SD) HAQ-DI score was 1.27 (0.50) for the face-to-face group and 1.26 (0.49) for the 
telephone-based treatment group. Patients in the face-to-face treatment group showed a 
larger improvement in daily function over one year follow-up compared to the patients in the 
telephone-based treatment group, however this difference was not statistically significant 
(mean group difference HAQ-DI (95% CI): -0.03 (-0.14, 0.07), p = 0.58).
Costs of both treatment programs
The medical costs of the face-to-face treatment and telephone-based treatment programs 
were estimated at €387 and €252 per patient, respectively (Table 2). Including the non-
medical costs, the total program costs were estimated at €762 per patient for the face-to-face 
treatment program and €358 for the telephone-based treatment program. The higher total 
program costs for the face-to-face program were primarily due to the patients’ time costs. 
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Table 1. Utility scores, quality-adjusted life years (QALYs) and mean differences between both treatment 
groups1
Face-to-face
treatment group
(n = 75)
Telephone-based
treatment group
(n = 72)
Group difference
(95% CI)2
p
EQ-5D utility score
Baseline 0.57 ± 0.25 0.57 ± 0.26 0.000 (-0.081, 0.082) 0.99
6 weeks 0.63 ± 0.24 0.58 ± 0.26 0.048 (-0.026, 0.123) 0.20
13 weeks 0.61 ± 0.27 0.58 ± 0.32 0.030 (-0.050, 0.110) 0.46
26 weeks 0.59 ± 0.30 0.59 ± 0.26 -0.000 (-0.084, 0.082) 0.98
39 weeks 0.59 ± 0.30 0.59 ± 0.31 -0.011 (-0.099, 0.077) 0.81
52 weeks 0.59 ± 0.25 0.57 ± 0.26 0.019 (-0.069, 0.106) 0.67
EQ-5D QALY 0.60 ± 0.21 0.59 ± 0.21 0.012 (-0.042, 0.066) 0.67
TRS utility score
Baseline 0.70 ± 0.20 0.69 ± 0.16 0.009 (-0.042, 0.060) 0.74
6 weeks 0.78 ± 0.12 0.75 ± 0.11 0.033 (-0.007, 0.074) 0.11
13 weeks 0.76 ± 0.12 0.75 ± 0.18 0.012 (-0.035, 0.060) 0.61
26 weeks 0.76 ± 0.14 0.73 ± 0.13 0.025 (-0.022, 0.071) 0.31
39 weeks 0.75 ± 0.20 0.74 ± 0.16 0.007 (-0.044, 0.058) 0.79
52 weeks 0.74 ± 0.15 0.73 ± 0.13 0.015 (-0.039, 0.068) 0.59
TRS QALY 0.75 ± 0.10 0.74 ± 0.09 0.016 (-0.012, 0.044) 0.28
SF-6D utility score
Baseline 0.66 ± 0.10 0.68 ± 0.07 -0.017 (-0.045, 0.012) 0.25
6 weeks 0.69 ± 0.09 0.68 ± 0.08 0.021 (-0.005, 0.047) 0.12
26 weeks 0.69 ± 0.09 0.68 ± 0.09 0.022 (-0.010, 0.053) 0.18
52 weeks 0.70 ± 0.11 0.67 ± 0.10 0.033 (-0.004, 0.074) 0.08
SF-6D QALY 0.69 ± 0.08 0.68 ± 0.07 0.022 (0.000, 0.045) 0.05
1Values are the mean ± SD unless indicated otherwise
2Multilevel mixed linear regression analyses corrected for baseline values, sex and group-wise treatment
Abbreviations: SD = standard deviation; CI = confidence interval
Healthcare resource utilization and costs
The average annual volumes of healthcare and non-healthcare resource utilization, the 
percentage of patients using each resource and the costs per patient are presented for both 
treatment groups in Table 3. Over the one year follow-up period, the difference between 
both randomization groups in total one year non-program medical costs was estimated at 
€780 (95% CI: -2151, 590), non-significantly in favour of the face-to-face treatment group. 
Outside the treatment program, the mean number of sessions with a physical therapist per 
patient was 21 in both groups. Almost all patients purchased medication during the one year 
follow-up period i.e. 100% in the telephone-based treatment group and 97% in the face-
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to-face treatment group. Furthermore, in both groups less than 20% of patients visited a 
dietician.
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Figure 1. Average utility per patient for both treatment groups. 
Abbreviations: EQ-5D = European Quality of life; SF-6D = Short-Form-6D; TRS = Transformed Rating 
Scale 
The difference in total one year non-program non-medical costs between both treatment 
groups was estimated at €393 (95% CI: -3870, 3085), non-significantly in favour of the face-
to-face treatment program. Most of the non-medical costs were attributable to productivity 
losses. Including program costs, the mean total societal costs per patient was estimated 
at €10,324 for the face-to-face treatment program and €11,023 for the telephone-based 
treatment program, meaning a difference in total societal costs of €708 (95% CI: -5058, 3642) 
between both programs in favour of the face-to-face treatment program. This difference was 
not statistically significant.
Cost-effectiveness and cost-utility
The primary economic evaluation of the current study was the cost-utility analysis comparing 
the difference between both treatment groups in total societal costs to the difference in 
QALY based on the EQ-5D14. Because costs as well as QALYs were in favour of the face-to-face 
treatment program (i.e. the face-to-face program dominates the telephone program), the 
net benefit was also in favour of the face-to-face program, regardless society’s WTP (and 
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effectiveness and utility ratios were not estimated). Accordingly, the acceptability curve 
showed a 65 to 70% probability that the face-to-face treatment program was cost-effective 
for any WTP (Figure 2). The difference in net benefit between both programs did not reach 
statistical significance.
In the secondary analyses, cost-utility was also in favour of the face-to-face treatment 
program according to the SF-6D and TRS for all levels of society’s WTP. Since both costs and 
improvement in daily function (i.e. HAQ-DI) were in favour of the face-to-face treatment 
program, this program was more cost-effective, however differences in net benefits were not 
statistically significant. Over all analyses, there was a 65% to 90% chance that the face-to-face 
treatment program was more cost-effective at a range of WTP thresholds between €20.000 
and €80.000.
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Figure 2. Cost-effectiveness acceptability curve showing the probability that the face-to-face treatment 
program is cost-effective compared to the telephone-based treatment program over a range of values 
for the willingness to pay for an additional QALY 
Abbreviations: WTP = Willingness To Pay; EQ-5D = European Quality of life; SF-6D = Short-Form-6D; TRS 
= Transformed Rating Scale; HAQ-DI = Health Assessment Questionnaire Disability Index
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Discussion
We conducted an economic evaluation of two modes of non-pharmacological multidisciplinary 
therapy delivery i.e. face-to-face vs. telephone for patients clinically diagnosed with GOA. 
No differences in effectiveness between both treatment programs were found according 
to the HAQ-DI and EuroQol, whereas QALYs were significantly in favour of the face-to-face 
treatment group according to the SF-6D. The results showed that from a societal perspective, 
the face-to-face treatment program was more likely to be cost-effective. The medical costs 
of both treatment programs were estimated at €387 and €252, respectively. The higher total 
program costs for the face-to-face treatment program were primarily due to the patients’ 
time costs. The total societal costs were lower for the face-to-face treatment program than 
for the telephone-based program, however this difference was not statistically significant. 
The net benefit of the treatment programs was in favour of the face-to-face program, 
regardless society’s WTP. Over all analyses, there was a 65% to 90% chance that the face-to-
face program was more cost-effective at a range of WTP thresholds between €20.000 and 
€80.000 per QALY.
In view of the limited healthcare budgets, economic evaluations of interventions are 
needed to inform decision makers about the efficiency of healthcare resources. Prior to this 
economic evaluation, we expected the face-to-face treatment program to be considerably 
more costly since this program was more intensive and more strictly supervised. However, 
the medical program costs of both treatments were not that different. When accounting 
patients’ time and travel costs, the face-to-face program was more costly. However, from 
a societal perspective, the face-to-face treatment program resulted (non-significant) in 
less costs than the telephone-based program. These results imply that, from the societal 
perspective, the choice of treatment delivery does not have to be based on costs. During 
the trial, patients reported their level of satisfaction with the treatment programs showing 
that patients in the face-to-face group were significantly more satisfied than patients in the 
telephone-based treatment group. Probably, the choice of treatment delivery could be based 
on the preferences of patients and healthcare providers or on the availability of facilities and/
or healthcare systems.
Interestingly, in both treatment groups less than 20% of patients consulted a dietician, 
while the majority of patients (> 70% in both groups) were overweight (body mass index 
> 25 kg/m2). The underutilization of dietary therapy by patients with OA is consistent with 
a previous study investigating the healthcare use of patients with hip or knee OA33. This is 
striking as the impact of weight reduction on the predominant OA-related symptoms i.e. pain 
and function has been well demonstrated34 and is considered to be one of the mainstays of 
rehabilitation for people with knee and hip OA35,36. 
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Currently, no cost-effectiveness studies of non-pharmacological interventions for patients 
with GOA are available, hampering a proper comparison of our results with other studies. 
In patients with hip and knee OA exercise programs appear to be the best value for money, 
as shown in a systematic review11. However, high quality studies were limited. Also in hand 
OA, exercises are the most cost-effective treatment strategy37. Increasing evidence shows 
that non-pharmacological interventions can reduce the need for total joint replacement 
surgery or postpone surgery after more than five years in patients with hip OA38,39. This in 
turn might reduce healthcare costs substantially. Future high quality economic evaluations of 
non-pharmacological interventions for patients with GOA or its effect on the long-term need 
for joint replacement surgery are needed.
A number of methodological issues should be considered. First, the cost data reported 
by the patients were not ascertained by consulting other data sources. Self-reported 
healthcare utilization questionnaires are known to underreport healthcare use, whereby 
the degree of inaccuracy depends on the type of utilization (underreporting of utilization is 
exacerbated by increased utilization)40,41. Furthermore, cost questionnaires are susceptible 
to recall bias, however we tried to reduce recall bias by selecting a recall time frame of at 
most 13 weeks40,41. Second, we restricted the costs to GOA-related direct medical costs and 
non-medical costs. Although we asked participants about their GOA-related healthcare use, 
we are aware that the reported healthcare use cannot be exclusively attributed to GOA. 
No data were available on the utilization of informal care. Another limitation of the current 
study is the relatively small sample size. The clinical trial was powered based on the primary 
clinical outcome measure. Yet, the utility measures we used in the economic evaluation are 
known to be less responsive to measure changes in health status. As a consequence, it is 
possible that our economic evaluation was underpowered, a common limitation of economic 
evaluations conducted alongside clinical trials42. Finally, the generalizability of the study 
findings is restricted to Dutch patients clinically diagnosed with GOA who were referred for 
multidisciplinary treatment in a specialized outpatient rheumatology department. 
In conclusion, this economic evaluation showed from a societal perspective that a non-
pharmacological, multidisciplinary face-to-face treatment program for patients clinically 
diagnosed with GOA was at least twice as likely cost-effective relative to a telephone-based 
treatment program. 
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Abstract
Objective
Generalized osteoarthritis (GOA) is highly prevalent in OA. Individuals with GOA typically 
suffer from limitations of both upper and lower extremity function, yet we lack a validated 
instrument to assess their activity limitations. An appropriate instrument might be the Health 
Assessment Questionnaire Disability Index (HAQ-DI). Therefore, the aim of this study was to 
evaluate the measurement properties of the HAQ-DI in GOA.
Methods
Data were used from a randomized controlled trial comparing the effectiveness of two 
multidisciplinary treatment programs for patients with GOA. One hundred and thirty-
seven of 147 included patients completed a standardized set of questionnaires before 
and after treatment. Interpretability, validity, reliability and responsiveness of the HAQ-
DI were assessed using the Consensus Based Standards for the Selection of health Status 
Measurement Instruments Checklist (COSMIN). 
Results
Floor and ceiling effects were present. The content validity was questionable since the HAQ-
DI encompasses activities that are either not relevant or too easy to perform as judged 
by patients and experts. Construct validity was good since 90% of the hypotheses were 
confirmed. Factor analysis confirmed the unidimensionality of the HAQ-DI (root mean square 
error of approximation = 0.057, χ2/df ratio = 1.48). Cronbach’s alpha was 0.90, confirming 
internal consistency and the ICC was 0.81, reflecting good reliability. The minimal important 
change was 0.25 and the smallest detectable change was 0.60. We could not establish the 
responsiveness of the HAQ-DI. 
Conclusions
The HAQ-DI showed good construct validity, internal consistency and reliability, whereas its 
content validity and responsiveness were limited. We recommend updating the items of the 
HAQ-DI in future research focusing on functional limitations in GOA.
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Introduction
Patient-reported assessments of functional limitations have emerged as an integral part of 
clinical practice and research in osteoarthritis (OA). Numerous self-administered instruments 
(such as the Western Ontario and McMaster Universities Arthritis Index (WOMAC)) are 
available to assess activity limitations in OA1. However, many of these questionnaires focus 
on a specific localization of OA (e.g. hands, hips or knees), limiting their use in the assessment 
of patients with generalized osteoarthritis (GOA). Individuals with GOA typically suffer from 
OA in multiple joints2 resulting in limitations of both upper and lower extremity function. To 
comprehensively assess activity limitations in people with GOA, instruments should contain 
items of both upper and lower extremity function. A growing body of evidence suggests that 
GOA is highly prevalent in patients with OA3,4, yet we lack a validated instrument to assess 
their activity limitations.
An appropriate instrument to measure activity limitations in patients with GOA might 
be the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), as it comprises 
activities of fine movement of the upper extremities, locomotor activities of the lower 
extremities, and activities that involve both upper and lower extremities5. Since the HAQ-
DI has been designed for individuals with rheumatoid arthritis (RA), it comprises activities 
frequently impaired in RA patients. The HAQ-DI could be a useful instrument to assess and 
monitor functional limitations in patients with GOA as well as the two conditions have many 
similarities. In both RA and GOA, pain and stiffness are major symptoms and multiple joints, 
involving the upper and lower extremities, are affected. However, there are also differences, 
such as the pattern of joint involvement. Functional disabilities might therefore differ 
between the two conditions. Therefore an assessment of the measurement properties of 
the HAQ-DI in patients with GOA seems warranted. The aim of this study was to evaluate the 
measurement properties (i.e. interpretability, validity, reliability and responsiveness) of the 
HAQ-DI in patients with GOA.
  
Methods
Study design and participants
The current study was part of a randomized controlled trial comparing the effectiveness of 
two non-pharmacological multidisciplinary treatment programs for patients with GOA. The 
Institutional Review Board of the Radboud University Nijmegen Medical Centre approved the 
study and patients signed informed consent. The complete study design has been described 
previously (Dutch Trial Register NTR2137)2. 
Patients clinically diagnosed with GOA were included when they had at least two objective 
signs indicating OA in two or more joint areas (malalignment, crepitation, limited range of 
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motion, palpable osteophytes or nodules or radiographic signs including the presence of joint 
space narrowing and/or osteophytes); complaints in three or more out of eight joint areas; 
and were limited in daily activities (HAQ-DI score ≥ 0.5). Patients diagnosed with another 
rheumatic disease were excluded2. 
Data collection and procedure
Participants completed a standardized set of questionnaires prior to the start of the 
treatment (baseline) and at 6, 26, and 52 weeks. Data from baseline and the six week 
follow-up were used. Patients were included if they completed the baseline measurement. 
The recommendations of the Consensus-based Standards for the selection of health status 
Measurement Instruments (COSMIN)6 and the quality criteria for measurement properties 
proposed by Terwee et al.7 were followed to assess the measurement properties of the HAQ-
DI.
Outcome measures
Participants completed the Dutch consensus HAQ-DI8 determining difficulties with the 
performance of 20 daily activities scored from 0 (without difficulty) to 3 (unable to do) and 
classified into 8 categories: dressing and grooming, arising, eating, walking, personal hygiene, 
reaching, gripping and usual activities5. The total HAQ-DI score represents a disability index 
ranging from 0 (no disability) to 3 (very severe disability). We did not correct HAQ-DI scores 
for using assistive devices, preventing an overestimation of the patients’ functional disability. 
In addition, we measured quality of life (36-item Short Form Health Survey (SF-36) and 
the EuroQol five-dimension questionnaire (EQ-5D)), fatigue (Checklist of Individual Strength 
(CIS)), self-efficacy (General Self-efficacy scale (GSES)) and illness cognitions (Illness Cognition 
Questionnaire (ICQ)). Patient-specific complaints (Patient Specific Complaints questionnaire 
(PSK)) was measured by asking patients to select the three most important GOA-related 
activity limitations and to score their severity on a 0-10 scale. In the follow-up questionnaire, 
a seven-point Likert transition question was used to measure changes in daily function 
ranging from completely recovered to vastly worsened9.
Interpretability
The scale and category scores of the HAQ-DI were assessed for normality and missing data. 
We assessed floor and ceiling effects at baseline for each HAQ-DI category, which were 
considered present if > 15% of patients scored the worst (3) or best (0) possible score. We 
determined the minimal important change (MIC) score using an anchor-based method10.
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Content validity
We assessed whether the HAQ-DI items adequately represent daily function from both the 
patient’s and health professional’s perspective. We compared the International Classification 
of Functioning, Disability and Health (ICF) codes of all HAQ-DI items presented in a study 
of Stamm et al.11 with the ICF codes of an aggregated list (unpublished observations) 
representing the 10 most important activity limitations reported by patients with GOA. 
Content validity was arbitrarily considered good when all 10 activity limitations were covered 
by the HAQ-DI. Second, we asked 17 health professionals experienced with GOA to estimate 
the relevance of each HAQ-DI item, expressed as the percentage of GOA patients having 
actual difficulty performing that item. Items were considered not relevant when health 
professionals expected items were difficult to perform for ≤ 50% of patients.
Construct validity and responsiveness
We assessed construct validity by testing predefined hypotheses about expected correlations 
between HAQ-DI scores and scores on related measures (convergent), unrelated measures 
(discriminant) or differences between groups (discriminative)7. Since we consider 
responsiveness as a measure of longitudinal validity, we assessed responsiveness in analogy 
with construct validity by testing pre-defined hypotheses using change scores7. In this way, 
responsiveness is independent of the magnitude of a change but measures the quality of 
the measurement instrument. In addition, for our responsiveness analysis we formulated 
two hypotheses on the size of the area under the receiver operating characteristic (ROC) 
curve (AUC)7. An expert group of researchers, health professionals and a rheumatologist 
independently formulated hypotheses that were discussed during a consensus meeting. 
Construct validity and responsiveness were considered positive if > 75% of the hypotheses 
were confirmed7.
Internal consistency and reliability
Confirmatory factor analysis (CFA) was performed using the following thresholds for a good 
model fit: Root Mean Square Error of Approximation (RMSEA) ≤ 0.06, Comparative Fit Index 
(CFI) ≥ 0.95 and χ2/df ratio ≤ 312. Internal consistency was considered adequate if Cronbach’s 
alpha > 0.7. Test-retest reliability was acceptable when the intra-class correlation coefficient 
(ICC
(2,1)
) ≥ 0.70 in stable patients (i.e. patients reported no change on the transition question). 
We determined the limits of agreement as a parameter of agreement13 and we quantified the 
smallest detectable change (SDC = SEM*1.96*√2)7.
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Statistical analysis
Pearson or Spearman Rank correlation coefficients (when appropriate) were computed 
to test the hypotheses. The CFA was conducted using LISREL software (Scientific Software 
International, Skokie, IL, USA). All other analyses were performed using STATA 10.1 (StataCorp, 
College Station, TX, USA). 
Results
Patient characteristics
A total of 147 patients completed the baseline measurement (93%) of whom 137 completed 
the follow-up measurement (93%). The majority of patients remained stable in their daily 
function after 6 weeks (Table 1).
Table 1. Socio demographic and disease related characteristics of 147 individuals with GOA
Patient and disease-related characteristics
Female, n (%) 125 (85)
Age, mean (SD), years 60 ± 8
BMI, mean (SD), kg/m2 28 ± 4.5
Education > 12 years, n (%) 43 (29)
Marital status, married, n (%) 113 (77)
Currently employed, n (%) 55 (37)
Duration of complaints ≥ 5 years, n (%) 110 (75)
Joint areas with symptomatic OA; median (IQR) 5 (4-6)
Localization of symptoms, n (%):
Upper extremities (neck, shoulder, elbow, hand) 138 (94)
Lower extremities (lumbar spine, hip, knee, foot) 145 (99)
Combination of upper and lower extremities 136 (93)
Changes in daily function rated on the transition question, n (%):
Completely recovered 1 (1)
Much improvement 7 (5)
Some improvement 57 (42)
No change 62 (45)
Some deterioration 8 (6)
Much deterioration 2 (1)
Abbreviations: SD = Standard Deviation; IQR = Interquartile Range
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Interpretability
The item “getting in or out of bath” was returned with > 10% missing values. HAQ-DI scores 
were normally distributed with a mean (SD) score of 1.27 (0.50) at baseline and 1.20 (0.47) at 
follow-up. Ceiling effects were present in the categories eating, dressing and gripping, and a 
floor effect was present in the category hygiene. The MIC for improvement was 0.25 points.
Content validity 
Seven of 10 ICF codes representing the most relevant activity limitations for patients with 
GOA were covered by the HAQ-DI items. Activities that were not covered were maintaining a 
body position (d415), recreation and leisure (d920) and driving (d475). Health professionals 
considered nine items of the HAQ-DI relevant for ≤ 50% of GOA patients, whereas 11 items 
were considered relevant for >50% of patients. The least relevant items were: lifting a cup to 
your mouth, shampoo your hair, wash your body and opening car doors. The most relevant 
items were: getting down a 5 pound object from above your head, opening a new milk carton 
and doing chores.
Construct validity and responsiveness
The HAQ-DI showed good construct validity since 9 out of 10 hypotheses (90%) were confirmed 
(Table 2). We were not able to confirm the hypothesized strong correlation between HAQ-
DI scores and the EQ-5D item usual activities since we found a correlation of 0.23. Four out 
of 10 hypotheses (40%) to assess the responsiveness of the HAQ-DI were confirmed (Table 
3). The correlation between change in HAQ-DI scores and change in SF-36 physical function 
scores was weak (-0.20), whereas we hypothesized a moderate correlation because of the 
associated constructs. We could not confirm the hypotheses on the AUC.
Internal consistency and reliability
The initial CFA (with uncorrelated measurement errors between categories) did not meet 
adequate fit criteria. Modification indices provided by LISREL suggested a correlated error 
term between eating and gripping. The modified model resulted in a good fit to the data: 
RMSEA = 0.057, CFI = 0.98 and χ2/df ratio = 1.48. Cronbach’s alpha was 0.90 (lower limit 95% 
CI: 0.88) confirming internal consistency. The ICC
(2,1)
 was 0.81 (95% CI: 0.71, 0.88) reflecting 
good reliability. The Bland-Altman plot showed a mean difference of 0.05 (95% CI: -0.03, 
0.13) between baseline and follow-up and the limits of agreement ranged from -0.54 to 0.65 
points. The SDC was 0.60 points.
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Discussion
This is the first study to comprehensively assess the measurement properties of the HAQ-DI 
in patients clinically diagnosed with GOA. The results showed a questionable content validity. 
The construct validity, internal consistency and reliability were confirmed; however, the 
responsiveness was limited.
Based on the results, we need to question the content validity of the HAQ-DI. Important 
activities frequently impaired in patients with GOA were not assessed by the HAQ-DI. 
Moreover, the ceiling effects suggest that the HAQ-DI measures activities that are either 
not relevant or too easy to perform for patients with GOA, a finding supported in RA. In 
particular, these activities are lifting a cup to your mouth, shampoo your hair and opening 
car doors which were also rated by the health professionals as least relevant. The activity 
getting in or out of bath also seems less relevant given the high number of missing values, a 
result supported in RA14. An explanation for our findings might be that certain activities of the 
HAQ-DI are “outdated” since the questionnaire was developed three decades ago5, a period 
during which some activities have become easier to perform due to technological and social 
developments.
We were not able to confirm the responsiveness of the HAQ-DI. This might be explained 
by the reported floor and ceiling effects in four of eight HAQ-DI categories, a finding 
supported by other studies15. Several studies examining the responsiveness of the HAQ-DI in 
rheumatic diseases showed conflicting results and/or used different approaches14-16. There 
is no consensus on which method is best to assess responsiveness; however, it has been 
recommended that anchor-based methods should be used, as traditionally accepted methods 
(e.g. effect size) measure the magnitude of change rather than longitudinal validity17. An 
important limitation in our responsiveness analysis is the very small number of patients with 
major improvements, which prevents firm conclusions. In addition, there is debate regarding 
the use of transition questions since they are biased by patients’ current status, particularly 
as the time span increases18. To limit recall bias, we decided to use only the six week follow-
up measurement.
The MIC of 0.25 in this study is comparable to that of patients with RA19. The SDC was 
0.60, indicating that important changes cannot be distinguished from measurement error in 
individuals. The HAQ-DI is therefore not suitable to monitor individual GOA patients in daily 
clinical practice.
Some limitations need to be addressed. One could question the extent to which our 
study population adequately represents GOA patients. We used a pragmatic GOA definition, 
as there is no widely accepted definition20. Moreover, we did not assess the WOMAC. We 
considered the face validity of the WOMAC inadequate as it only contains items on lower 
extremity function. However, in future research it would be worthwhile comparing the 
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measurement properties of existing physical function measures in GOA, such as the WOMAC 
or the SF-36, before making a start with developing new measurement instruments assessing 
functional limitations in patients with GOA.
In conclusion, the HAQ-DI showed good construct validity and reliability. Given the 
unsatisfactory content validity, we recommend an update of the items of the HAQ-DI when 
using the HAQ-DI in future clinical practice and research focusing on functional limitations in 
GOA. This update might also be worthwhile for RA and all other rheumatic diseases.
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Assessment and comparison of responsiveness of 
four patient reported outcome measures to assess 
physical function in patients with knee osteoarthritis: 
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Abstract
Objective
The aim of this study was to evaluate the responsiveness of physical function of four disease-
specific patient reported outcome measures (PROMs) in patients with knee osteoarthritis 
(OA) following currently recommended standards.
Methods
Patients with knee OA receiving conservative treatment following a stepped care approach 
at an outpatient clinic were invited to complete a set of questionnaires at baseline and three 
months. Questionnaires included four commonly used measures of physical function i.e. Knee 
Injury and Osteoarthritis Outcome Function Short Form (KOOS-PS), Lequesne Algofunctional 
index (LAI), Lower Extremity Functional Scale (LEFS) and Western Ontario and McMaster 
University Osteoarthritis Index Physical Function subscale (WOMAC-PF). Responsiveness 
of physical function was investigated according to the COSMIN standard by testing 15 a 
priori defined hypotheses and was considered positive if > 75% of the hypotheses could be 
confirmed.
Results
Of the 161 included patients, 61% was female with a mean age of 59.0 years. We could confirm 
12 out of 15 predefined hypotheses (80%) about expected correlations for the WOMAC-PF 
whereas for the KOOS-PS, LAI and LEFS, 11 (73%), 10 (67%) and 11 (73%) hypotheses could 
be confirmed.
Conclusions
This is the first study that comprehensively evaluated and compared the responsiveness of 
physical function assessed with KOOS-PS, LAI, LEFS and WOMAC-PF according to the latest 
standards. Our results suggest that the WOMAC-PF is potentially better able to detect 
changes over time in physical function and therefore should be the measure of first choice in 
clinical trials evaluating the effectiveness of an intervention in knee OA patients.
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Introduction
Knee osteoarthritis (OA) is a common chronic and degenerative musculoskeletal disorder and 
a major cause of reduced physical function1-3. Physical function is therefore one of the core 
outcome dimensions in clinical practice and research in knee OA4. Since no curative treatment 
is currently available for knee OA2, treatment is usually aimed at improving symptoms 
(function, pain, stiffness) using a variety of pharmacological and non-pharmacological 
interventions including surgery5. The effectiveness of such interventions are frequently 
evaluated by clinicians in daily practice and researchers in clinical trials using core outcome 
measures that address the domains of pain and function as advocated6,7. Therefore the ability 
of a measurement instrument to detect changes over time (i.e. the responsiveness) regarding 
the construct being measured8-10, is of particular importance when selecting an instrument.
Several disease-specific patient reported outcome measures (PROMs) are available 
to evaluate physical function in patients with knee OA. Among those, the Lequesne 
Algofunctional index (LAI) and the physical function subscale of the Western Ontario and 
McMaster University Osteoarthritis Index (WOMAC-PF) are recommended as measures of 
first choice in OA trials11,12. Recently, two new disease specific measures have been developed 
to evaluate physical function in patients with knee OA: the short version of the Knee disability 
and Osteoarthritis Outcome Score (KOOS-PS)13 and the Lower Extremity Functional Scale 
(LEFS)14. So far, no studies have examined the responsiveness of these latter instruments and 
compared them head-to-head in a single study.
A large number of definitions and methods have been proposed for assessing 
responsiveness, but the most adequate method to evaluate responsiveness is still under 
debate in the literature15. There is growing consensus that responsiveness should be 
considered as a measure of longitudinal construct validity since responsiveness refers to 
measuring changes in the construct to be measured. In accordance, responsiveness should, 
analogue to construct validity, be evaluated by testing predefined hypotheses about expected 
correlations between changes in (un)related measurements or expected differences in 
changes10,12. With this approach, the validity of the change scores can be assessed in contrast 
to the magnitude of the change score as assessed with traditionally accepted methods such 
as effect sizes (ES) or standardized response mean (SRM)15. These latter methods are known 
to be related to the treatment effect, rather than the quality of a measurement instrument.
To our knowledge, no studies evaluated the responsiveness of PROMs assessing physical 
function by postulating a priori hypotheses using the Consensus-based Standards for the 
selection of health status Measurement Instruments (COSMIN) methodology in patients with 
knee OA in a head to head comparison. In the current study we compared the responsiveness 
of physical function of the disease-specific PROMs KOOS-PS, LAI, LEFS and WOMAC-PF in 
patients with knee OA by testing predefined hypotheses about expected correlations 
between changes in measurements or expected differences in changes. 
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Methods
Participants and intervention
Recruitment to the study took place between July 2012 and January 2014. Consecutive 
patients referred by orthopedic surgeons to a specialized knee and hip OA rheumatology 
outpatient clinic were invited for this cohort study. All patients fulfilled the American College 
of Rheumatology clinical OA criteria16,17 and were invited the day after their first outpatient 
visit to our department. The main exclusion criterion was: short term indication (within 3 
months) for knee replacement surgery. The local Medical Research Ethics Committee, region 
Arnhem-Nijmegen (The Netherlands) approved the study design (study number 2012/375). 
All patients signed informed consent.
Stepped care approach
All patients received multimodal conservative treatment based on a published Dutch 
multidisciplinary stepped care approach for diagnosis and treatment of knee and hip OA18. 
At the rheumatology outpatient department, during a 90 minute group visit (4-6 patients) 
led by a physician assistant and a specialized nurse and supervised by a rheumatologist (as 
described elsewhere19) patients received education, physical therapy (referral for both aerobic 
and strengthening exercises according to the graded activity principle), step up analgesics 
guided by a patient’s pain level (change of policy regarding pain medication was considered 
in case of pain > 4 on a numeric rating scale), life style advice concerning physical activity 
and advice on weight loss in patients with a BMI ≥ 28. In this group visit, most components 
of individual visits were retained such as private one-to-one conversations, while creating 
more time for patient education and discussion20. If prescription of analgesics was considered 
necessary, we started with paracetamol (acetaminophen) in a fixed dose of thrice a day 1000 
mg. In case of lack of efficacy of recent consistent use of paracetamol, a non-steroidal anti-
inflammatory drugs (NSAID) was added. After 4 weeks patients were contacted by telephone 
and if necessary the analgesics were switched.
Data acquisition
At baseline and at three months, patients completed a standardized set of questionnaires 
including socio-demographic information (age, sex, duration of complaints, and localization 
of symptoms). The set of questionnaires included four disease-specific PROMs to measure 
physical function. Other outcome measures included in the set of questionnaires were derived 
from hypotheses that were a priori postulated by an expert group (see responsiveness). A 
reminder was sent to those patients who did not respond within three weeks. Patients were 
included in the analysis of the current study if they completed both the baseline and follow-
up measurement.
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Patient Reported Outcome Measures (PROMs)
Knee injury and Osteoarthritis Outcome Physical Function Short Form (KOOS-PS)
The 7-item short measure of physical function (KOOS-PS) is derived from the subscale 
“activities of daily living” (four items) and “sport and recreation” (three items) of the KOOS13. 
With every item, patients rate the degree of difficulty they have experienced over the previous 
week due to their knee pain on a 5-point Likert scale (0-4). Raw scores can range from 0-28 
which were converted to normalized scores ranging from 0-100 with a score of 0 indicating 
no difficulty. The KOOS-PS has shown to be valid and reliable in knee OA13,21-23. 
Lequesne Algofunctional index (LAI)
The LAI is an 11-item questionnaire measuring the degree of functional disability24 with 4 
questions pertaining to activities of daily living. The total score can range from 0-24 points. 
The degree of functional disability corresponds with the following scores: a score ≥ 14 points 
indicates extremely severe disability, a score of 11-13 indicates very severe disability, a score 
of 8-10 severe disability, a score of 5-7 indicates moderate disability and a score of 1-4 
indicates minimal disability. The LAI has demonstrated good reliability, whereas its validity 
has been questioned25. 
Lower Extremity Functional Scale (LEFS)
The LEFS is a 20-item condition-specific questionnaire designed for use in patients with 
musculoskeletal conditions affecting lower extremity function, including knee OA26. The 
instrument asks patients about their ability to perform general activities of daily living, general 
recreational activities, specific daily physical tasks, and specific recreational or occupational 
related tasks on the day of filling in (0-4). The total score ranges from 0 to 80 points, with 
higher scores representing higher levels of functioning. The LEFS has been shown to be valid 
and reliable in patients with knee OA14,27.
Western Ontario and McMaster University Osteoarthritis Index Physical Function (WOMAC 
PF) 
The KOOS includes the WOMAC OA index in its complete and original format (with permission, 
(www.koos.nu). We used the 17-item subscale Activities of Daily Living (Likert scale version) 
from the KOOS to calculate the WOMAC physical function (WOMAC-PF) score (and thus four 
items are overlapping with the KOOS-PS). Standardized scores, ranging from 0-100 were used, 
where higher scores reflect better health status. The WOMAC has been the most extensively 
studied instrument in individuals with knee OA and has shown to be valid and reliable28.
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Patient’s assessment of change
In the follow-up questionnaire, patients were asked to rate the extent to which their daily 
function and pain had been changed since the start of the treatment on a 7-point Likert scale, 
i.e. very much worsened, much worsened, slightly worsened, no change, slightly improved, 
much improved and very much improved.
Other patient related outcome measures
In addition to the abovementioned PROMs, patients were asked to rate their functioning 
and pain in the preceding week on a 0-10 point Numeric Rating Scale (NRS) where 0 equals 
no symptoms. The patient global assessment (PGA) of knee OA impact during the last week 
before visit was assessed on this NRS scale as well. Moreover, physical function and mental 
health were measured with corresponding subscales of the Short Form 36 Health Survey 
(SF-36), a widely used generic health status questionnaire comprising eight areas of health 
status, with higher scores indicating better health (range 0-100)29,30. Fatigue was measured 
with the 8-itemed “Subjective Fatigue” subscale of the Checklist Individual Strength (CIS)31. 
The total score can range from 8-56 points where scores of ≥ 35 represent severe fatigue. 
Self-efficacy was assessed with the Dutch General Self Efficacy Scale (DGSS)32 and higher 
scores, ranging from 10 to 40, reflect higher self-efficacy. Pain coping was assessed with the 
Pain Coping Inventory List (PCI)33, which is a 33-item questionnaire and measures active and 
passive pain coping strategies on a 4-point Likert scale ranging from ‘hardly ever’ to ‘very 
often’. Higher scores on the subscales active or passive coping indicate more use of an active 
or passive coping style. The Hospital Anxiety and Depression Scale (HADS) was used to assess 
anxiety and depression34-36. Both subscales consist of 7 items with possible scores ranging 
from 0 to 21 for each subscale. Higher scores indicate higher levels of disorder.
Responsiveness
The Consensus-based Standards for the selection of health status Measurement Instruments 
(COSMIN) and the quality criteria for measurement properties as proposed by Terwee et al. 
were followed for the assessment of responsiveness9,10. We defined responsiveness as the 
ability of an instrument to detect changes over time in the construct to be measured9,15. 
Since we considered responsiveness as a measure of longitudinal validity, the basic approach 
we used to assess responsiveness was to postulate and test predefined specific hypotheses 
formulated by an expert group in analogy to construct validity9. These a priori defined 
hypotheses addressed expected correlations between changes in scores on the KOOS-PS, 
LAI, LEFS and WOMAC-PF with changes in scores on other clinical (un)related measures (pain, 
mental health, fatigue, self-efficacy, coping, anxiety and depression) or expected differences 
in correlation in changes between groups. In this way, responsiveness is independent of 
the magnitude of a change but measures the quality of the measurement instrument. We 
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installed an expert group consisting of researchers, epidemiologists and physical therapists 
with published studies on OA and well versed with the current literature providing PROMs 
and a rheumatologist with clinical and research experience in the field of knee OA. Members 
of the expert group independently formulated hypotheses that were discussed in a group 
meeting until consensus was reached. In addition, we added one hypothesis on the size of the 
area under (AUC) the receiver operating characteristic (ROC) curve10, measuring the ability 
of a questionnaire to distinguish patients who have and have not changed, according to an 
external anchor. We calculated the ROC curve for the improved patients using the change in 
physical function scores of the PROMs and the patients’ rating of change in physical function 
assessed by the transition question. The rating of change was dichotomized to identify 
patients that were (very) much improved in physical function and remained stable (slightly 
improved, not changed, slightly worse). A correlation of -0.3 ≤ r ≤ 0.3 was considered weak, 
whereas a correlation of r > 0.3 or r < -0.3 was considered moderate. An AUC of at least 
0.70 was considered adequate10. Responsiveness was considered positive if > 75% of the 
hypotheses were confirmed10.
Statistical analysis
The distributions of the study variables were inspected. Descriptive statistics were provided as 
mean and standard deviation (SD) or median and interquartile range (IQR) when appropriate 
for continuous variables and numbers with percentages for categorical variables. Descriptive 
statistics were used to describe the study population. Paired t-tests were used to compare 
baseline with three-month values. First, the scale scores of the KOOS-PS, LAI, LEFS and 
WOMAC-PF were assessed for normality and missing data. We assessed floor and ceiling 
effects for each questionnaire at baseline which were considered present if > 15% of the 
patients scored the worst or best possible score, respectively. Pearson or Spearman rank 
correlation coefficients when appropriate were computed to test the hypotheses. ROC curves 
were estimated for the change in KOOS-PS, LAI, LEFS and WOMAC-PF to distinguish between 
patients who indicated to be (very) much improved and who indicated to be stable in physical 
function after 3 months. All analyses were performed using STATA 13.1. 
Results
Patient characteristics
In total, we invited 272 patients to participate in the current study of whom 185 (68%) 
completed the baseline measurement. Of these patients, 161 (87%) completed the follow-up 
measurement and were included in the current analysis. No differences were found between 
the participants and non-participants with regard to sex, whereas the group of participants 
had a significantly higher age than the non-participants (59 years vs. 56 years, p = 0.02). 
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The majority of the cohort consisted of women (61%), with a mean (SD) age of 59 (9.3) 
years and BMI of 29.7 kg/m2 (SD 5.0). The demographic and disease related characteristics 
at baseline are presented in Table 1. Scores of the KOOS-PS, LAI, LEFS and WOMAC-PF were 
normally distributed at both baseline and follow-up. At the scale level of the abovementioned 
instruments, there were ≤ 5% missing values at both time points. Ceiling or floor effects were 
not present regarding the measures of KOOS-PS, LAI, LEFS and WOMAC-PF.
Three month follow-up
For the whole group of patients, the majority of the PROMs remained stable after 3 months, 
but significant improvements were observed in physical function measured with the KOOS-
PS (p=0.03) and for fatigue (assessed by the CIS, p=0.03). The majority of patients (n=129, 
80.6%) indicated on the transition question that they had remained stable in their daily 
function after 3 months (Table 1). Fourteen (8.8%) patients indicated (very) much worsening 
in their physical function. The 17 patients (10.6%) who indicated (very) much improvement, 
showed significant improvements in physical function after 3 months in all four disease-
specific PROMs compared with baseline (p<0.05) (Table 2) and in most of the other assessed 
PROMs (NRS function, NRS pain, NRS PGA, physical function SF-36, mental health SF-36, 
fatigue, passive coping and depression, data not shown).
 
Responsiveness
Table 3 presents the correlation coefficients between changes in physical function in the four 
PROMs and changes in scores on related and unrelated constructs. We could confirm 12 out 
of 15 predefined hypotheses (80%) about expected (or absence of) correlations using the 
WOMAC-PF. The responsiveness of the WOMAC-PF could therefore be established as >75% 
of the hypotheses were confirmed (Table 4). For the KOOS-PS, LAI and LEFS, respectively 
11 (73%), 10 (67%) and 11 (73%) hypotheses were confirmed and the 75% according to 
our definition of positive rating for responsiveness was not reached. For all four PROMs, 
we were unable to confirm the hypothesized weak correlation between change in physical 
function and change in NRS pain since we found a moderate correlation ranging between 
0.33 and 0.49 (hypothesis 2). Concerning hypothesis 12, for three of the four questionnaires, 
we were unable to confirm the hypothesized weak correlation between change in physical 
function and transition in pain since we found a moderate correlation above 0.33, except for 
the KOOS-PS where the weak correlation with transition in pain was confirmed (r=-0.28). In 
addition, for all questionnaires we were unable to confirm a higher strength of correlation 
between change in physical function with change in NRS function than between change in 
physical function and change in NRS pain (hypothesis 13).
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Table 1 Socio-demographic and disease-related characteristics of 161 patients with knee OA1
Socio-demographic characteristics
Female; n (%) 99 (61)
Age, years; n (%) 59 (9)
Body Mass Index (BMI), kg/m2 29.7 (5.0)
Localization of symptoms:
Left knee; n (%) 39 (24))
Right knee; n (%) 56 (35)
Both sides; n (%) 66 (41)
Duration of complaints > 5 years 59 (37)
PROMs regarding physical function
KOOS-PS (range 0-100) 53.6 (16.8)
LAI (range 0-24) 11.0 (4.0)
LEFS (range 0-80) 40.6 (14.1)
WOMAC-PF (range 0-100) 51.8 (19.4)
Other PROMs
NRS function (range 0-10) 5.5 (2.4)
NRS pain (range 0-10) 5.6 (2.1)
NRS PGA (range 0-10) 5.6 (2.6)
Physical function (SF-36) (range 0-100) 31.8 (9.1)
Mental health (SF-36) (range 0-100) 39.8 (4.7)
Fatigue (CIS) (range 8-56) 34.4 (11.8)
Self-efficacy (DGSS) (range 0-100) 32.3 (5.0)
Active coping (PCI) (range 0-4) 2.3 (0.5)
Passive coping (PCI) (range 0-4) 2.0 (0.4)
Anxiety (HADS) (range 0-21) 6.0 (4.4)
Depression (HADS) (range 0-21) 5.8 (3.8)
Changes in daily function rated on the transition question
Very much improved 4 (2.5)
Much improved 13 (8.1)
Slightly improved 28 (17.5)
No change 59 (36.9)
Slightly worsened 42 (26.3)
Much worsened 13 (8.1)
Very much worsened 1 (0.6)
1Values are the mean (SD) unless indicated otherwise.
Abbreviations: KOOS-PS = Knee Injury and Osteoarthritis Outcome Physical Function Short Form; LAI = 
Lequesne Algofunctinal index; LEFS = Lower Extremity Functional Scale; WOMAC-PF = Western Ontario 
and McMaster University Osteoarthritis Index; NRS = Numeric Rating Scale; PGA = Patient Global 
Assessment; SF-36 = Short Form 36 Health Survey; CIS = Checklist Individual Strength; DGSS = Dutch 
General Self Efficacy; PCI = Pain Coping Inventory; HADS = Hospital Anxiety and Depression Scale.
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Only for the WOMAC-PF we could confirm the stronger correlation between change in physical 
function with transition function than the correlation with transition pain (hypothesis 14). 
The LAI, LEFS and WOMAC-PF showed a good ability to distinguish patients who were (very) 
much improved and who were stable in physical function with an AUC of ≥ 0.7 (Figure 1). 
For all four PROMs, we were unable to confirm the hypothesized weak correlation between change 
in physical function and change in NRS pain since we found a moderate correlation ranging between 
0.33 and 0.49 (hypothesis 2). Concerning hypothesis 12, for three of the four questionnaires, we 
were unable to confirm the hypothesized weak correlation between change in physical function and 
transition in pain since we found a moderate correlation above 0.33, except for the KOOS-PS where 
the weak correlation with transition in pain was confirmed (r=-0.28). In addition, for all 
questionnaires we were unable to confirm a higher strength of correlation between change in 
physical function with change in NRS function than between change in physical function and change 
in NRS pain (hypothesis 13). Only for the WOMAC-PF we could confirm the stronger correlation 
between change in physical function with transition function than the correlation with transition pain 
(hypothesis 14). The LAI, LEFS and WOMAC-PF showed a good ability to distinguish patients who 
were (very) much improved and who were stable in physical function with an AUC of ≥ 0.7 (Figure 1).  
 
Figure 1. ROC curves showing the sensitivity and 1-specificity of the change in four PROMs assessing 
physical function in patients who indicated to be (very) much improved compared with patients who 
indicated to be stable after 3 months. 
Abbreviations: KOOS-PS = Knee Injury and Osteoarthritis Outcome Physical Function Short Form; LAI = 
Lequesne Algofunctinal index; LEFS = Lower Extremity Functional Scale; WOMAC-PF = Western Ontario and 
McMaster University Osteoarthritis Index  
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Figure 1. ROC curves showing the sensitivity and 1-specificity of the change in four PROMs assessing 
physical function in patients who indicated to be (very) much improved compared with patients who 
indicated to be stable after 3 months.
Abbreviations: KOOS-PS = Knee Injury and Osteoarthritis Outcome Physical Function Short Form; LAI = 
Lequesne Algofunctinal index; LEFS = Lower Extremity Functional Scale; WOMAC-PF = Western Ontario 
and McMaster University Osteoarthritis Index
Discussion
This is the first study that comprehensively assessed and compared the responsiveness of 
the disease-specific PROMs KOOS-PS, LAI, LEFS, and WOMAC-PF to assess physical function 
in patients with clinical knee OA. According to the COSMIN standard we tested predefined 
hypotheses about expected (or absence of) correlations between changes in constructs. 
Our results suggest that the WOMAC-PF is potentially better able to detect physical function 
changes over time in patients with knee OA than the KOOS-PS, LAI and LEFS.
The strengths of our study are that a stringent study protocol was developed and that an 
anchor-based approach was used to assess responsiveness with 15 predefined hypotheses 
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according the latest COSMIN standard. Secondly, the responsiveness of four PROMs was 
measured at the same time in the same population of patients with knee OA undergoing the 
same treatment, which increases the comparability between the four PROMs9,12,37. Results 
of previous studies assessing responsiveness were based on traditional methods, e.g. ES 
and SRM which are known to be dependent of the kind of intervention. This could explain 
the inconsistency of previous findings on the responsiveness of PROMs assessing physical 
function in knee OA. For example: the LAI has been found to be more responsive than the 
WOMAC-PF in patients with knee OA following exercise therapy and rehabilitation25,38, whilst 
the WOMAC-PF subscale was found to be more responsive after hip or knee replacement39, 
but not superior to the LEFS40. Because the responsiveness measured with the COSMIN 
standard is expected not to impact differently in different interventions, further research is 
warranted to assess, preferably in a head-to-head comparison, whether our results are valid 
for other interventions as well.
Contrary to our hypotheses, for all four PROMs, the strength of association of changes 
in physical function with changes in NRS pain and transition in pain was stronger than 
hypothesized. Whether physical function and pain can be assessed independently with 
PROMs is much debated14,27,40-43. Our findings suggest that the PROMs examined in this study 
suffer from construct contamination when assessing physical functioning. A previous finding 
from our research group that the LEFS can discriminate better between these two constructs, 
could not be confirmed in the current study. It has been suggested that performance-based 
physical functioning is less influenced by pain than self-reported physical functioning44 and, 
thus, that performance-based measures are probably better than questionnaires to capture 
the construct of physical functioning. So far, there is little insight in the measurement 
properties of performance-based measures in knee OA43,45,46. Further research addressing 
the added value of performance-based measures above questionnaires to measure physical 
function in knee OA is warranted. Further research to measure physical function is warranted.
There were some limitations in this study. Firstly, a response shift could have influenced 
our results, although we deemed a time frame of 3 months long enough to detect 
improvement and brief enough to minimize the risk of a response shift47,48. Secondly, because 
of the homogenous population, the results of our study seem to be reserved to patients with 
symptomatic knee OA in secondary care. Nevertheless, our cohort is comparable with other 
cohorts, consisting mainly of obese women with knee OA49,50. In addition, because we studied 
the responsiveness head-to-head, it is unlikely that our sample characteristics could have 
influenced the results of the comparability between the four PROMs. Finally, fewer patients 
than expected indicated (very) much improvement in their daily function after 3 months19. 
Although the COSMIN standard stresses that responsiveness is independent of the magnitude 
of the change, it is possible that the relatively small number of improved patients could have 
influenced the strength of the correlations we found. This warrants further research.
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In conclusion, our results suggest that the WOMAC-PF should be the measure of first 
choice in clinical trials evaluating the effectiveness of an intervention to assess physical 
function in patients with knee OA.
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Abstract
Objective
To enhance guideline-based non-surgical management of hip or knee osteoarthritis (OA), a 
multidisciplinary, stepped care strategy has been implemented in primary care in a region 
of the Netherlands. To facilitate this implementation, the self-management booklet “Care 
for Osteoarthritis” was developed and introduced. The aim of the booklet was to educate 
patients about OA, to enhance the patient’s active role in the treatment course, and to 
improve the communication with healthcare providers. To successfully introduce the booklet 
on a large scale we assessed barriers and facilitators for patients to using this booklet.
Methods
Seventeen primary care patients with hip or knee OA who received the self-management 
booklet participated in this qualitative study using semi-structured interviews. Purposive 
sampling was used to ensure diversity of the patients’ view about the booklet. The interviews 
were transcribed verbatim and analysed using a thematic analysis approach.
Results
Three core themes with patient perceived barriers and facilitators to use the booklet 
emerged from the interviews: 1) the role of healthcare providers, 2) the patient’s perceptions 
about OA and its manageability, and 3) the patient’s perceptions about the usefulness of the 
booklet and patient’s information needs. Regarding the first theme, a barrier was the lack 
of encouragement from healthcare providers to use the booklet in the treatment course of 
OA. Moreover, patients had doubts concerning the healthcare providers’ endorsement of 
non-surgical treatment for OA. Barriers from the second theme were: thinking that OA is not 
treatable or that being pro-active during the treatment course is not important. In contrast, 
being convinced about the importance of an active participation in the treatment course was 
a facilitator. Third, patients’ perceptions about the usefulness of the booklet and patients’ 
information needs were both identified as barriers as well as facilitators for booklet use.
Conclusions
This study contributes to the understanding of patient perceived barriers and facilitators to 
use a self-management booklet in the treatment course of OA. The results offer practical 
starting points to tailor the implementation activities of the booklet nationwide and to 
introduce comparable educational tools in OA primary care or in other chronic diseases. 
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Introduction
Osteoarthritis (OA) is the most common joint disorder and the major cause of chronic 
musculoskeletal pain and disability in elderly worldwide1. About 18.0% of women and 9.6% of 
men older than 60 have symptomatic OA; its prevalence is increasing due to the increased life 
expectancy2. General practitioners (GPs) are frequently consulted by patients with hip or knee 
OA. The core treatment for OA, a combination of pharmacological and non-pharmacological 
treatment modalities such as weight management and exercise are mainly performed in 
primary health care3,4. The success of those interventions are often related to adequate self-
management, therefore international guidelines stress the importance of self-management 
in OA5. Self-management refers to interventions, training, and skills with which patients with 
a chronic condition can learn how to effectively take care of themselves6. In the last decade, 
a growing number of studies have examined the effectiveness of self-management programs 
for OA, with some studies showing improvements in pain and disability7-9.
One strategy to enhance self-management in the treatment of chronic diseases is the use 
of patient booklets. Based on the evidence-based, multidisciplinary, patient-centred, stepped 
care strategy for hip or knee OA i.e. BART (Beating osteoARThritis)10, a patient-friendly self-
management booklet “Care for Osteoarthritis” (Zorgwijzer Artrose©)11 was systematically 
developed in collaboration with OA patients and GPs12 and introduced in primary health 
care in a region of the Netherlands. This booklet consists of three sections. The first section 
provides information about OA in general and gives an overview of the healthcare providers 
involved in OA care. The second section provides information about non-surgical evidence-
based treatment options for hip and knee OA and its optimal sequence in three steps which 
is based on the stepped care strategy for hip or knee OA. To enhance the patient’s active 
role in the treatment of OA as well as the communication with healthcare providers, the 
third section of the booklet contains tools to monitor symptoms, to evaluate the effect of 
treatment, to prepare consultations, and to formulate a comprehensive overview of the 
treatment options that already have been carried out. To successfully introduce this booklet 
on a large scale, we should evaluate its implementation among the stakeholder group of end 
users, i.e. the patient13. 
Several studies have demonstrated the outcome of using patient booklets in the 
management of a chronic disease with small improvements in physical activity14, 
knowledge15-17, and health status outcome17-22. These studies also showed low dissemination 
rates of the booklets19,21,22, which could be an explanation for the relatively small effects 
that were found. Although one study examined potential barriers for the introduction of a 
diabetes passport using focus groups, participants in that study had never actually used the 
booklet23. To our knowledge, no studies comprehensively described why patients do or do 
not use such booklets in the treatment course of a chronic disease. 
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Previous qualitative studies have explored barriers for patients to use other non-surgical 
management recommendations for OA, such as physical exercise24-28 or medication24,28. 
Commonly identified barriers that limit the patients’ use of these recommendations were 
patients’ perceptions about OA and its symptoms25-27,29 and patients’ expectations regarding 
the benefits of non-surgical treatment for OA25-29. However, barriers and facilitators for 
patients to use a self-management booklet in OA still seems to be unknown. 
The aim of this qualitative interview study was to evaluate the introduction of the booklet 
“Care for Osteoarthritis” by 1.) exploring how patients used the booklet and 2.) identifying 
patient reported barriers and facilitators to use the booklet. This knowledge can then be 
used as starting points to implement the booklet nationwide and to introduce comparable 
educational tools in OA primary care or in other chronic diseases.
Method
Study Design
A qualitative research approach was used in order to explore patient perceived barriers and 
facilitators to use the booklet “Care for Osteoarthritis”30. We conducted semi-structured 
interviews31 guided by theoretical concepts of a broad health-related behaviour model; 
i.e. the Integrated Change (I-Change) model32. This qualitative approach offers patients the 
opportunity to present their views in their own words about the use of the booklet and 
allow them to address themes of which the researchers might not be aware of. Written 
informed consent from participants to record the interview was obtained prior to the start 
of the interview. The Institutional Review Board of the University Medical Centre, Nijmegen 
approved the study (protocol number: 2012/133). 
Participants
We invited a sample of patients who had participated in an umbrella project that aims to 
implement the stepped care strategy for hip and knee OA in primary care in a region of 
the Netherlands and to evaluate the implementation process (i.e. the BART-project)10. In this 
broader project executed from August 2010 to March 2013, a cohort of 313 patients who 
visited their primary care general practices with a new episode of hip or knee complaints due 
to (symptomatic) hip or knee OA were included by their GP. To implement the stepped care 
strategy, several implementation activities aligned to patients as well as different healthcare 
providers were developed, performed and evaluated in the BART-project33,34. Patients 
received the booklet “Care for Osteoarthritis” from their GP or from one of the researchers 
and were instructed on how to use it. Every six months for two years quantitative data 
were collected by patient-reported questionnaires to identify the patient’s health seeking 
behaviour and health status. Considering the large individual variation in the course of OA 
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symptoms and the likelihood that the patient would consult the booklet during a period 
characterized by complaints, we approached the participants for this qualitative study 12 
months after they had received the booklet. To ensure diversity of the patients’ view about 
the booklet, purposive sampling was used to identify potential participants. We randomly 
selected participants based on their answer to the question included in the questionnaire of 
the BART-project one year after baseline: “Do you use the booklet “Care for Osteoarthritis”?” 
(yes, regularly / yes, occasionally / yes, but not in the past six months / no, never). Except the 
category “yes, regularly”, we selected patients in blocks from all the other categories. We 
were not able to include patients in the category “yes, regularly” as only one patient selected 
that answer in the questionnaire but refused to participate in this qualitative study.
Data collection
Data collection took place between 12 and 18 months after distributing the booklet through 
semi-structured interviews at the participants’ homes. Two female researchers (AS, NC) 
working at the rheumatology research department of a specialized hospital in the Netherlands 
conducted the interviews. The equipment we used to record the interviews provided 
both audio and video tapes. However, before the start of the data analysis we decided for 
pragmatic reasons to use only the audio tapes. Alternately, one of the researchers guided the 
interview and asked the questions, while the other researcher made field notes. In two cases, 
the partner of the participant was present during the interview. Both researchers were also 
responsible for the data collection in the BART-project; no other relationship existed with the 
participants prior to the interviews. 
An interview guide with open-ended questions was developed (Table 1) with topics that 
were derived from a broad behavioural model i.e. the I-Change model. This model postulates 
that behaviour is the result of a person’s intention which is in turn influenced by four factors: 
motivational factors (e.g. attitudes, social influences, efficacy), awareness factors (e.g. 
knowledge, risk perceptions, cues to action), information factors (e.g. quality of messages 
or sources used) and predisposing factors (e.g. personality, environment)32. We selected the 
I-Change model as the theoretical framework for the current study as we aimed to identify a 
broad spectrum of barriers and facilitators for patients to use the booklet. Since the I-Change 
model incorporates insights of several behavioural models, its integrated nature made it 
feasible to explore a broad spectrum of potential barriers and facilitators. The interview guide 
was structured around four constructs of the I-Change model: behaviour (i.e. booklet use), 
motivation factors (i.e. attitude towards the booklet and OA, efficacy to use the booklet), 
awareness factors (knowledge about OA, severity of OA, self-management) and information 
factors (i.e. information received from healthcare providers). In addition, we were interested 
if patients had suggestions for improvement of the booklet. We did not ask patients about 
their current intention with regard to using the booklet as patients were interviewed 12 
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months after they had received the booklet; predisposing factors were already assessed 
by the questionnaires of the BART-project. The co-authors reviewed the questions for both 
content and format. The use of an interview guide ensured that the main issues related to 
the model would be discussed. The questions had an open-ended format to provide patients 
with the scope to talk about their experiences and perspectives freely and in their own 
words. Three pilot interviews were held, which led to an adjustment in the wording of the 
questions. The number of interviews performed was determined by consensual agreement 
of the researchers that analytical saturation had been achieved i.e. the coding process (as 
described below) revealed no new information35.
Table 1. Interview guide
Behaviour Do you use the booklet?
How do you use the booklet?
Motivation Why do you use (or not use) the booklet?
Are you interested in information about OA and the treatment options?
What do you think about the booklet?
Awareness What do you know about OA and the treatment options? 
How severe are your symptoms in daily life? 
What can you do to influence OA symptoms?
Information What did your healthcare provider tell you about the booklet when you 
received it?
Did you ever discuss the booklet with a healthcare provider?
What did healthcare providers tell you about OA?
Suggestion for improvement Do you have any suggestions to improve the booklet?
Data analysis
To analyse the data, a thematic analysis approach was used in order to systematically organize 
the data and then to identify repeated patterns (themes) across the data with regard to the 
research question36. First, each interview was transcribed verbatim to facilitate transparency37. 
The interview transcripts were carefully read by the researchers who also conducted the 
interviews to ensure validity of the transcripts. Subsequently fragments of meaning within 
the text in relation to the research question were coded after each interview had taken place. 
To increase the reliability of the coding process triangulation of researchers was used: both 
researchers independently coded the interviews. Afterwards, the two researchers compared, 
discussed, and, if necessary, adjusted their coding. All interviews were analysed with support 
of the qualitative analysis software program MAXQDA®10 (VERBI software GmBH, Germany) 
to order the data. Further analysis was conducted after all the interviews were coded. 
The two researchers grouped similar codes together into sub-themes, which in turn were 
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organized and clustered together into core themes. As the analysis progressed, the constant 
comparison and review of the data yielded a number of core themes and sub-themes. During 
this iterative process, these core themes became the basis for the exploration of barriers 
and facilitators in the patients’ use of the booklet. Peer debriefing was used: the emerging 
themes were discussed with the co-authors and an expert in qualitative research (FdB). 
Results
Participants
Twenty-six patients were approached by telephone to participate in the study. Of those, nine 
refused to participate because they either did not believe that they could give meaningful 
information that would contribute to the research question (n= 5) or were not comfortable 
with being interviewed (n= 4). Five of these nine non-participants had reported in the 
questionnaire of the BART-project that they had never used the booklet. Interviews were 
conducted with 17 patients, of whom 12 were women and 5 men, with a median age of 67 
years (52-85) (Table 2). Median Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) score was 77 (55-94). The median interview duration was 35 minutes (20-58). Due 
to a technical defect, the audio and video tapes of one interview were missing; field notes of 
this interview were used for analysis. All other data were complete.
 
Booklet use
The data analysis showed that the booklet was used in different manners: some patients only 
read the booklet while others used the self-management tools in the third section of the 
booklet. Based on the interviews, we categorized patients according to their booklet use; we 
determined which patients were actual ‘users’ (i.e. made notes in the booklet, brought the 
booklet to the consultation with a healthcare provider, or used the tools), which ‘readers’ 
(i.e. only read the booklet), and which ‘non-users’ (i.e. neither read nor used the booklet). 
The answers presented below illustrate the difference in how users, readers and non-users 
responded to the questions regarding their booklet use.
8 (u): “For me the booklet serves as a mnemonic device. When I read the booklet, I mark 
important information and discuss this with the GP during a consultation.”
10 (r): “I only read the booklet once and then put it away. After that I have never used the 
booklet.”
6 (n): “I never read the booklet.”
According to the abovementioned categorization, the study population included four users, 
eight readers, and five non-users. Patients’ answer to the question “do you use the booklet” 
varied across the method of administration i.e. questionnaire or interview (Table 2). For 
the categorization of booklet use we decided to use all the information gathered by the 
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interviews, rather than the information obtained from the self-report questionnaires of the 
umbrella project, because in the interviews patients received room to explain and clarify the 
utilization of the booklet in more detail. 
Table 2. Characteristics of the 17 participants and their booklet use
Participant 
number
Gender Age Duration 
interview 
(minutes)
Duration of 
complaints 
(years)
OA severity 
(WOMAC)1
Booklet use 
questionnaire2
Booklet use 
interview3
1 F 71 51 >10 71 Ynr R
2 F 85 ? <1 73 Ynr U
3 M 67 33 1-5 90 Ynr R
4 M 67 47 5-10 73 N N
5 M 52 30 >10 71 Yo N
6 F 68 45 1-5 82 N N
7 F 63 25 1-5 71 N N
8 M 65 58 1-5 84 Yo U
9 F 69 25 >10 79 N R
10 F 59 22 <1 61 Yo R
11 F 67 24 1-5 94 Ynr U
12 F 60 39 5-10 64 Yo U
13 M 71 55 5-10 55 Yo R
14 F 59 37 >10 89 N R
15 F 71 58 5-10 79 Yo R
16 F 76 20 <1 82 Yo N
17 F 70 23 1-5 77 N R
1 standardized WOMAC scores (from questionnaire). Higher scores indicate worse pain, stiffness, and 
functional limitations
2 categorization based on answers given in the questionnaire
3 categorization based on answers given in the interview
Abbreviations: F = female; M = male; ? = data missing; Ynr = Yes, but not recently; Yo = Yes, occasionally; 
N = Not ever; U = User; R = Reader; N = Non-user
Barriers and facilitators for booklet use
Based on the interviews several patient perceived barriers and facilitators to use the self-
management booklet in OA care emerged from the data analysis (Table 3). These barriers and 
facilitators can be divided into three core themes: 1) the role of healthcare providers, 2) the 
patient’s perceptions about OA and its manageability and 3) the patient’s perceptions about 
the usefulness of the booklet and patient’s information needs.
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Theme 1: the role of healthcare providers
We identified three barriers and a facilitator in booklet use related to healthcare providers. 
First, the majority of patients reported that they had not received any clear information 
about how to use the booklet from their healthcare providers. Among those who had been 
informed to read the booklet, some reported that while having been advised to read the 
booklet, no instructions were given about how to use it. 
7 (n): “The GP did not give me any information about the booklet when I received it.” 
13 (r): “When I received the booklet, the GP only told me to have a look inside.”
Despite the limited information patients had received about the booklet, this did not impede 
some patients from using the booklet.
11 (u): “The GP did not explain how to use the booklet, I figured it out by myself” 
The facilitator for booklet use seems to be the encouragement of healthcare providers to use 
the booklet in the management of OA. One patient reported to be encouraged by the GP to 
use the booklet to monitor symptoms and to discuss this during their consultation.
2 (u): “I take the booklet every time I visit the GP. Together with the GP I fill in the third section 
of the booklet, I monitor my symptoms by using the booklet and I discuss this with the GP.”
None of the other patients reported that they have used the booklet during a consultation 
after receiving it; in short they were neither encouraged to monitor their symptoms using the 
booklet nor asked to bring it to subsequent consultations. One patient even suggested that 
the GP actually discouraged the use of the booklet.
12 (u): “When I tried to discuss the content of the booklet with my GP, he told me that the 
booklet is redundant as they have all the information in the computer.”
Patients reported the limited time during a consultation as a reason for the lack of information 
and the limited encouragement they received from their healthcare providers to use the 
booklet.
4 (n): “The booklet was never discussed with the GP, they do not have time for that, you only 
have ten minutes.” 
Thirdly, patients perceived doubts concerning the healthcare providers’ endorsement of non-
surgical treatment modalities for OA what might be a barrier for booklet use. Such doubts 
were reported by the ’non-users’ in particular.
13 (r): “The GP told me that a total knee replacement was the only option for me. I asked him 
about physical therapy, but he told me it would not be useful for me.” 
6 (n): “The GP told me that it will only get worse, instead of better.”
16 (n): “The orthopaedic surgeon told me that there is nothing we can do.” 
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Theme 2: the patient’s perceptions about OA and its manageability
Analysis of the interviews showed that whether or not patients used the booklet might have 
been influenced by their own perceptions about OA and how to manage it. Barriers to use 
the booklet were patients’ perceptions that OA is not treatable, that their complaints were 
not severe enough, or that being pro-active during the treatment course is not important. 
15 (r): “In my opinion, there is nothing to do about OA. Therefore I do not need any advice.”
14 (r): “For me, the complaints are not very serious. I am doing fine.”
4 (n): “I cannot change anything about OA. The GP is the expert. He knows what to do”. 
On the other hand, a patient’s perception about OA can also be a facilitator: some perceived 
that an active participation was important in the treatment course of OA and therefore used 
the booklet. 
8 (u): “I think I can control the symptoms myself. In my opinion, it is important to know what 
to do, instead of waiting until it gets worse and afterwards regretting that I should have acted 
earlier.”
11 (u): “I think I can minimize the symptoms caused by OA by managing it myself.”
In addition, the patients’ concern about the prognosis of OA seems another facilitator to use 
the booklet.
8 (u): “I think the symptoms will deteriorate rather than improve. I hope it will not get worse 
and I shall make every effort to do so.” 
After having studied the perceptions about OA among the three patient groups, some 
differences can be addressed. Non-users and readers were less positive with respect to the 
extent to which OA is treatable and considered active participation in their own treatment 
course less important, whereas users perceived that active participation is indeed important 
in the management of OA. 
Theme 3: the patient’s perceptions about the usefulness of the booklet and patient’s 
information needs
This theme refers to patient perceptions about whether the booklet can be a useful tool in 
the management of OA as well as to patient information needs; both could serve as either 
barriers or facilitators. Some patients believed that the booklet is not a useful tool or were 
not aware of the aims of the booklet. As a consequence, these patients did not read or use 
the booklet. 
6 (n): “I have not read the booklet. In my opinion the booklet is not useful as it will not change 
anything about my complaints.” 
In contrast, patient’s perceptions about the usefulness of the booklet might also be a 
facilitator as some patients thought that the booklet provided the opportunity to make a 
comprehensive overview of the treatment options that already have been tried (referring to 
the third section of the booklet) or that it makes information accessible. 
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Table 3. Overview of the patient reported barriers and facilitators to use the self-management booklet
Theme 1: role of healthcare providers
Barriers Lack of clear information about how to use the booklet given by the healthcare providers
Lack of encouragement from healthcare providers to use the booklet in the treatment 
course of OA
Patients’ doubts concerning the healthcare providers’ endorsement of non-surgical 
treatment modalities for OA
Facilitator Encouragement from healthcare providers to use the booklet in the treatment course of 
OA
Theme 2: patient’s perceptions about OA and its manageability
Barriers Patients’ perceptions of OA as inevitable or not curable
Patients’ perceptions that the complaints due to OA are not severe enough
Thinking that being pro-active during the treatment course is not an effective strategy to 
control the disease course
Facilitator Being convinced of the importance of an active participation in the treatment course of 
OA
Theme 3: patient’s perceptions about the usefulness of the booklet and patient’s information 
needs
Barriers Patients’ perceptions that the booklet is not a useful tool to manage their OA or not 
being aware of the aims of the booklet
Having already sufficient knowledge about OA or sufficient support from healthcare 
providers
Not willing to know everything about OA or not paying any attention to OA
Facilitators Patients’ perceptions that the booklet is a useful tool to manage their OA 
Lack of knowledge about OA or being interested in having more information
1 (r): “This tool creates a clear overview of all received treatment options for all healthcare 
providers.
8 (u): “An advantage of the booklet is that you can read it as many times you want. You have 
all the time to read it. I already have read it three or four times.”
The second barrier and facilitator are the patient’s information needs. Patients were not 
willing to seek information as they believed that they already knew the information found in 
the booklet, did not want to know everything about OA, did not pay any attention to their OA, 
or felt to be sufficiently supported by their healthcare providers.
4 (n): “I definitely do not want to know everything about my disease.”
17 (r): “The booklet is not an appropriate tool for me, I ignore having OA. Only if you are 
convinced of really having OA, then the booklet might be useful.” 
9 (r): “I do not use the booklet, as I have adequate support from my GP, physical therapist, and 
physician assistant.”
On the other hand, information needs of the patient also serve as facilitators: some patients 
believed that their knowledge about OA was insufficient or were interested in having more 
information and, therefore, read or used the booklet. 
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8 (u): “I had little knowledge about OA. Therefore, I considered it important to learn more.”
In this theme differences between users, readers and non-users could also be addressed. In 
particular, the non-users did not perceive the booklet to be very useful, whereas readers or 
users did. Some readers and non-users were not willing to seek information whereas users 
were interested in more information. 
Discussion
To our knowledge, this is the first qualitative study that provides insight into patient perceived 
barriers and facilitators to use a self-management booklet in the treatment course of OA. 
Three core themes with barriers and facilitators emerged from the interviews. Regarding the 
first theme, a barrier to use the booklet was the lack of encouragement from healthcare 
providers to use the booklet in the treatment course of OA. Moreover, patients had doubts 
concerning the healthcare providers’ endorsement of non-surgical treatment for OA. In 
contrast, encouragement from healthcare providers to use the booklet was a facilitator. 
Barriers from the second theme were: thinking that OA is not treatable or that being pro-
active during the treatment course is not important, whereas being convinced of the 
importance of an active participation was a facilitator. Third, patients’ perceptions about the 
usefulness of the booklet and patients’ information needs were both identified as barriers as 
well as facilitators for booklet use.
Before discussing the results, some limitations need to be addressed. First, it is important 
to recognize that the patients’ perceptions might not coincide with their own or their 
healthcare providers actual behaviour. We did not cover the healthcare providers’ perceptions 
about the booklet because this study was restricted to patients, while barriers and facilitators 
can also act at other levels of the health care system13. Second, we did not include patients 
who reported to use the booklet regularly in the questionnaire of the BART-project. During 
the current study, only one patient reported to use the booklet regularly but refused to 
participate as the patient believed not being able of giving meaningful information. Moreover, 
the patients answers to the question “do you use the booklet” were inconsistent between 
the questionnaires and interviews. We categorized booklet use based on the interviews as 
we considered these answers most valid because in the interviews we were able to explore 
in more detail how patients used the booklet. Although this could have resulted in missing 
relevant barriers or facilitators, we believed this was not very likely as the data collection was 
continued until analytical saturation was achieved. Another limitation might be recall bias, 
particularly in the non-users as patients were interviewed 12 to 18 months after receiving 
the booklet. Finally, the identified themes present some of the reasons for patients with OA 
to make use of a self-management booklet, other themes could emerge due to differences in 
ethnic background, culture or healthcare systems.
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According to the interviewed patients, they received little encouragement from their 
healthcare providers to use the booklet: patients reported that healthcare providers gave 
no or few instructions regarding how to use the booklet, did not encourage booklet use, and 
did not refer to it in subsequent consultations. This finding is in line with a study examining 
booklet use in hypertensive patients; only 10% of these patients were asked by their GP about 
the booklet after receiving it22. Patients in our study perceived lack of consultation time as 
an explanation for the limited encouragement they received; probably practice nurses could 
be involved38. Another explanation might be that patients have low expectations regarding 
the GP’s encouragement of the booklet what prevented patients from discussing the booklet 
as has been shown in a study on the implementation of a diabetes passport23. Nonetheless, 
our results imply that patients need information and encouragement from their healthcare 
providers to use the booklet in the management of OA. 
Interestingly, patients in our study reported doubts concerning the healthcare providers’ 
endorsement of non-surgical treatment modalities for OA. It has been shown in previous 
qualitative studies that GPs and rheumatologists consider existing non-surgical treatments 
insufficiently effective, with a total knee replacement as ultimate and only efficient treatment 
option24. Rosemann et al.39 showed that GPs hardly tried to motivate patients to change their 
behaviour to effectively manage OA, as GPs considered its success rate too low. The doubts 
of patients in our study concerning the healthcare providers’ views of non-surgical treatment 
for OA might have hindered patients to use the booklet as the healthcare provider’s attitudes 
and beliefs can affect the patients’ perceptions40 and preferences for treatment41,42. Recently 
it has been shown that attitudes of healthcare providers remain a major barrier for patients 
to be more actively involved in their treatment course43. A more explicitly expressed positive 
attitude of healthcare providers towards the benefits of non-surgical treatment for OA might 
encourage patients to use the booklet.
Patient’s reluctance to use the booklet might have been caused by the patient’s 
perceptions of OA as inevitable or not curable, a barrier also found in studies examining the 
patients’ use of other non-surgical OA recommendations24,27,28. Some patients in our study 
perceived that being pro-active is not an effective strategy to control the disease course. In 
a study on illness perceptions it has been stated that patients create their own beliefs about 
whether the illness is controllable or curable, which determines self-management behaviour44. 
Considering this, healthcare providers should explore the patient’s illness perceptions before 
introducing the booklet and if considered inadequate, the perceptions should be discussed in 
order to improve booklet use. However, it should be noted that, despite additional guidance, 
the booklet might not be an appropriate tool for every patient. For example, some patients 
tend to leave the control of their disease to powerful others (the doctor knows best) and do 
not want to be involved in making decisions regarding their treatment43,45-47; these patients 
might benefit from a more direct approach such as verbal instruction. 
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The results suggest that some patients did not perceive the booklet as a useful tool to 
manage OA and therefore did not use it. Perhaps the lack of instructions given in the booklet 
itself is a contributing factor. Besides, the need for information varied among patients. Some 
patients were not interested in reading or actively searching for information. These findings 
are supported in studies on factors influencing patient’s reading and seeking of written 
information, showing that the patients’ lack of interest in seeking information was associated 
with their coping styles45,46. For example, some patients search for all kinds of information, 
whereas others avoid information48. Therefore, healthcare providers need to move from a 
‘one size fits all’ method of providing information to a more patient specific approach that 
considers the unique needs of each patient. 
Conclusions
Given the above mentioned findings, patients need encouragement from their healthcare 
providers to use the self-management booklet in the treatment course of OA, as patients 
legitimise non-use of the booklet by the lack of encouragement given by their healthcare 
providers and by their perceived doubts concerning the healthcare providers’ endorsement 
of non-surgical treatment for OA. Moreover, patients’ illness perceptions, perceptions about 
the usefulness of the booklet and patients’ information needs are important factors in booklet 
use. This study contributes to the field of primary health care by understanding barriers and 
facilitators for patients to use a self-management booklet in the treatment course of OA. 
The results offer starting points to tailor the implementation activities of the booklet “Care 
for Osteoarthritis” on a large scale or to introduce comparable tools in OA primary care or in 
other chronic diseases. 
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Abstract
Objective
To develop a consensual list of the most important aspects of activity pacing (AP) as an 
intervention within the context of non-pharmacological rheumatology care. 
Methods
An international, multidisciplinary expert panel comprising 60 clinicians and/or healthcare 
providers experienced with AP across 12 different countries participated in a Delphi survey. 
Over four Delphi rounds, the panel identified and ranked the most important goals of AP, 
behaviours of AP (the actions people take to meet the goal of AP), strategies to change 
behaviour in AP and contextual factors that should be acknowledged when instructing AP. 
Additionally, topics for future research on AP were formulated and prioritized.
Results
The Delphi panel prioritized 9 goals, 11 behaviours, 9 strategies to change behaviour and 10 
contextual factors of AP. These items were integrated into a consensual list containing the 
most important aspects of AP interventions in non-pharmacological rheumatology care. Nine 
topics for future research on AP with the highest ranking were included in a research agenda 
highlighting that future research should focus on the effectiveness of AP interventions and 
on appropriate outcome measures to assess its effectiveness, as selected by 64% and 82% of 
the panellists, respectively.
Conclusion
The diversity and number of items included in the consensual list developed in the current 
study reflect the heterogeneity of the concept of AP. This study is an important first step in 
achieving more transparency and homogeneity in the concept of AP in both rheumatology 
daily clinical practice and research.
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Introduction
Activity pacing (AP) is a recommended non-pharmacological, non-surgical intervention for 
the management of rheumatic diseases in international clinical guidelines1-3. In daily clinical 
practice, AP frequently emerges as a primary component of self-management programs 
within the context of multidisciplinary treatment4-6. Furthermore, AP has been shown to 
be the advice most frequently given by British and Dutch rheumatology nurses to patients 
with rheumatoid arthritis (RA)7. It is one of the self-management strategies most frequently 
applied by patients with a variety of rheumatic conditions8-12. However, despite its wide 
endorsement in clinical practice, to date AP is still a poorly understood concept with a wide 
variety in definitions, interpretations and methods of delivery13-15. 
In research and clinical rheumatology practice, AP is mainly based on the principle of 
energy conservation, assuming that individuals with a chronic disease have limited energy 
resources and therefore need to undertake activity regulation to allow completion of valued 
activities16. However, the widespread use of AP in rheumatology care is purely pragmatic 
as stated in a recently published review describing the current knowledge on AP16. There 
is a large variation in goals and AP behaviours (the actions people take to meet the goal of 
AP) proposed in the literature5,15,17,18. Also in chronic pain, in which AP is a central concept 
in theories and treatment, there is no consensus on the interpretation of AP due to a wide 
variety in how AP has been described (e.g. operant conditioning vs. energy conservation)14,16,19. 
Recently, various attempts have been made to clarify the concept of AP in the chronic pain 
literature16,20. In general, AP has now been conceptualized as an intervention whereby 
individuals balance activity and rest in order to maintain or increase physical function and to 
participate in necessary and valued activities16,20,21.
The implications of a poor conceptualization of AP are significant in both research 
and rheumatology practice14. Due to differences in conceptual constructs of AP, empirical 
evidence of the effectiveness of AP is limited and contradictory14,22. In addition, diversity in 
perspectives among therapists on what AP is and how it should be applied as an intervention 
might impede an effective management of the disease14,23. Considering this, we assume the 
initial issue in research on AP in rheumatology care is to clarify this poorly defined concept. 
Nielson et al.16 concluded that identifying the goal(s) of AP, behaviours of AP, strategies to 
change behaviour in AP (e.g. overactivity or underactivity) and contextual factors influencing 
AP will be a first step towards assessing its effectiveness. 
The aim of the current study was to develop a consensual list including the most important 
aspects of AP interventions related to all rheumatic conditions. An international expert panel 
prioritized the most important aspects for four dimensions of AP (i.e. the goals, behaviours, 
strategies to change behaviour and contextual factors that should be acknowledged when 
teaching AP). This list might be an important first step in achieving more transparency and 
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homogeneity in the concept of AP in both rheumatology clinical practice and research. 
Additionally, a research agenda was developed highlighting topics for future research on AP.
Methods
Study design
As we aimed to develop a consensual list containing the most important aspects of AP 
interventions among international experts, we deemed the Delphi technique to be an 
appropriate method. The Delphi technique is a widely used and accepted iterative multistage 
process to transform expert opinion into group consensus within a certain topic24. This 
method is especially applied when sufficient information or evidence regarding a certain 
topic is unavailable25. Typically, round 1 is used to generate items and involves open-ended 
questions, allowing participants freedom in their responses. Subsequently, these items are 
grouped together and presented to all panellists in a questionnaire form to vote in 2-4 rounds26. 
During this process the range of items is expected to decrease. The local ethics committee 
(CMO region Arnhem, Nijmegen) approved the study (protocol number: 2012/523).
International working group and panel selection
Prior to the start of the current study we appointed an international working group (all co-
authors) consisting of 15 healthcare professionals or clinicians (i.e. 5 physical therapists, 
4 occupational therapists, 3 psychologists, 2 specialized rheumatology nurses and a 
rheumatologist) experienced with teaching AP to patients with a rheumatic disease and/or 
with published studies on AP involving a rheumatic disease, across 12 different countries. 
The working group members participated as panellists and were involved in establishing 
the final study procedures and preparation of the manuscript. Additionally, we asked each 
working group member to nominate at least five individuals (preferably working in their own 
discipline) who were eligible to participate in the Delphi panel (snow-ball technique). To be 
eligible, individuals had to meet one of the following two criteria: 1.) having at least five years 
experience in treating patients with a rheumatic disease or 2.) having a publication record in 
the area of AP involving a rheumatic disease. Potential participants were contacted by e-mail 
to inform them about the study and to request their participation. There is no agreement 
on the optimal panel size for Delphi studies and no clear guidelines exists25,27. Most studies 
use panels of between 15 to 35 experts28. We considered 50 experts sufficient to ensure 
validity of the study results i.e. to cover the entire spectrum of perspectives from healthcare 
providers with different backgrounds and expertise and to allow for drop-outs.
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Data collection
Literature search
We conducted a pragmatic literature search in order to gather available evidence on the 
concept of AP. PubMed was searched for articles published up to July 2013 using the key 
words ((connective tissue diseases[MeSH] OR rheumatic diseases[MeSH] OR musculoskeletal 
diseases[MeSH] OR arthritis) AND (activity pacing OR “energy conservation”)). With this 
search we included all rheumatic conditions. We only searched for energy conservation as 
different term for AP as in rheumatology care AP is mainly based on the principle of energy 
conservation. This search yielded 65 hits. Furthermore, included articles were hand searched 
for additional relevant studies. This literature search was not a systematic review and no 
judgment was made about the quality of the evidence. The results of the literature search 
assisted in defining the questions of the first Delphi round. Based on this search, we identified 
four important dimensions of AP that need to be clarified: i.e. the goal(s) of AP, the behaviours 
of AP, the strategies to change behaviour in AP and contextual factors influencing AP (such as 
environmental factors, personal factors or disease characteristics). We therefore formulated 
the following questions of the first Delphi round, which were first reviewed by the members 
of the working group: 1.) describe all possible goals of AP; 2.) describe all possible behaviours 
of AP; 3.) describe all possible strategies to change behaviour in AP; and 4.) describe all 
contextual factors that should be taken into account when teaching AP. This search did not 
highlight the need of a validated AP measure. Additionally, the literature search was used to 
identify individuals with a publication record in the area of AP involving a rheumatic disease 
who were invited to participate in the Delphi survey.
Delphi survey
The questionnaires of the Delphi rounds were delivered over four rounds by email. Only 
panellists who completed the first round questionnaire were invited to participate in 
the subsequent rounds. When panellists completed the first round questionnaire, non-
completion of a preceding round questionnaire did not prohibit them from contributing 
to subsequent rounds. In order to increase response rates, reminders were sent after each 
Delphi round. The first round was used to generate items. In order to reduce the number of 
items generated in the first round, items of the first round were refined during 3 following 
rounds through merging items with a similar content and prioritizing the most important 
items26,29. Anonymity among experts was maintained throughout all rounds.
Item generation – Delphi Round 1
Following the invitation, individuals who agreed to participate were asked to respond to 
the previous mentioned four open-ended questions. We used open-ended questions in 
order to generate items and to allow participants complete freedom in their responses24. 
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The results obtained in this round were collated and categorized according to their content 
independently by two researchers experienced with qualitative research (NC, CHvdE). During 
a consensus meeting the researchers discussed their categorization until agreement was 
reached. In order to guarantee transparency, we decided not to merge items with a more or 
less similar content in this stage.
Round 2
In the second round, we asked the panellists to rate the appropriateness of each item on a 
scale ranging from 1 (completely inappropriate) to 10 (completely appropriate). Considering 
the abundance of items generated in the first round, we decided to break up the work in the 
second round by asking each panellist to rate the items of only one of the four dimensions 
of AP. In this way we ensured the panellists’ motivation to carefully rank the items and 
minimized the risk for drop-outs. Each dimension was ranked by 15 panellists. To ensure that 
all domains were equally distributed with regard to professional background and country, 
purposive sampling was used to allocate dimensions to the panellists. In order to cover all 
items, panellists were explicitly encouraged to include additional items that were considered 
missing in round 1. Furthermore, to collect the key scientific questions on AP, we asked the 
panellists to formulate topics for further research on AP.
Round 3
In order to significantly reduce the number of items and maintain those considered to be 
‘very appropriate’ by the panellists, items with a median appropriateness score ≥ 8 in round 
2 (arbitrarily defined) and the proposed additional items were subjected to Delphi round 3. 
In this round we asked all panellists to select the 10 items they felt were most appropriate for 
each dimension of AP and the topics for future research, respectively.
Round 4
Prior to the start of the final Delphi round, redundant items were eliminated by merging 
items with a similar content. Two researchers independently merged items (NC, CHvdE). 
Afterwards, the two researchers compared, discussed and finally established the remaining 
items through a consensus meeting. The researchers agreed on the items that could be 
merged. In total, 25 goals, 76 behaviours, 25 strategies, 38 contextual factors and 75 topics 
for further research were merged into 18 goals, 53 behaviours, 20 strategies, 29 contextual 
factors and 56 research topics. The scores of the merged items were combined. Then, 
items selected by <20% of the panellists in round 3 were removed. The remaining items 
were subjected to the final Delphi round. In this final round, we asked panellists to select 
the ten items they felt were most important for each dimension of AP and the research 
topics, respectively, and subsequently to rank those ten items from most important (1) to 
least important (10) within each dimension.
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Ranking of items
After the panellists completed the final Delphi round, we ranked the remaining items in two 
ways: 1.) in order of the number of panellists that selected the item as being important and 2.) 
in order of the weighted sum ranking (0-100%) calculated by giving scores to the ranks given 
by the panellists in the final round i.e. the most important items (rank 1) scored 10 points 
and the least important items (rank 10) scored 1 point. For each item, the weighted rank 
scores were summed and divided by the theoretical maximum score (number of panellists x 
10 points) and expressed as a percentage (100% maximum).
Results
Panellists 
A total of 93 potential panellists were invited to participate in the Delphi survey, of whom 
68 (73%) responded positively to the invitation. Of these panellists, 60 (88%) completed the 
first round questionnaire, whereas eight (12%) panellists only completed the demographic 
questions and were excluded from the current analysis. Demographic characteristics of the 
panellists are summarized in Table 1. The multidisciplinary Delphi panel consisted of 20 (33%) 
physical therapists, 17 (28%) occupational therapists, 12 (20%) specialized rheumatology 
nurses, 8 (13%) psychologists and 3 (5%) rheumatologists across 12 different countries. The 
majority was female (88%) and the mean (SD) age was 45 (10) years. Panellists were mainly 
active in clinical patient care (n = 27; 45%), research (n = 25; 42%), education (n = 6; 10%) or 
another area (n = 2; 3%). The response rates in rounds 2, 3 and 4 were 49 (82%), 45 (75%) 
and 46 (77%) panellists, respectively (Table 2). In total, 38 (63%) panellists completed all four 
Delphi rounds.
Delphi survey
Item generation – Delphi Round 1
In the first Delphi round, the panellists formulated 132 goals of AP, 133 behaviours of AP, 165 
strategies to change behaviour in AP and 157 contextual factors that should be acknowledged 
when teaching AP. All items generated in the first round could be categorized into one of the 
four dimensions of AP. 
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Table 1. Demographic characteristics of the international multidisciplinary Delphi panel
Demographic characteristics (n = 60)
Female; n (%) 53 (88)
Age, years; mean ± SD 45 ± 10
Country: n (%)
Austria 6 (10)
Belgium 1 (2)
Canada 2 (3)
Denmark 1 (2)
Italy 1 (2)
Lithuania 2 (3)
Norway 10 (17)
Spain 5 (8)
Sweden 11 (18)
The Netherlands 16 (27)
United Kingdom 2 (3)
United States 3 (5)
Primary health profession; n (%)
Physical therapist 20 (33)
Occupational therapist 17 (28)
Specialized rheumatology nurse 12 (20)
Psychologist 8 (13)
Rheumatologist 3 (5)
Current work setting; n (%)
Hospital 29 (48)
Ambulatory / Outpatient 32 (53)
Primary care 1 (2)
University / Professional Education 28 (47)
Public health 2 (3)
Private practice 6 (10)
Other 5 (8)
Mainly active in the last 5 years; n (%)
Clinical patient care / Rehabilitation 27 (45)
Research 25 (42)
Education 6 (10)
Other 2 (3)
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Characterizing the concept of activity pacing in rheumatic diseases  |  133
8
Table 2. Response to each round of the Delphi survey
Round 1 Round 2 Round 3 Round 4 Completed all rounds; n(%)
Physical therapist 20 14 14 16 12 (60)
Occupational therapist 17 13 13 12 10 (59)
Rheumatology nurse 12 11 7 9 7 (58)
Psychologist 8 8 8 6 6 (75)
Rheumatologist 3 3 3 3 3 (100)
Item reduction – Delphi Rounds 2, 3 and 4
In the second round, the Delphi panel rated 22 goals, 61 behaviours, 25 strategies and 34 
contextual factors with a median appropriateness score ≥ 8, which were together with the 
additional items (i.e. 3 behaviours, 15 behaviours and 4 contextual factors) subjected to 
the next Delphi round. Besides, 75 topics for further research on AP were identified by the 
panellists in round 2. In the third round, 17 goals, 21 behaviours, 18 strategies, 20 contextual 
factors and 18 topics for further research on AP were selected by ≥ 20% of the responding 
panellists as most appropriate items and thus subjected to the final round. Based on the ranks 
given by the panellists in the final round, we selected for each dimension of AP fifty percent 
of items with the highest weighted sum ranking. These items were included in our consensual 
list of most important aspects of AP interventions; resulting in 9 goals, 11 behaviours, 9 
strategies and 10 contextual factors (Table 3). Also in this table, the number of panellists 
that selected an item in the final round as being important, are presented. Furthermore, 
nine topics for future research on AP with the highest weighted sum ranking were included 
in a research agenda (Table 4). According to our panellists, future research should focus on 
the effectiveness of AP interventions and on appropriate outcome measures to assess its 
effectiveness as selected by 64% and 82% of the panellists, respectively.
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Table 3. Consensual list of most important aspects of activity pacing as an intervention in rheumatology 
care
Goals of activity pacing (n = 46) Weighted
sum ranking
Selected by
panellists, n (%)
1. To balance between activity and rest according to individual 
goals, preferences and involvement in meaningful activities
55% 39 (85)
2. To participate in daily activities that are essential or of great 
value for the individual
51% 37 (80)
3. To enable the patient to make behavioural changes to reduce or 
avoid the cycle of being overactive or underactive
46% 34 (74)
4. To maintain/improve health, quality of life and well-being 45% 33 (72)
5. To increase the ability to participate in patient’s prioritized areas 36% 30 (65)
6. To increase awareness of what’s important to one selves 33% 24 (52)
7. To improve the level of functioning during the day 31% 29 (63)
8. To move pain contingent activity to goal contingent activity 31% 27 (59)
9. To be able to deal with fatigue in the activities of daily living 29% 30 (65)
Behaviours of activity pacing (n = 44) Weighted
sum ranking
Selected by
panellists, n (%)
1. Plan and prioritize necessary and valued activities 53% 34 (77)
2. Break up tasks into manageable pieces depending on individual 
patterns and context
45% 29 (66)
3. Reflect upon activities and make a plan of how to manage, 
prioritize and distribute activities without getting exhausted
39% 29 (66)
4. Listen to your body and how it responds to activity 38% 24 (55)
5. Realistic planning 36% 27 (61)
6. Perform physical exercise regularly 32% 24 (55)
7. Be awareness of symptoms and how they are related to activities 30% 24 (55)
8. Do activities which give energy 30% 22 (50)
9. Perceive oneself as being able to self-manage 26% 22 (50)
10. Cognitive reframing; how important is it really to do this? 26% 21 (48)
11. Learn to find the right pace of doing activities 24% 23 (52)
Strategies to change behaviour in activity pacing (n = 44) Weighted
sum ranking
Selected by
panellists, n (%)
1. Identify activities that are important, meaningful, necessary or 
enjoyable
58% 37 (84)
2. Identify barriers and support to activity pacing 54% 36 (82)
3. Start off with a small change (baseline) and building on this 41% 34 (77)
4. Weigh the importance of different activities and prioritize 
between them
35% 27 (61)
5. Discuss how to implement activity pacing in home and work 
environment with family and colleagues
35% 27 (61)
6. Be aware of what gives and what takes energy 35% 26 (59)
7. Use motivational interviewing 33% 25 (57)
8. Set goals together with the health professional: starting with a 
goal that is meaningful
32% 26 (59)
9. Be aware of thoughts connected to pain, activity and fatigue 31% 26 (59)
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Contextual factors (n = 44) Weighted
sum ranking
Selected by
panellists, n (%)
1. Patient’s readiness and motivation to change behaviour 65% 38 (86)
2. Patient’s self-efficacy 47% 33 (75)
3. Patient’s opinion on benefits and barriers of behavioural change 45% 31 (70)
4. Social support form partner, relatives, friends or colleagues 38% 33 (75)
5. Patient’s own goals regarding activity 37% 27 (61)
6. Patients need to be seen as experts in their illness and life 
situation
34% 24 (55)
7. Ability to communicate, reflect on and discuss activity patterns 
and suggestions for change
31% 27 (61)
8. Patient’s resources and abilities to manage their lives 28% 20 (45)
9. Patient’s comorbidities 25% 19 (43)
10. Patient’s fear of exercise and injury 24% 23 (51)
Table 4. Research agenda representing consensus topics for future research on activity pacing in 
rheumatology care
Research topics (n = 44) Weighted
sum ranking
Selected by
panellists, n (%)
1. Select appropriate outcome measures to assess the 
effectiveness of activity pacing
48% 36 (82)
2. Assess whether or not activity pacing is effective 48% 28 (64)
3. Develop and evaluate the effectiveness of various interventions 
aiming to improve activity pacing
40% 27 (61)
4. Study whether activity pacing improves patients’ activity level 38% 27 (61)
5. Study whether improved activity pacing improves patients’ 
well-being
35% 25 (57)
6. Develop and test an evidence-based activity pacing group 
program
32% 24 (55)
7. Study whether activity pacing improves fatigue 32% 22 (50)
8. Explore how to help patients to self-manage activity pacing 31% 25 (57)
9. Study if work, vocational or leisure activity increase after 
activity pacing
27% 25 (57)
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Discussion
In the current study, we developed a consensual list containing the most important 
aspects of AP interventions in non-pharmacological rheumatology care. An international, 
multidisciplinary expert panel prioritized 9 goals of AP, 11 behaviours of AP, 9 strategies 
to change behaviour in AP and 10 contextual factors that should be acknowledged when 
teaching AP. Given the poor conceptualization of AP in the literature, such a list is a first step 
in achieving more transparency and homogeneity in the concept of AP in both rheumatology 
research and daily clinical practice. Furthermore, the Delphi panel prioritized nine topics 
for future research on AP, showing that research should focus on the effectiveness of AP 
interventions and on appropriate outcome measures to assess its effectiveness.
Interestingly, our panellists agreed that the most important overall goal of AP is to facilitate 
participation in meaningful and valued activities. The two highest ranked goals of AP referring 
to participation in meaningful activities were selected by the vast majority of panellists. This 
finding is interesting as previous studies (survey and pilot studies) suggested reducing pain 
and fatigue, symptoms associated with rheumatic diseases as the most important overall 
goal of AP7,22,30. Yet, a recent published concept analysis of AP as a chronic pain intervention 
supports our finding that the overall goal of AP is to participate in meaningful activities20. 
Considering the findings of our Delphi study and the concept analysis of Jamieson-Lega et al.20 
increasing research points to the overall goal of AP to facilitate participation in meaningful 
and valued activities. Healthcare providers in clinical practice and researchers need to be 
aware of this overall goal of AP that represents a consensus among an international group of 
health professions.
Based on a content analysis of AP in chronic pain, the two key categories of AP behaviours 
are ‘slowing down’ and ‘breaking up activities into smaller pieces’31. These behaviours appear 
to reflect what most researchers mean when using the term AP31. ‘Breaking up tasks into 
manageable pieces’ was considered as one of the most important behaviours of AP by our 
panellists. In contrast, ‘slowing down’ was identified in the first Delphi round, but excluded in 
the final round. Interestingly, since ‘slowing down’ is reflected in many of the current pacing 
measures31. It is possible that the panellists expected that ‘slowing down’ might enhance 
inactivity which is in contrast to the overall goal of AP that was endorsed by the panellists (i.e. 
facilitating engagement in meaningful and valued activities). The more recently developed 
activity pacing questionnaire (APQ) supports our finding as the item ‘I did my activities 
at a slower speed’ was excluded as result of a Delphi technique32. That study also shows 
‘breaking up activities into manageable pieces’ to be an important aspect of AP. Planning 
and prioritizing activities was according to our panellists the most important AP behaviour, 
which is supported by Antcliff et al.32. Furthermore, this Delphi study was the first to show 
that a patient’s self-efficacy, motivation to change behaviour and social support are likely to 
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be the most important contextual factors that should be acknowledged when developing AP 
interventions.
This is the first consensus study on AP focusing on rheumatic diseases in isolation. 
Broadly, two approaches of AP can be distinguished i.e. the operant approach and energy 
conservation16,19. Although similar in some respects, these two approaches emphasize 
different treatment goals: operant-based interventions aim to decrease disability and 
increase activity level whereas energy conservation interventions seek to preserve energy for 
valued activities while reducing pain and fatigue16. In this Delphi study we did not specify the 
theoretical basis with which we evaluated AP, however it seems that our findings are mainly 
related to the approach of energy conservation. 
Healthcare professionals in daily clinical practice can use the list of most important aspects 
when setting up AP interventions for patients with a rheumatic disease. Together with the 
patient, the healthcare professional can go through the list and select one or multiple aspects 
of each dimension of AP that can be combined into an intervention. The selected items can 
be individually tailored to the patient’s specific needs and abilities. Tailored AP instruction 
is important; preliminary studies have shown tailored AP instruction to be more effective 
in reducing physical activity variability and joint stiffness than a more general approach in 
patients with hip and knee OA15,18. Furthermore, our list might improve a shared conceptual 
understanding of AP and reduce variability in applying AP approaches among healthcare 
professionals working within multidisciplinary treatment. This in turn, might improve 
alignment of care and a more effective management of rheumatic diseases.
To date, empirical evidence of the effectiveness of AP interventions in rheumatology care 
is limited and contradictory, which can be explained by a poor conceptualization of AP14,33. For 
example, in some studies AP has been shown to be associated with lower levels of disability34 
or fatigue22, where other studies found AP to be associated with higher levels of disability5, 
pain and fatigue19,30. A more uniform concept of AP might facilitate intervention studies 
that are needed to gain consistent empirical evidence on the effectiveness of AP and allows 
research studies to be more easily replicated and compared in systematic reviews. This need 
for research on the effectiveness of AP interventions was highlighted by our panellists. Yet, 
the panel considered the standardization of outcome measures to assess the effectiveness of 
AP as most important topic for future research. This need is supported by a recently published 
narrative review on the measurement properties of AP measures developed and used in 
research to date (like the Chronic Pain Coping Inventory or Coping with Rheumatic Stressors 
questionnaire)31. The authors concluded that existing questionnaires measure a wide variety 
of outcome domains and items within the same questionnaire often do not reflect a specific 
goal of AP. Therefore, the first step in future research might be to reach consensus on the 
most important outcome domains/goals of AP. Subsequently, appropriate outcome measures 
reflecting those domains need to be developed.
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It should be noted that although we achieved agreement on four important dimensions 
of AP, there was a great variety of experts’ perspectives on the concept of AP given the 
abundance of goals, behaviours, strategies and contextual factors generated in the first round. 
Furthermore, as we considered it important to guarantee transparency of the panellists’ 
responses, some overlap exists in items between the four dimensions of AP. For example, 
‘do activities which give energy’ was considered an AP behaviour, whereas ‘be aware of 
what gives and what takes energy’ was selected as strategy. Future research based upon the 
consensual list presented here and experiences from clinical practice using our list is needed 
to further improve the conceptualization of AP.   
A particular strength of the current study is the use of an international Delphi panel across 
12 different countries, enabling generalization of the findings to other western countries. 
The results can however not be generalized to non-western societies and unfortunately we 
did not include panellists from Australia or New Zealand. In total, 60 panellists participated 
recognizing that no optimal number of experts for a Delphi study exist25,27. In order to enhance 
external validity of the study results, effort was made to ensure panel diversity with respect 
to healthcare profession and work setting24. A further strength is the relatively high response 
rate throughout all Delphi rounds. Although not all panellists were able to contribute to all 
rounds, results did not differ when analysing only the responses of panellists with complete 
input. There are a number of limitations inherent to Delphi studies that should be considered 
when interpreting the results. First, we tried to reduce selection bias by using snow-ball 
sampling; nevertheless, some selection bias in the composition of the Delphi panel might 
have occurred as experts from the Netherlands, Norway and Sweden were over-represented. 
Besides, the majority of panellists were physical and occupational therapists what might 
have influenced the results. We qualitatively explored noticeable differences in responses 
across professions, but these differences were not apparent. Another limitation might be 
researcher bias since cut-off scores were not selected prior to the data collection, but were 
based on pragmatic considerations (to keep the amount of data manageable to ensure the 
panellists’ motivation to carefully rank the items and minimize the risk for drop outs). The 
cut-off scores were discussed with the working group members. Third, due to differences in 
background and expertise among panellists, items considered important by individual experts 
might have been eliminated during the four-round Delphi survey. Especially in the second 
Delphi round where we broke up the work between panellists, items considered important 
by individual experts might have been removed. Furthermore, the Delphi technique has 
been criticised as panellists only have a limited opportunity to discuss the issues raised or to 
elaborate on their views24. In the current study we did not show panellists the group votes 
on subsequent rounds to re-consider their ideas what might be a limitation. Besides, it is 
important to note that the results of any Delphi study represent expert opinion rather than 
a correct answer or indisputable fact24,25,27. Finally, the patient’s viewpoint is lacking in the 
current study, constituting an important limitation. We recognize that patients might offer an 
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alternative perspective on the concept of AP. The patient perspective needs to be included in 
the development of AP interventions or when developing appropriate outcome measures to 
evaluate its effectiveness.
In conclusion, we generated a consensual list including the most important aspects of 
AP interventions within rheumatology care. This is an important first step towards achieving 
more transparency and homogeneity in the concept of AP in rheumatology daily clinical 
practice and research. This in turn might improve an effective management of rheumatic 
diseases, facilitate intervention studies that are needed to gain consistent empirical evidence 
on the effectiveness of AP and allows research studies to be more easily replicated and 
compared. Future research on AP should focus on the effectiveness of AP interventions and 
on the development of standardized outcome measures to assess its effectiveness.
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To date, research on the non-pharmacological, non-surgical management of generalized 
osteoarthritis (GOA) is very limited. This is mainly due to the fact that research and clinical 
practice are commonly focused on a specific localization of OA, usually the hips, knees and 
hands. Yet, the involvement of multiple joint sites is relatively frequent in patients with OA. In 
studies enrolling patients based on OA in a specific joint, a relatively large subgroup of patients 
(approximately 50%) can be classified as having GOA1-4. However, the impact of multiple 
joint involvement on clinical outcomes has received limited attention in joint specific OA 
cohorts5. The involvement of multiple joints in OA likely imposes specific demands regarding 
the optimal management. In order to gain knowledge about the non-pharmacological, non-
surgical management of patients with GOA, this thesis focused on the health status of patients 
with GOA and the (cost)-effectiveness of two non-pharmacological treatment programs for 
patients with GOA. Furthermore, in order to optimize the non-pharmacological management 
of patients with rheumatic diseases in general, we performed an international Delphi study 
among experts from 12 different countries to characterize the concept of activity pacing as 
a non-pharmacological intervention in rheumatology care. This final chapter summarizes 
the results of this thesis and discusses the main findings, focusing on the methodological 
limitations, implications for clinical practice and directions for future research. 
Summary
Chapter 2 
We comprehensively described the health status of patients clinically diagnosed with GOA 
who were referred for a non-pharmacological multidisciplinary treatment program. A total of 
147 patients completed questionnaires on joint involvement, health related quality of life and 
daily function. The predominantly affected joints with OA in our study population were the 
hands and knees, with also the combination of hand and knee OA to be most common. The 
results showed that patients with GOA experience a markedly reduced physical health related 
quality of life. Furthermore, patients with GOA experience moderate to severe limitations in 
performing activities of daily living. The participants reported a broad spectrum of important 
activity limitations and participation restrictions; activities concerning mobility and domestic 
life were considered as most important activity limitations, especially walking. The results of 
this study point to the need of developing interventions for patients with GOA targeting the 
physical component of health related quality of life and mobility limitations. Furthermore, the 
broad spectrum of activity limitations as reported by the patients underlines that treatment 
should be tailored to the problems and needs of the individual patient.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
146  |  Chapter 9
Chapter 3
In chapter 3, a pragmatic single-blind randomized clinical superiority trial was conducted 
involving 147 patients clinically diagnosed with GOA randomly allocated to either a six 
week non-pharmacological multidisciplinary face-to-face treatment program or a six week 
telephone-based treatment program. The aim of both programs was to improve daily 
function and to enhance self-management skills to control the consequences of the disease. 
Daily function (primary outcome) and secondary outcomes were assessed at baseline, 
6, 26 and 52 weeks. Data were analysed using multilevel regression models corrected for 
baseline values, sex and group-wise treatment. We found no differences in effectiveness 
between both treatment programs on the primary outcome over one year follow-up (group 
difference (95% CI):  -0.03 (-0.14, 0.07)) or on secondary outcome measures, except for pain, 
where a significant difference favouring the face-to-face treatment group was found (group 
difference (95% CI): 1.61 (0.01, 3.21)). Within both treatment groups, we observed small 
significant improvements on several domains, especially in the face-to-face treatment group. 
However, these improvements were relatively small and unlikely to be of clinical importance. 
Interestingly, many patients preferred the more traditional face-to-face treatment delivery.
Chapter 4
Next to the disease burden, OA represents a significant economic burden on individuals, 
healthcare systems and society. It is therefore important that a clinical evaluation of an 
intervention is accompanied by an economic evaluation in order to inform decision makers 
about the efficiency of healthcare resources and to guide decision making processes. 
Alongside the randomized clinical trial described previously, we conducted an economic 
evaluation of our treatment programs. Chapter 4 describes, from a societal perspective, the 
cost-effectiveness and cost-utility analysis of both treatment programs. Program costs were 
estimated from time registrations. During the one year follow-up period, participants reported 
all GOA-related direct medical costs (i.e. healthcare-related) and non-medical costs (i.e. other 
health-related) using cost questionnaires at 6, 13, 26, 39 and 52 weeks. Quality adjusted life 
years (QALYs) were estimated using three utility measures i.e. the EuroQol-5D, the EuroQol 
rating scale and the Short Form-6D. Daily function was measured using the HAQ-DI. The net 
benefits of both treatment programs were estimated for a range of society’s willingness to 
pay (WTP) values using the formula: net benefit = WTP × effect (QALY or HAQ-DI) – costs. The 
more cost-effective treatment program was the program with the higher average net benefits, 
depending on a range of thresholds for the society’s WTP. Given the statistical uncertainty of 
differences between costs and QALYs we constructed cost-effectiveness acceptability curves 
(CEAC). The medical costs of the face-to-face treatment and telephone-based treatment 
programs were estimated at €387 and €252 per patient, respectively. The difference in total 
societal costs was non-significantly in favour of the face-to-face program (difference (95% CI): 
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€708 (€-5058, 3642)). QALYs were similar for both groups according to the EuroQol, but were 
significantly in favour of the face-to-face group according to the SF-6D (difference (95% CI): 
0.022 (0.000, 0.045)). Since both societal costs and effects were in favour of the face-to-face 
treatment program, the economic assessment favoured this program, regardless society’s 
willingness to pay. At a range between €20.000-€80.000, there was a 60%-90% chance that 
the face-to-face program had better cost utility. This economic evaluation showed from a 
societal perspective that the face-to-face treatment program was at least twice as likely cost-
effective relative to the telephone-based treatment program.
Chapter 5
The measurement properties of the widely used Health Assessment Questionnaire Disability 
Index (HAQ-DI) to measure daily function in patients with GOA were evaluated in chapter 
5. Individuals with GOA typically suffer from restrictions of both upper and lower extremity 
function. Yet, we lack a validated instrument to assess their activity limitations since 
existing questionnaires all focus on a specific localization of OA, limiting their use in GOA. 
The recommendations of the Consensus-based Standards for the selection of health status 
Measurement Instruments (COSMIN) checklist were followed to assess the interpretability, 
validity, reliability and responsiveness of the HAQ-DI. For this study data from the baseline and 
six week follow-up measurements of the clinical trial were used. First, it was found that floor 
and ceiling effects were present. Moreover, the content validity appeared to be questionable 
as the HAQ-DI encompasses activities that are either not relevant or too easy to perform for 
patients with GOA as judged by patients and healthcare professionals experienced with GOA. 
The construct validity of the HAQ-DI was rated positive and a confirmatory factor analysis 
confirmed unidimensionality. Cronbach’s alpha was 0.90, confirming internal consistency and 
the intra-class correlation coefficient was 0.81, reflecting a good reliability. We could not 
establish the responsiveness of the HAQ-DI. Considering the limited content validity of the 
HAQ-DI, we concluded that the items of the HAQ-DI need to be updated when using the 
HAQ-DI in future clinical practice and research focusing on functional limitations in people 
with GOA. Probably, certain activities of the HAQ-DI are “outdated” since the questionnaire 
has been developed more than three decades ago, a period during which some activities 
have become easier to perform due to technological and social developments. We believe, 
this update of the HAQ-DI might also be worthwhile for other rheumatic diseases.
Chapter 6
In this chapter we compared the responsiveness of four widely used patient reported 
outcome measures (PROMs) for the assessment of physical function in people with knee 
OA receiving conservative treatment i.e. the Western Ontario and McMaster University 
Osteoarthritis Index subscale physical function (WOMAC-PF), the Lequesne Algofunctional 
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index (LAI), the Lower Extremity Functional Scale (LEFS) and the short measure of the Knee 
disability and Osteoarthritis Outcome Score (KOOS-PS). Responsiveness was investigated by 
testing predefined hypotheses formulated by an expert group regarding expected correlations 
between changes in physical function with changes in other (un)related measures, as currently 
recommended. Responsiveness was considered positive if > 75% of the hypotheses could be 
confirmed. We could confirm 12 out of 15 predefined hypotheses (80%) using the physical 
function subscale of the WOMAC. For the LAI, LEFS and KOOS-PS, respectively 9, 11 and 11 
hypotheses were confirmed (60%, 73% and 73% respectively). Our findings suggest that the 
WOMAC-PF is potentially better able to detect changes over time in physical function than 
the LAI, LEFS and KOOS-PS in a population of patients with knee OA receiving conservative 
treatment. We recommend that clinicians and researchers should prefer the WOMAC-PF 
subscale in future clinical trials to evaluate the effectiveness of an intervention. 
Chapter 7
To enhance guideline-based non-pharmacological, non-surgical management of patients 
with hip or knee OA, our research group implemented an evidence-based, multidisciplinary, 
stepped care strategy for hip and knee OA in one region in the Netherlands. The implementation 
strategy included the provision of a self-management booklet on the stepped care strategy 
for patients, entitled “Care for Osteoarthritis”, by general practitioners in primary care. The 
aim of the booklet was to educate patients about OA, to enhance the patient’s active role 
in the treatment course, and to improve the communication with healthcare providers. To 
successfully implement the self-management booklet on a larger scale, chapter 7 describes 
a qualitative interview study on patients’ barriers and facilitators to using the booklet. Three 
core themes with patient perceived barriers and facilitators to use the booklet emerged from 
the interviews: 1) the role of healthcare providers, 2) the patient’s perceptions about OA 
and its manageability, and 3) the patient’s perceptions about the usefulness of the booklet 
and patient’s information needs. Regarding the first theme, the lack of encouragement 
from healthcare providers during the treatment course was reported by patients as barrier. 
Moreover, patients had doubts concerning the healthcare providers’ endorsement of non-
surgical treatment for OA. Barriers from the second theme were thinking that OA is not 
treatable or that being pro-active during the treatment course is not important. In contrast, 
being convinced that an active participation in the treatment course is important was reported 
as a facilitator. Regarding the third theme, patients’ perceptions about the usefulness of the 
booklet and patients’ information needs were both identified as barriers as well as facilitators 
for booklet use.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Summary and general discussion  |  149
9
Chapter 8
Activity pacing frequently emerges as a primary component of self-management programs 
within the context of multidisciplinary treatment of rheumatic diseases. However, activity 
pacing is still a poorly understood concept with a wide variety in definitions, interpretations 
and methods of delivery. The implications of a poor conceptualization of activity pacing 
are significant in both research and rheumatology practice. Therefore, we developed a 
consensual list containing the most important aspects of activity pacing interventions in 
rheumatology care. In a four-round Delphi survey an international, multidisciplinary expert 
panel consisting of 60 clinicians and healthcare professionals across 12 countries prioritized 9 
goals of activity pacing, 11 behaviours of activity pacing (the actions people take to meet the 
goal of activity pacing), 9 strategies to change behaviour in activity pacing and 10 contextual 
factors that should be acknowledged when teaching activity pacing. The results of this 
study are an important first step in achieving more transparency and homogeneity in the 
conceptualization of activity pacing in daily clinical practice and research. This in turn might 
facilitate an effective management of the disease and allows research studies to be more 
easily replicated. Furthermore, the Delphi panel prioritized nine topics for future research 
on activity pacing, showing that research should focus on the effectiveness of activity pacing 
interventions and on appropriate outcome measures to assess its effectiveness. 
Discussion
In this section the main findings of this thesis are put into perspective and will be discussed. 
Based on these findings, implications for clinical practice and directions for future research 
are presented.
No differences in effectiveness between two non-pharmacological treatment programs 
As shown in our randomized clinical trial we could not confirm our hypothesis that a 
multidisciplinary face-to-face treatment program was superior with respect to effect on daily 
function and other clinical outcomes compared to a telephone-based treatment program 
for patients with GOA. Only on one secondary outcome measure (i.e. pain) we found a 
significant difference in favour of the face-to-face treatment program. The limited differences 
in effectiveness between both treatment programs can perhaps be explained by the limited 
contrast in the content of both programs. The contents of both treatment programs were 
very comparable, but several critical differences were apparent i.e. the mode of care delivery, 
the number of involved healthcare providers, the number of group sessions and the number 
of sessions including an exercise program. Nevertheless, these differences are possibly too 
small to achieve a sufficient and clinically relevant contrast in effectiveness between both 
treatment programs.
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Is there a role for non-pharmacological treatment in patients with GOA?
So far, no disease modifying therapies are available for OA. Therefore, current guidelines 
recommend multimodal treatment combining pharmacological and non-pharmacological 
treatment modalities. When these modalities do not provide sufficient relief, total joint 
replacement is known to be a very effective treatment option to significantly improve pain 
and function in patients with hip and knee OA6,7. However, research showed multiple joint 
involvement in OA to be an important predictor of worse pain, physical function, fatigue and 
quality of life after joint replacement surgery4,8. Therefore, it has been hypothesized that in 
patients with GOA, joint replacement surgery might not be as effective as in patients with 
single joint OA. Besides, joint replacement surgery is unattractive in relatively young patients 
due to the frequent need for revision surgery after 10-15 years7. Considering this, there is 
a major need for effective non-pharmacological treatment options for patients with GOA. 
Unfortunately, scientific knowledge on the management of patients with GOA is lacking so far. In 
2014, the Osteoarthritis Research Society International (OARSI) published recommendations 
for the non-surgical management of OA including multiple joint OA (i.e. OA in other joints in 
addition to the knee). However, due to the limited available intervention studies, the authors 
considered balneotherapy (defined as the use of baths containing thermal mineral waters) 
the only appropriate recommendation for the management of multiple joint OA, whereas 
no other recommendations could be formulated9. In absence of recommendations for the 
management of GOA, we used recommendations for the non-pharmacological management 
of patients with hip and knee OA7,10 as starting points to develop two treatment programs 
for individuals with GOA. Unfortunately, within both treatment groups, we observed only 
small improvements on daily function and other clinical outcomes where we expected 
larger improvements, especially in the face-to-face treatment group. A number of possible 
explanations for these limited benefits are discussed below. 
First, during the development process, we decided to direct our treatment programs on 
individual goal setting with respect to multiple domains of daily living. At the start of the 
treatment program each individual participant formulated adequate and realistic goals which 
were closely monitored, discussed and if necessary adjusted during the treatment program. 
As GOA may cause various impairments and limitations in activities, individual treatment 
goals varied considerably among patients. As a result, the treatment programs evaluated in 
this thesis targeted on a variety of dimensions important for patients with GOA, such as pain, 
fatigue, physical activity, acceptance of the disease and social support. A consequence of 
delivering treatment programs covering a wide variety of dimensions is that it may be difficult 
for individual patients to select the most relevant information for themselves. It is therefore 
conceivable that treatment programs with more guidance on individually tailored treatment 
plans, focussing on a lesser number of treatment modalities would be more beneficial than 
the treatment programs investigated in this thesis. 
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Another possible explanation for the disappointing benefits of our treatment programs 
might be our assumption that treatment effects observed in patients with hip or knee OA could 
be extrapolated to patients with GOA. Since we developed both treatment programs based 
on the latest evidence in hip and knee OA7,10, we expected clinical relevant improvements in 
daily function and other clinical outcomes in both groups. However, effect sizes of treatment 
modalities observed in joint-specific OA cohorts (although including patients with GOA) are 
likely to be lower for individuals with GOA. Previous studies showed a considerably worse 
health status of patients with multiple joint involvement compared to patients without 
multiple joint involvement3,5. Furthermore, the complex involvement of multiple joints 
in lower extremity function suggests a more compromised health status4. It is therefore 
conceivable that patients with GOA require more complex and intensive treatment programs 
than patients with single joint OA. Probably, our treatment programs needed to be more 
intensive with a longer follow-up period in order to obtain clinically relevant improvements 
on clinical outcomes. 
Third, the choice of our primary outcome measure could be argued. When performing 
studies on the effectiveness of interventions, researchers should include a primary outcome 
measure which is related to the main objective of the intervention. In our randomized clinical 
trial, we aimed to improve daily function in patients with GOA and we therefore considered 
daily function as primary outcome measure. Since no validated patient reported outcome 
measures (PROMs) are available to assess daily function in people with GOA, we considered 
the widely used and validated HAQ-DI to be the most appropriate outcome measure11. 
During the trial, we evaluated the measurement properties of the HAQ-DI in patients with 
GOA showing a positive construct validity and reliability, but a limited content validity and 
responsiveness. Based on these findings, we need to conclude that the HAQ-DI might not 
have been the most appropriate primary outcome measure to assess daily function in our 
clinical trial. Ideally, the measurement properties of a primary outcome measure are known 
before starting a trial, but due to time constraints this is often not feasible in practice. Future 
research is warranted to evaluate the measurement properties of existing (OA specific) 
physical function instruments or to develop a new measurement instrument in order to 
accurately measure daily function in patients with GOA. 
Given the limited benefits of our treatment programs, we believe it is important at this 
point to critically reflect on the following question: “What is the value of self-management 
support programs in patients with GOA?”. Also in joint specific OA studies increasing evidence 
supports the existence of no or only small effects (ES = 0.06 for pain and physical function) of 
self-management programs, as reported in systematic reviews12,13 and clinical guidelines14,15. 
Furthermore, as shown in our qualitative interview study on the use of a self-management 
booklet for patients with hip and knee OA (chapter 7) many patients perceive OA as inevitable 
and not curable and are therefore reluctance towards self-management. Considering the 
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above-mentioned, we hypothesize that we need to move away from focussing on self-
management towards more intensive and supervised treatment programs for patients with 
GOA. Probably, future non-pharmacological treatment programs for patients with GOA 
need to combine exercises with weight loss as increasing evidence recognizes that this 
combination of treatment modalities should be the mainstays of rehabilitation for people 
with knee and hip OA16,17. Several studies enrolling patients based on OA in a specific joint 
have reported substantial improvements in pain, physical function and quality of life after 
long-lasting programs combining exercise with weight loss. First, the high quality Intensive 
Diet and Exercise for Arthritis (IDEA) randomized clinical trial compared the effectiveness of 
an exercise-only program, diet for weight loss-only program and a combined exercise and 
diet for weight loss program of 18 months in 454 overweight adults with knee OA18. After 
18 months, patients in the combined treatment group reported less pain, better physical 
function and quality of life compared to patients in the other groups. In addition, the Arthritis, 
Diet, and Activity Promotion Trial (ADAPT) showed the combination of modest weight loss 
plus moderate exercise to provide better improvements in function, pain and performance 
measures of mobility in overweight patients with knee OA compared with either intervention 
alone19. Furthermore, preliminary evidence showed a clinically relevant improvement in 
physical function and pain in people with hip OA following an 8-month exercise in combination 
with weight loss treatment program20. We hypothesize that patients with GOA might benefit 
more from a long-term supervised treatment program combining weight loss (10-15% weight 
reduction) with intensive exercises (1 hour, 3 days/week), rather than a self-management 
program targeting on multiple domains of daily living. Future research is needed to gain 
empirical evidence for this. 
Patient preferences
Directly after finishing the treatment program we asked a part of the participants several 
questions about their perceptions of the treatment programs. The questionnaire used to 
evaluate this comprised visual analogue scales (score range 0-10) to assess the level of 
satisfaction with the treatment program and the overall usefulness of the treatment (Table 
1). Satisfaction scores showed that patients in the multidisciplinary face-to-face treatment 
group were significantly more satisfied than patients in the telephone-based treatment 
group. The face-to-face program was rated with a total mean (SD) score of 7.7 (1.4) whereas 
the telephone-based program was rated with a total mean (SD) score of 6.4 (1.9) (p <0.00). 
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Table 1. Patients’ perceptions of both treatment programs
Face-to-face 
treatment
 (n = 32)
Telephone-based 
treatment
(n = 21)
p
Was the content of the treatment consistent with your 
expectations?
7.5 (1.5) 5.7 (2.2) 0.001
Was the content of the treatment consistent with your 
GOA-related complains and limitations?
7.4 (1.5) 5.8 (2.3) 0.004
How confident are you that the treatment was helpful to 
cope with the consequences of the disease? 
7.3 (1.5) 6.1 (2.5) 0.025
Would you recommend the treatment to family or friends? 7.7 (2.5) 6.1 (2.6) 0.037
How useful was the treatment program? 7.6 (1.6) 6.0 (2.3) 0.004
Are you satisfied with the treatment program? 7.8 (1.8) 6.1 (2.3) 0.006
Where you treated with dignity and respect by the 
admitting healthcare professionals?
8.5 (1.3) 7.8 (1.7) 0.105
Did you receive adequate information during the treatment 
program? 
7.8 (1.3) 7.0 (1.8) 0.045
Overall, how would you value the treatment program? 7.8 (1.6) 6.5 (1.8) 0.010
These results indicate that patients preferred the more traditional face-to-face treatment 
program. We also observed a preference for the multidisciplinary face-to-face program 
during the recruitment phase of the trial. The recruitment of patients proceeded at a 
slower pace than expected. We expected a relatively high accrual rate (>80%) since our 
study was a pragmatic trial resembling clinical practice. However, many eligible patients 
declined to participate in the trial, mainly because they preferred the multidisciplinary face-
to-face treatment program or were reluctant towards the telephone-based treatment. This 
was unexpected because the face-to-face program is much more intensive and requires 
considerably more time than the telephone-based program. The preference for face-to-face 
treatment is supported by a study examining the acceptability of face-to-face, internet and 
telephone treatment delivery in primary care, showing the highest level of interest in face-
to-face treatment delivery21. Furthermore, Tijhuis and colleagues22 showed that patients 
with rheumatoid arthritis (RA) were more satisfied with care provided by a multidisciplinary 
team than with care provided by a clinical nurse specialist. A number of studies support the 
effectiveness of multidisciplinary team care, especially in patients with RA23. However, team 
care has now been questioned for several reasons. One major reason is that there is too little 
evidence for the cost-effectiveness of team care24,25. Furthermore, it should be kept in mind 
that more care providers does not always mean better care: greater team size may interfere 
with patient preferences for continuity of care with a single healthcare provider and might 
impede communication22,26. Therefore, the choice of treatment delivery could be based on 
the availability of facilities, the preferences of patients and healthcare providers, healthcare 
systems and/or economic considerations. 
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Which treatment program is more cost-effective?
The effectiveness of interventions has traditionally been evaluated in terms of clinical 
aspects and patient-related outcomes. In recent years, however, outcome measures have 
expanded to include economic analyses to inform decision makers about the efficiency of 
healthcare resources due to the increasing costs of healthcare combined with the limited 
healthcare budgets. The results of our economic evaluation showed that from a societal 
perspective, the face-to-face treatment program was more likely to be cost-effective relative 
to the telephone-based treatment program. However, since the difference in net benefit 
between both treatment programs did not reach statistical significance, we cannot make 
any firm treatment recommendations based on these results. The results imply that, from 
the societal perspective, the choice of treatment delivery does not have to be based on 
costs, but could be based on the patients and healthcare providers preferences or on the 
availability of facilities and/or healthcare systems. Future studies on the effectiveness of non-
pharmacological interventions for patient with GOA should include high quality economic 
evaluations to assist healthcare providers to choose the best treatment for the patient, 
bearing in mind the economic consequences. 
Conceptualization of non-pharmacological interventions
A clear description of non-pharmacological interventions is essential for researchers and 
clinicians in order to replicate interventions, compare results across studies in systematic 
reviews and implement interventions in practice27,28. However, especially in the context of 
non-pharmacological treatment, the description of interventions is a challenging task29. 
Hoffmann and colleagues27 showed that only 39% of non-pharmacological interventions 
were described in sufficient detail to enable replication of the intervention in practice. 
Comparable results have been shown in interventions studies of exercise programs for 
patients with hip and knee OA awaiting joint replacement30. Therefore, guidelines and 
tools are necessary to facilitate standardization in the description of non-pharmacological 
interventions. A recommended non-pharmacological intervention within rheumatology care 
that lacks a clear description is activity pacing. In clinical rheumatology practice, activity 
pacing frequently emerges as a primary component of multidisciplinary self-management 
programs to decrease pain and fatigue31,32. In chapter 8 of this thesis we aimed to characterize 
the concept of activity pacing among healthcare professionals with different backgrounds 
and expertise (i.e. rheumatologists, physical therapists, occupational therapist, rheumatology 
nurses and psychologists) from 12 different countries. In a four-round Delphi survey we asked 
the experts to identify items related to the concept of activity pacing. This resulted in an 
abundance of items, underlying the great variety of the experts’ perspectives on the concept 
of activity pacing. The abundance of items was refined through merging and prioritizing until 
agreement was reached. Subsequently, we developed a consensual list containing the most 
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important aspects of activity pacing interventions. This is an important first step towards 
achieving more transparency and homogeneity in the concept of activity pacing interventions 
in rheumatology care and research. This in turn might facilitate an effective management 
of rheumatic diseases and allows research studies to gain consistent empirical evidence 
on the effectiveness of activity pacing interventions. Future research based upon both our 
consensual list and experiences from clinical practice using the list, is expected to further 
improve the concept of activity pacing.
Are we adequately measuring physical function in patients with OA? 
An array of disease specific PROMs is available to assess physical function in patients with 
knee OA. In addition, the measurement properties of these PROMs have been evaluated 
extensively33. Within the literature, the LAI and WOMAC are recommended as physical 
function measures of first choice in OA trials enrolling patients with knee OA33,34. Furthermore, 
the guideline of the Dutch Society for Physical therapy recommends the LAI as first measure 
to monitor and evaluate physical function in patients with knee OA35. However, in this thesis 
(chapter 6) we showed a superior responsiveness of the WOMAC subscale physical function 
in comparison with the LAI, KOOS-PS and LEFS in patients with knee OA who received 
multimodal non-pharmacological treatment. Based on these findings, we suggest that 
the WOMAC-PF is potentially better able to detect changes over time in physical function 
than the LAI, LEFS and KOOS-PS. We therefore recommend that clinicians and researchers 
should prefer the WOMAC-PF subscale in future clinical trials to assess self-reported physical 
function in people with knee OA. Whilst the importance of routinely measuring PROMs to 
monitor individual patients in clinical practice is well recognised and recommended in clinical 
practice guidelines, it has largely failed to be delivered in practice36. Research has shown 
that the implementation of PROMs in clinical practice is hampered by the lack of healthcare 
providers’ knowledge with respect to the use of PROMS e.g. they often do not know which 
instrument to use for what patient, how to interpret scores and are not familiar with the 
clinical application of PROMs36,37. Therefore, strategies need to be developed in order to 
improve the standardized use of PROMs by healthcare professionals in daily clinical practice. 
Methodological issues
In this paragraph, we discuss several limitations that should be considered when interpreting 
the results of this thesis. These issues mainly consider our randomized clinical trial. 
Study design
A randomized controlled trial is considered the gold standard to examine the effectiveness 
of any intervention. Such a trial, however, poses a great challenge in healthcare settings, 
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particularly in multidisciplinary rehabilitation. Until recently, the optimal control group in 
randomized clinical trials was generally considered to be a group receiving no treatment (e.g. 
placebo or waiting list)38. However, considering the large array of proven effective treatments 
and ethical considerations, the use of control groups receiving no treatment when effective 
therapies exist has been debated during the last decade38,39. Proven effectiveness of a wide 
variety of OA non-pharmacological treatment modalities within the literature made us decide 
to conduct a trial on the optimal mode of treatment delivery since research on the optimal 
modes of therapy delivery is limited. Based on increasing evidence showing telephone-
based interventions to be cost-efficient40 and to improve symptoms and promote lifestyle 
changes41,42, we decided to compare the effectiveness of two modes of care delivery i.e. 
supervised face-to-face treatment delivery and telephone treatment delivery. This presented 
us with the issue of design choice i.e. a superiority or non-inferiority trial38,43. After extensive 
discussions, we decided to design our study as a superiority trial because we expected the 
multidisciplinary, face-to-face treatment program to be superior in effect since this program 
is more intensive and more strictly supervised44. However, based on progressive insights on 
clinical trial designs within our research group, a more appropriate design might have been a 
non-inferiority trial evaluating whether the telephone-based treatment program was inferior 
in effect to the face-to-face treatment program by more than a predefined non-inferiority 
margin43,45,46. In a superiority trial, the aim is to show that a new treatment is more effective 
than an existing treatment, whereas in a non-inferiority trial the aim is to show that a new 
treatment is no less effective than an existing treatment (but might have safety advantages 
or lower costs)38,45,47. In our trial, the face-to face treatment program was an already existing 
program given at the outpatient department (expected to be effective since the content was 
based on evidence-based recommendations) and the telephone-based treatment program 
was the newly developed, less intensive program, with expected lower costs. Therefore, in 
hindsight a non-inferiority design would have been a more appropriate design. Ideally, the 
best trial design would have been a three-arm trial including a group receiving no treatment 
(i.e. waiting list), a group receiving the face-to-face treatment program and a group receiving 
the telephone-based treatment program38,48,49. Such a design measures effect size (new 
treatment vs. no treatment) and allows comparison of a new treatment with active control in 
a setting where the comparison between active control and no treatment provides evidence 
of the ability of a trial to distinguish active from inactive treatment or whether the study did 
not work (i.e. assay sensitivity)47,48. Including a third arm would increase the sample size, but 
it is possible to make the group receiving no treatment smaller than the other groups as the 
treatment vs. no treatment difference is generally larger than the new treatment vs. active 
control difference38,47. This makes the trial more acceptable to patients as there is less chance 
of being randomized to the group receiving no treatment47.
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Definition of GOA
As previously addressed in this thesis, to date there is no clear and consistent definition for 
what actually constitutes GOA and a number of alternative terms have been used, such as 
polyarticular OA, multiple joint involvement, joint pain comorbidity or multi-joint symptoms5. 
Previous studies which enrolled patients based on OA in a specific joint have established that 
multiple joints are commonly involved in OA (especially in hip and knee OA)3-5. For example, 
Peruccio et al.4 showed in a knee OA cohort undergoing joint replacement surgery that 46% 
of patients reported ≥4 symptomatic joints, other than the surgical knee. Furthermore, the 
authors showed a significant influence of specific symptomatic joints on post-surgery pain 
and function, including the ankle/feet/toes, spine/lower back and neck. In patients with hip 
and knee OA, Hoogeboom et al.3 showed 58% of patients to report symptoms in more than 
one joint. It should be noted however, that in those studies the nature of the additional 
musculoskeletal complaints was unknown and might be unrelated to OA. Despite the high 
prevalence of multiple joint involvement in OA, research and clinical practice do not routinely 
consider the involvement of multiple joints, but often focus on single joint sites in isolation. 
As a consequence, there remains a gap in understanding the association between multiple 
joint involvement and clinical outcomes in patients with OA. We hypothesize that a clear and 
consistent definition of GOA might contribute to diminish this gap.
In the current thesis we used a pragmatic definition of GOA. At this point, we believe 
it is important to take a critical look at this definition. An asset of this definition is that we 
were one of the first to formulate a pragmatic definition of GOA from a clinical rather than 
a radiographic perspective that was easily applicable in daily clinical practice. Since clinical 
symptoms are poorly correlated with radiographic OA50 and symptoms are likely to be more 
important in functional outcomes, we consider it important to include clinical symptoms 
next to structural changes in the definition of GOA51. Furthermore, we believe that our study 
population adequately represents patients with GOA considering the observed patterns of 
joint involvement in chapter 2. We showed the combination of hand and knee OA to be most 
common in our patient group, which is consistent within the literature on patterns of joint 
involvement, showing that the hands and knees aggregate together much more often than 
other joints52-54. A limitation of our definition might be that we used a rather “broad” definition 
of GOA. We did not require a specific joint or combination of joints to be affected, whereas 
existing GOA definitions often define GOA by the existence/presence of hand or knee OA53,55-
57. As a consequence of our “broad” definition, we included a very heterogeneous group 
of patients with a broad range of problems, making individualized treatment within groups 
difficult. However, the little agreement on the necessity or appropriateness of including a 
specific joint or combination of joints in the definition of GOA makes it difficult to determine 
which joints should be involved in the definition of GOA. We believe the initial issue in 
research on GOA is to obtain international consensus on an appropriate definition of GOA 
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for clinical and research use, which is supported by a recently published systematic review 
on GOA5. The authors concluded that a uniform definition will facilitate research studies on 
possible risk factors of GOA and clinical trials on the effectiveness of therapy. The need for 
a uniform definition of GOA is also supported by a European League Against Rheumatism 
(EULAR) expert committee developing a research agenda comprising the most important 
research needs to improve OA care58. One of their research priorities was to develop criteria 
to diagnose and classify GOA. Consensus on the definition of GOA could be obtained by use 
of an international Delphi study among international experts. We further believe that a more 
comprehensive approach to the management and care of OA is warranted. Both researchers 
and clinicians in daily clinical practice should account for the involvement of multiple joints 
in patients with OA3,4. 
Generalizability
For the studies described in chapters 2, 3, 4 and 5, all included patients were recruited from 
two specialized outpatient rheumatology departments of the Sint Maartenskliniek, the 
Netherlands. The patients enrolled in our randomized clinical trial were diagnosed with GOA 
and referred by their rheumatologist for multidisciplinary treatment. This might have led to 
selection bias since we selected patients with a relatively high clinical burden as shown in 
chapter 2. Therefore our study population might not be representative for the general GOA 
population. This limited generalizability should be taken into account when interpreting the 
study results.
To conclude
Based on the findings of this thesis, a critical look at these findings and the most recent 
literature on the non-pharmacological, non-surgical management of patients with OA some 
final conclusions can be made. We can conclude that GOA has a broad impact on the physical 
component of quality of life and the performance of daily activities, reflecting a high clinical 
burden. Furthermore, we demonstrated no differences in treatment effect between patients 
with GOA who followed a non-pharmacological face-to-face self-management program and 
those who received a telephone-based self-management program. No clinically important 
improvements on a range of outcome domains were observed within both treatment 
programs. These findings contribute to the increasing evidence of the limited benefits of 
self-management programs for people with OA. We hypothesize that patients with GOA 
might benefit more from a long-term, individually tailored, supervised treatment program 
combining weight loss with intensive exercises, rather than a self-management program 
targeting on multiple domains of daily living. Future research is needed to gain empirical 
evidence for this. Furthermore, measurement instruments with adequate measurement 
properties are needed to adequately assess physical function in patients with GOA. Yet, 
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the initial issue in research on GOA is to obtain international consensus on an appropriate 
definition of GOA for both clinical and research use. Such a definition might contribute to an 
improved understanding of the influence of multiple joint involvement on clinical outcomes 
in OA. We further believe that a more comprehensive approach to the management of OA is 
warranted. Researchers and clinicians in daily clinical practice should routinely consider the 
involvement of multiple joints in patients with OA.
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Hoofdstuk 1: inleiding
Artrose is de meest voorkomende chronische gewrichtsaandoening. In wetenschappelijk 
onderzoek en in de klinische praktijk wordt vaak uitgegaan van een mono-articulaire 
benadering van artrose, terwijl bij artrose vaak meerdere gewrichten tegelijkertijd 
zijn aangedaan. Behalve de knieën of heupen zijn de handen en de gewrichten van de 
wervelkolom relatief vaak aangedaan. Een term die veelvuldig gebruikt wordt om artrose in 
meerdere gewrichten tegelijkertijd te beschrijven is gegeneraliseerde artrose (GOA). Echter, 
een systematisch literatuuronderzoek liet zien dat er tot op heden geen eenduidige definitie 
van GOA bekend is. In dit proefschrift wordt GOA als volgt gedefinieerd:
- Klachten aan tenminste 3 gewrichtsgroepen én 
- Objectieve artrotische afwijkingen aan tenminste 2 gewrichtsgroepen
Prevalentiecijfers van GOA zijn beperkt en inconsistent. Verschillende studies suggereren dat 
in cohorten van artrose van de heup en/of knie een relatief grote groep patiënten (tot 50%) 
geclassificeerd kan worden als GOA. Desondanks is er nog weinig bekend over de impact 
van GOA op het dagelijks functioneren en kwaliteit van leven. De belangrijkste symptomen 
van GOA zijn pijn, stijfheid, verlies van functie en een verminderde kwaliteit van leven. 
Momenteel bestaat er nog geen curatieve behandeling voor artrose. Niet-medicamenteuze 
behandelopties zijn daarom veelal gericht op het verlichten van symptomen, het 
verbeteren van functioneren en het leren omgaan met de aandoening. Tot op heden is 
de niet-medicamenteuze behandeling van artrose vrijwel exclusief gericht op mensen met 
artrose van de heup, knie of hand. Dit geldt ook voor wetenschappelijke studies: er is tot 
nu toe nauwelijks wetenschappelijk bewijs voor de effectiviteit van niet-medicamenteuze 
interventies voor mensen met GOA. De belangrijkste doelen van dit proefschrift waren het 
verkrijgen van inzicht in de impact van GOA op het dagelijks functioneren en kwaliteit van 
leven en daarnaast de evaluatie van de (kosten)effectiviteit van twee niet-medicamenteuze 
behandelprogramma’s voor mensen met GOA.
Hoofdstuk 2: de impact van GOA op het dagelijks functioneren en kwaliteit van leven
In deze studie hebben we de impact van GOA op het dagelijks functioneren en kwaliteit 
van leven onderzocht. In totaal hebben 147 patiënten gediagnosticeerd met GOA door een 
reumatoloog en verwezen naar multidisciplinaire zorg een set gestandaardiseerde vragenlijsten 
ingevuld. De resultaten lieten zien dat de handen en knieën het vaakst waren aangedaan. De 
patiënten ervoeren matig tot ernstige beperkingen in het uitvoeren van dagelijkse activiteiten 
in een breed spectrum aan activiteiten. Met name activiteiten gerelateerd aan mobiliteit 
en huishoudelijke activiteiten werden frequent genoemd, met als belangrijkste beperkende 
activiteit lopen. Daarnaast was de kwaliteit van leven verminderd, met name de fysieke 
component. Deze studieresultaten suggereren dat de fysieke component van de kwaliteit 
van leven en activiteiten gerelateerd aan mobiliteit belangrijke aangrijpingspunten zijn voor 
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niet-medicamenteuze interventies voor mensen met GOA. Gezien het brede spectrum aan 
belangrijke functionele beperkingen is het van belang dat interventies afgestemd worden op 
de individuele problemen van de patiënt. 
Hoofdstuk 3: effectiviteit niet-medicamenteuze behandeling GOA
We hebben een gerandomiseerde, enkelvoudige geblindeerde pragmatische trial uitgevoerd 
waarin we de effectiviteit van twee niet-medicamenteuze interventies voor mensen met 
GOA hebben vergeleken tot 1 jaar na de start van de behandeling. In totaal werden 147 
patiënten gerandomiseerd in ofwel een 6 weken durende multidisciplinaire face-to-face 
groepsbehandeling bestaande uit 7 groepssessies of een 6 weken durende telefonische 
behandeling bestaande uit 2 groepssessies gecombineerd met 4 individuele telefonische 
contactmomenten. De belangrijkste doelen van beide behandelprogramma’s waren 
het verbeteren van het dagelijks functioneren en het verbeteren van zelfmanagement 
vaardigheden om beter om te gaan met de gevolgen van GOA. De hypothese was dat de face-
to-face behandeling effectiever was in het verbeteren van het dagelijks functioneren gezien de 
hogere intensiteit, groepsinteractie en supervisie. De belangrijkste uitkomstmaat van de studie 
was dagelijks functioneren gemeten met de HAQ-DI op baseline, 6, 26 en 52 weken. Secundaire 
uitkomstmaten waren onder andere pijn, vermoeidheid, zelf-effectiviteit en acceptatie. We 
vonden in deze studie geen verschillen in effectiviteit tussen beide behandelprogramma’s op 
geen van de uitkomstmaten, behalve voor pijn na 1 jaar; de face-to-face behandeling was 
effectiever in het verminderen van pijn dan de telefonische behandeling. Binnen de groepen 
vonden we kleine, significante verbeteringen op verschillende uitkomstmaten, maar deze 
verbeteringen waren niet klinisch relevant. Een interessante bevinding was dat deelnemers 
meer tevreden waren over de face-to-face behandeling.
Hoofdstuk 4: welk behandelprogramma is kosteneffectief?
Voor beleidsmakers is het van belang dat klinische evaluaties van nieuwe therapieën of 
technologieën gepaard gaan met economische evaluaties. Om deze reden hebben wij 
vanuit een maatschappelijk perspectief een kosten-effectiviteitsanalyse gedaan waarin we 
de kosten en effectiviteit van bovengenoemde behandelprogramma’s met elkaar hebben 
vergeleken. Naast de kosten voor de behandelprogramma’s, hebben we gedurende een 
jaar alle directe medische en niet-medische kosten als gevolg van GOA gemeten met behulp 
van vragenlijsten die werden afgenomen op baseline, 6, 13, 26, 39 en 52 weken. Daarnaast 
hebben we op drie verschillende manieren kwaliteit van leven (en dus utiliteiten) gemeten. 
De totale maatschappelijke kosten (over één jaar) van de telefonische behandeling waren 
hoger dan die van de face-to-face behandeling, echter dit verschil was niet significant. De 
resultaten van deze kosteneffectiviteit analyses toonden dat de face-to-face behandeling een 
grotere kans had om kosteneffectief te zijn dan de telefonische behandeling.
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Hoofdstuk 5: klinimetrische eigenschappen HAQ-DI
Eén van de belangrijkste consequenties van GOA is een vermindering van het dagelijks 
functioneren. Voor zowel onderzoekers als clinici is het van belang dat het dagelijks 
functioneren van mensen met GOA valide en betrouwbaar kan worden gemeten. Tot 
op heden zijn er geen specifieke zelf-gerapporteerde vragenlijsten beschikbaar om het 
dagelijks functioneren te meten in deze patiënten groep. Artrose specifieke vragenlijsten 
voor het meten van het dagelijks functioneren zijn beschikbaar, maar deze richten zich op 
de onderste extremiteiten en zijn daarom niet geschikt voor mensen met GOA aangezien 
deze groep patiënten beperkingen ervaart in activiteiten van zowel de bovenste als onderste 
extremiteiten. De Health Assessment Questionnaire Disability Index (HAQ-DI) bevat 
activiteiten van zowel de bovenste als onderste extremiteiten. Om deze reden hebben we 
de HAQ-DI als primaire uitkomstmaat gekozen om dagelijks functioneren te meten in onze 
trial. In dit hoofdstuk hebben we de psychometrische eigenschappen (interpreteerbaarheid, 
validiteit, betrouwbaarheid en responsiviteit) van de HAQ-DI geëvalueerd. De resultaten 
lieten zien dat de HAQ-DI vloer- en plafondeffecten heeft. Daarnaast was de content validiteit 
beperkt aangezien de HAQ-DI activiteiten bevat die niet relevant of te makkelijk uitvoerbaar 
zijn voor mensen met GOA. De construct validiteit en betrouwbaarheid waren goed. Echter, 
de responsiviteit was beperkt. Gezien de beperkte content validiteit adviseren wij de items 
van de HAQ-DI te actualiseren om in de toekomst dagelijks functioneren te meten bij mensen 
met GOA. Deze actualisatie is hoogstwaarschijnlijk ook relevant voor andere reumatische 
aandoeningen. 
Hoofdstuk 6: welke vragenlijst is het meest responsief? 
In tegenstelling tot GOA, zijn er voor het meten van het dagelijks functioneren bij mensen 
met knie artrose verschillende valide en betrouwbare vragenlijsten beschikbaar. Voor het 
monitoren van patiënten of het evalueren van de effectiviteit van interventies is het van 
belang dat verandering in dagelijks functioneren adequaat gemeten kan worden. Het meten 
van verandering wordt ook wel responsiviteit genoemd. In deze studie vergelijken we de 
responsiviteit van vier veelgebruikte vragenlijsten om dagelijks functioneren te meten bij 
mensen met knie artrose: 1.) the Western Ontario and McMaster University Osteoarthritis 
Index subscale physical function (WOMAC-PF), 2.) the Lequesne Algofunctional index 
(LAI), 3.) the Lower Extremity Functional Scale (LEFS) and 4.) the short measure of the 
Knee disability en Osteoarthritis Outcome Score (KOOS-PS). We hebben de responsiviteit 
van deze vragenlijsten gemeten en vergeleken door het opstellen van hypotheses over 
verwachtte correlaties tussen veranderingen in dagelijks functioneren en veranderingen in 
andere gerelateerde en niet gerelateerde constructen (zoals pijn, mentaal functioneren, 
acceptatie). Wanneer >75% van de hypotheses kon worden bevestigd was er sprake van 
een goede responsiviteit. Een expertgroep bestaande uit onderzoekers, epidemiologen, 
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fysiotherapeuten en een reumatoloog formuleerden 15 hypotheses. Voor de WOMAC-PF 
konden 12 van de 15 hypotheses (80%) bevestigd worden, voor de LAI, LEFS en KOOS-PS 
konden respectievelijk 9 (60%), 11 (73%) en 11 (73%) hypotheses bevestigd worden. Deze 
resultaten suggereren dat de WOMAC-PF superieur is in het meten van veranderingen in 
dagelijks functioneren in patiënten met knie artrose. 
Hoofdstuk 7: percepties van patiënten over de “Zorgwijzer Artrose” 
Om de niet-medicamenteuze zorg voor mensen met heup en knie artrose te optimaliseren, 
heeft onze onderzoeksgroep een behandelstrategie voor heup en knie artrose 
geïmplementeerd in een regio in Nederland. Deze implementatie richtte zich ook op 
patiënten gezien hun belangrijke rol in de behandeling van artrose. Om deze reden is er een 
patiëntvriendelijk zelfmanagementboekje ontwikkeld, de “Zorgwijzer Artrose ©”. Het doel van 
deze zorgwijzer was om patiënten te informeren over artrose en de behandelmogelijkheden, 
een actieve rol van patiënten bij hun behandeling te stimuleren en de communicatie tussen 
de patiënt en zorgverleners te verbeteren. De meningen van 17 patiënten ten aanzien van 
de inhoud en het gebruik van deze zorgwijzer werden bestudeerd in een kwalitatieve studie 
met semigestructureerde interviews. Hierbij werden patiënt-gerapporteerde barrières en 
faciliterende factoren om de zorgwijzer te gebruiken geïdentificeerd en onderverdeeld in de 
volgende thema’s: 1.) de rol van zorgverleners, 2.) de perceptie van patiënten ten aanzien 
van artrose en de behandelmogelijkheden en 3.) de perceptie van patiënten ten aanzien 
van het nut van het boekje en het krijgen van informatie. In het eerste thema werd ‘het 
gebrek aan aanmoediging van de zorgverleners’ geïdentificeerd als barrière om de zorgwijzer 
te gebruiken. Tevens gaven patiënten aan dat zij twijfelden of hun zorgverleners niet-
medicamenteuze behandelopties onderschreven. In het tweede thema werden de volgende 
cognities geïdentificeerd als barrières om de zorgwijzer te gebruiken: ‘artrose is niet te 
behandelen’ en ‘een proactieve houding is niet belangrijk tijdens de behandeling’. De cognitie 
‘een proactieve houding draagt bij aan een goede uitkomst’ was tevens een faciliterende 
factor om de zorgwijzer wel te gebruiken. In het derde thema werden ‘de perceptie dat 
de zorgwijzer nuttig is’ en ‘de behoefte om geïnformeerd te worden’ zowel als barrière en 
faciliterende factor geïdentificeerd om de zorgwijzer te gebruiken.
Hoofdstuk 8: wat is energie verdelen?
“Energie verdelen” is een belangrijk component van zelfmanagement interventies voor 
mensen met een reumatische aandoening om pijn en vermoeidheid te verminderen. Echter, 
zowel in de literatuur als in de klinische praktijk bestaat er grote variatie in de beschrijving 
van energie verdelen. Om deze reden hebben wij een internationale werkgroep opgezet 
en een internationale Delphi studie uitgevoerd. In 4 rondes hebben wij 60 onderzoekers, 
paramedici en/of reumatologen afkomstig uit 12 verschillende landen en deskundig op het 
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gebied van energie verdelen gevraagd naar de belangrijkste doelen, gedragingen, strategieën 
en contextuele factoren van energie verdelen. Dit resulteerde in een “consensual list” met 
daarin 9 doelen, 11 gedragingen, 9 strategieën en 10 contextuele factoren. Paramedici kunnen 
deze lijst gebruiken om samen met de patiënt de meest relevante aspecten te selecteren 
voor een interventie op maat. De resultaten van deze studie dragen bij aan het verkrijgen 
van transparantie en homogeniteit in het concept energie verdelen in wetenschappelijk 
onderzoek en in de klinische praktijk.
Hoofdstuk 9: discussie 
In dit hoofdstuk worden de belangrijkste resultaten van de onderzoeken besproken en 
bediscussieerd. Ook worden er een aantal implicaties voor de klinische praktijk en suggesties 
voor verder onderzoek aangegeven. 
Onze gerandomiseerde trial liet zien dat er geen verschil in effectiviteit was tussen een 
multidisciplinaire face-to-face groepsbehandeling en een telefonische behandeling (behalve 
voor pijn) voor mensen met GOA. Binnen de groepen zagen we kleine verbeteringen op 
verschillende domeinen die niet klinisch relevant waren. Hiervoor kunnen een aantal mogelijke 
verklaringen worden gegeven. Ten eerste, goal setting was een belangrijk component in 
onze behandelprogramma’s. Patiënten werden tijdens de start van de behandeling gevraagd 
individuele doelen te formuleren die werden gemonitord en bediscussieerd tijdens de 
behandeling. Omdat GOA kan leiden tot een breed spectrum aan beperkingen ontstond er 
een grote variatie aan individuele doelen. Hierdoor richtten de behandelprogramma’s zich 
op veel verschillende dimensies zoals pijn, vermoeidheid, acceptatie, lichamelijke activiteit 
en sociale ondersteuning. Een gevolg hiervan zou kunnen zijn dat het voor individuele 
patiënten moeilijk was om voor hen relevante informatie te selecteren. Daarnaast kan het 
zo zijn dat onze verwachtingen te hoog waren. We verwachtte dat een combinatie van niet-
medicamenteuze interventies bewezen effectief bij artrose van de heup en knie ook bij GOA 
effectief zouden zijn. Echter, aangezien meerdere studies laten zien dat GOA (of multiple joint 
involvement) een grotere impact heeft op klinische uitkomsten dan artrose aan één gewricht, 
is het aannemelijk dat patiënten met GOA een intensievere en complexere interventie nodig 
hebben. 
De kleine verbeteringen van onze behandelprogramma’s zijn vergelijkbaar met resultaten 
van de effectiviteit van zelfmanagement interventies beschreven in de literatuur. Recent laat 
een systematisch literatuuronderzoek zien dat de effecten van zelfmanagement interventies 
voor mensen met artrose erg klein zijn. In de literatuur groeit de consensus over de combinatie 
van intensief oefenen en gewrichtsverlies als belangrijkste behandeling voor mensen met 
artrose. Op basis van de bevindingen in dit proefschrift en de recente literatuur suggereren 
wij dat we wellicht meer moeten focussen op intensief oefenen gecombineerd met 
gewichtsverlies gedurende een langere periode in plaats van zelfmanagement interventies 
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gericht op een breed scala aan domeinen. Onderzoek is nodig om dit aan te tonen. Daarnaast 
is er onderzoek nodig naar vragenlijsten die op een adequate manier dagelijks functioneren 
kunnen meten bij mensen met GOA. Bovenal is echter belangrijk dat er internationale 
consensus wordt bereikt over een uniforme definitie van GOA zodat er meer systematisch 
en reproduceerbaar (effectiviteits)onderzoek kan worden verricht naar deze aandoening die 
gekenmerkt wordt door een grote ziektelast.
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